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Abstract
An LC-MS method was set up and validated for determining low concentrations of phenethyl 
isothiocyanate (PEITC) in rat plasma. Following administration of dietary doses to rats, 
PEITC was rapidly absorbed, reaching peak plasma levels within an hour, and achieved high 
bioavailability, which increased substantially after repeated administration. However, PEITC 
displayed dose-dependent pharmacokinetic behaviour with bioavailability decreasing with 
increasing dose.
Dietary doses of PEITC administered to rats enhanced hepatic CYP2B activity and expression 
whereas a modest inhibition of CYP2E1 was observed. Increase in hepatic CYPlAl and 1A2 
apoprotein levels was not accompanied by similar rises in activity. Further studies revealed 
that PEITC inhibited CYPlAl activity in a mechanism-based fashion. In the lung, CYP2B 
activity was competitively inhibited. A marked rise in glutathione ^'-transferase (GST) and 
NADPH:quinone oxidoreductase (NQOl) activities in liver was noted after the same 
treatment, while in kidney only NQOl was elevated, and in the lung no change was evident.
Incubation of rat liver slices with PEITC decreased CYP1A2 activity and suppressed 
apoprotein levels, whereas a moderate rise in GST and, to a greater extent, in NQOl activity 
was observed. When human liver slices were similarly incubated with PEITC, CYP1A2 
activity was impaired as in rat. PEITC was a mechanism-based inhibitor of CYPlAl in 
hepatic microsomes. When GST and NQOl were monitored in the four donors, inter­
individual variability was observed.
Long-term exposure of PEITC to rats prior to a single dose of 2-amino-3-methylimidazo[4,5- 
/Iquinoline (IQ) suppressed urinary excretion of indirect-acting mutagens indicating an 
increase in the overall metabolism of IQ, which was not related to changes in CYP1A2 and 
GST activities implying that other enzymes are modulated. Finally, PEITC antagonised the 
benzo(a)pyrene-mediated induction of CYPlAl in rat liver slices, whereas inconsistent 
results were obtained in liver slices from four human donors.
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1.1 Function of diet in carcinogenesis
The state of human health depends crucially on the dietary pattern of each individual. For 
decades, several methods of cooking such as hying and grilling of protein-rich foods have 
been associated with formation of carcinogens such as 2 -amino-3 ,8 -dimethylimidazo[4 ,5- 
/Iquinoxaline (MelQx) and 2-amino-3-methylimidazo[4,5-/[quinoline (IQ) (Archer, 1988; 
Lars son et al., 1983; Snyderwine et al., 2002; Steineck et al., 1993). The consumption of such 
carcinogen-containing diets is increasing, hence cancer is one of the most threatening diseases 
worldwide. Much research has focused on the characterisation of novel toxic compounds in 
food as well as alleviation of their toxicity. Recently, acrylamide which is found in heat- 
treated carbohydrate-rich foods such as h*ied potatoes has been confirmed as a potent cancer- 
causing chemical in human indicating that even the cooking of vegetables can generate 
carcinogenic compounds (Hogervorst et al., 2007; Tareke et al., 2002).
On the other hand, epidemiological data strongly recommends the dietary intake of food rich 
in vegetables can reduce cancer risk (Steinmetz and Potter, 1991). A number of substances, 
present in fhiit and vegetables, appear to be involved in cancer prevention, including 
isothiocyanates (ITCs), indole-3-carbinol (13C), allium compounds, isoflavones, (3-carotene, 
vitamin E, flavonoids and dietary fibre (Steinmetz and Potter, 1996). To date, there is 
increasing evidence that consumption of broccoli and other cruciferous vegetables correlates 
with decreased risk for developing cancer of the pancreas, lung, colon, bladder and prostate 
(Balcerek, 2007; Bianchini and Vainio, 2004; Matusheski and Jeffery, 2001; Tang et al., 
2008). Glucosinolates which are phytochemicals found in these vegetables and their 
breakdown products such as isothiocyanates are believed to be associated with their potential 
health benefits. However, mechanisms responsible for the protective effect of these 
compounds are likely to be multiple, probably involving complex interactions, and are poorly 
understood (Conaway et al., 2002; lARC, 2004;M yzaketal., 2004). Among isothiocyanates,
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phenethyl isothiocyanate has gained increasing attention since its ability to impede 
carcinogenesis at many stages of the cancer process has been clearly demonstrated.
1.2 Carcinogenesis
Carcinogenesis is a multi-stage process of cancer development which originates by exposure 
of DNA to harmful molecules that can be both endogenous and exogenous. The development 
of cancer malignancy is believed to occur in three stages: mutation of a single cell (initiation), 
proliferation of the mutant cells (promotion) and additional mutations in the tumour 
(progression) leading to the formation of a malignant tumour (Kawamori et al., 1999; 
Moolgavkar and Knudson, Jr., 1981; Yuspa, 2000). Prevention of carcinogenesis at the 
initiation stage by enhancing elimination of dangerous molecules that tend to form DNA 
adducts m the cells is one of the possible chemoprevention mechanisms, and therefore is a 
pivotal characteristic of chemopreventive agents.
The xenobiotic elimination process is known as biotransformation and occurs in various
tissues, resultmg in a change in the chemical stmcture of the toxic compound from lipophilic
to hydrophilic as to enable its excretion (Plant, 2003). However, biotransformation can be
considered as either a beneficial or a harmful process. Detoxification process is recognised
when It results in metabolites with lower toxicity. In many cases, however, biotransformation
is known as bioactivation where the metabolites are more toxic than their parent compounds,
and may interact with DNA causing DNA damage leading to cancer development (Castell et
al., 2005; Ravindranath et al., 1984). The rate at which the deactivation and bioactivation
reactions occur will, in part, determine the toxicity of a substance (loannides and Lewis, 
2004).
Liver IS the primary site of biotransformation because of its large size and very high 
concentration of biotransformation enzymes. However, kidney and lung contain 10-30% of
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the enzyme content in liver and may contribute significantly to biotransformation; 
microsomes (endoplasmic reticulum) contain mostly phase I enzymes whereas phase II 
enzymes reside primarily in the cytosolic fraction (Sipes and Badger, 1999). For these 
reasons, liver has become the major organ of interest for the study of biotransformation 
reactions study in animals, although intestine, kidneys and lungs are also the significant 
targets (Williams et al., 2000). Biotransformation reactions depend on a number of factors 
including animal species, age, gender, genetic variability, nutrition, diseases, and xenobiotic 
exposure. Among these, the most important factor in human appears to be genetic variation, 
whereas gender may influence only hormone-related CYP450 enzymes; the metabolic 
capacity of enzymes is more stable during adulthood and decreases in the aged (Swarbrick 
and Boylan, 2002).
1.3 Glucosinolates and their release of isothiocyanate derivatives
Cruciferous vegetables, i.e. watercress, Brussels sprouts, broccoli, cabbage, kai choi, kale, 
horseradish, radish and turnip are categorised within the family Cruciferae. Recent scientific 
research has focused on the chemopreventive effect of cruciferous vegetables due to their 
high content of beneficial substances, glucosinolates and their metabolites such as 
isothiocyanates (ITCs) and indoles (Verhoeven et al., 1997). However, three important 
glucosinolate-containing plants do not belong to this family namely caper, papaya and Indian 
cress (Nugon-Baudon and Rabot, 1994). About 120 naturally occurring glucosinolates have 
been identified so far but their type and content varies among vegetables; the amount being 
highest in Brussel sprouts > swede > savoy cabbage > broccoli (Steinbrecher et al., 2009). 
Glucosinolates exert their chemopreventive activity by enhancing the elimination of 
carcinogenic substances from the body, inducing apoptosis (programmed cell death) of pre- 
cancerous cells and by arresting cell proliferation. One such glucosinolate is gluconasturtiin, 
the precursor of phenethyl isothiocyanate, which has been shown to be a dominant
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chemopreventive chemical in watercress (Canistro et al., 2004). The general structure of 
glucosinolates is shown in Figure 1.1.
OH O
. s .
OH T
H p r e  1.1 General structure of glucosinolate. The R group can be aliphatic, aromatic 
heterocyclic and is derived from an amino acid (Shapiro et al., 1998).
or
When the tissue of cruciferous plants is disrupted by mechanical food processing or 
masticating, glucosinolates are released from the vacuoles and hydrolysed by cytosolic 
myrosinase, a thioglucoside glucohydrolase enzyme (EC 3.2.3.1) residing separately from the 
substrate in specific cells named idioblasts (Nugon-Baudon and Rabot, 1994). Gut flora such 
as Escherichia coli and Bacteroides vulgatus, have also been reported to contribute to dietary 
glucosinolate hydrolysis (Rabot et al., 1993; Shapiro et al., 1998). Myrosinase breaks the P- 
thioglucosidic bond of the glucosinolate molecule to produce glucose, sulphate and unstable 
aglycone intermediates, which then undergo non-enzymatic intramolecular (Lossen) 
rearrangement to yield isothiocyanates, thiocyanates or nitriles (Fig. 1.2), depending on the 
specific glucosinolate and the prevailing reaction conditions (Fahey and Talalay, 1999).
Microwave cooking of vegetables causes a reduction in isothiocyanate release, presumably
due to dénaturation of myrosinase. However, glucosinolates may be further hydrolysed by gut
microflora but to a lower degree compare with plant myrosinase (Leoni et al., 1997).
Nonetheless, the isothiocyanates produced in the colon may be further degraded by
microflora, hence reducing the amount absorbed (Rouzaud et al., 2004). In human, 39% of
ITC metabolites from total glucosinolates was released in urine after thoroughly chewing of
Brussels sprouts, whereas 26% was excreted when swallowed whole (Vermeulen et al., 
2003).
R — C = N
N itr iie  
4-H2S0^ f  H2S
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Figure 1.2 Glucosinolates and their breakdown products following enzymatic hydrolysis 
by myrosinase.
1.4 Human dietary exposure
Consumption of cruciferous vegetables is entirely responsible for human dietary exposure to 
glucosinolates (McGregor et al., 1983). In initial crude studies, average intake of cruciferous 
vegetables was based on the amount of vegetable consumption regardless of the variation of 
glucosinolate content in plants from different cultivars, cultivation conditions, parts of the 
plant and cooking conditions (Nugon-Baudon and Rabot, 1994; Steinbrecher et al., 2009). 
The first summarised data, from 18 published studies, reported 140 estimates for 42 food 
items and a remarkable deviation in the various studies was observed (McNaughton and 
Marks, 2003). The consumption of cruciferous vegetables varies among populations. The 
average daily intake of total glucosinolates in UK was estimated at 75 mg/day/person (Sones 
et al., 1984). However, compared to the UK, the average consumption was found at lower 
level in Canada and the United States (Benns et al., 1978; Krul et al., 2002) and higher in 
Singapore (Zhao et al., 2001). Since isothiocyanates are of great importance because of their
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cancer prevention potential, daily intake for each individual is useful information in order to 
evaluate their chemopreventive activity based on human daiiy dietaiy patterns which, 
unfortunately, has not yet been reported.
1.5 Metabolism of isothiocyanates
Isothiocyanates (ITC) are typically lipophilic and may be highly reactive, volatile, 
malodorous compounds having a sharp and bitter taste. The central carbon atom of the 
isothiocyanate group (-N=C=S) is often highly electrophilic and the biological activities of 
ITCs may be primarily mediated through the reaction of this carbon atom with cellular 
nucleophilic targets such as glutathione (lARC, 2004). The glucosinolate precursor of 
phenethyl isothiocyanate is gluconasturtiin, found mostly in watercress (Nasturtium officinale 
R. Br.), and its hydrolysis reaction is shown in Figure 1.3.
OH
1^0— | 1 ^  \  /  Myrosinase/H20
^    ► /  CHg—N=C = S
■O3SO
Gluconasturtiin Phenethyl isothiocyanate
Figure 1.3 Generation of the breakdown product phenethyl isothiocyanate (PEITC) 
Irom myrosmase-dependent gluconasturtiin hydrolysis.
Once ITCs are absorbed across the intestinal cell membranes by passive diffusion, the 
prtmaiy metabolic route for ITCs is conjugation through the -N=C=S group with glutathione 
(GSH) to form S-(N-alkylthiocarbamoyl)glutathione derivatives, the reaction being catalysed 
by the enzyme glutathione 5-transferase (GST). The isothiocyanates are trapped within the 
cell, and the concentration of metabolites reaches a maximum after about 30 min in cultured 
cells. Subsequently, the metabolites are exported from cells by the exporter multidrug 
resistance proteins (MRPs) hence decreasing the cellular concentration of GSH (Thomalley,
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2002). The ITC-GSH conjugates are then further metabolised via the mercapturic acid 
pathway which is a major metabolic route for many xenobiotics (Mennicke et al., 1987). 
Sequential metabolites namely ITC-cysteinylglycine and ITC-cysteine are formed followed 
with fV-acetylation of the latter to generate the mercapturate via cytosolic #-acetyltransferase 
in the liver. Mercapturates are then released into the circulation and bile, and excreted in urine 
(Fig. 1.4) (Gasper et al., 2005). Thus the presence of these conjugates in the urine indicates 
uptake and metabolism of ITCs in the body, and therefore it may be used as biomarker of ITC 
exposure (Mennicke et al., 1987).
1.6 Epidemiological studies on glucosinolates intake and cancer risk
Epidemiological studies on the relationship between dietaiy consumption of cruciferous 
vegetables and cancer risk have been carried out mostly in Asian countries where these 
vegetables are extensively consumed. Consumption of cruciferous vegetables in a case- 
control study of Chinese men led to a reduced risk of lung cancer, primarily shown in 
individuals with genetic deletion of GSTMl and GSTTl, the major enzymes responsible for 
isothiocyanate metabolism (Zhang et al., 2005), presumably due to reduction of the 
elimination rate of isothiocyanates (London et al., 2000). In Singapore, the decreased risk of 
lung cancer was more pronounced among Chinese women smokers compared with 
nonsmokers, and was, once again, greater in the subjects with the GSTMl-null genotype 
(Zhao et al., 2001). Similar anticarcinogenic bioactivity of glucosinolates in lung cancer was 
reported in a case-control study carried out in the United States (Spitz et al., 2000). Moreover, 
an increase in urinary non-toxic metabolites of 4-(methylnitrosamino)-l-(3-pyridyl)-l- 
butanone (NNK), a major carcinogen found in tobacco, was observed following consumption 
of watercress for 3 days (Hecht, 1995). In 2004, the same group of researchers reported an 
inverse association between increased consumption of glucobrassicin, an abundant 
glucosinolate found in seven of nine cmciferous vegetables in Singapore, and urinary
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concentration of NNK metabolites (Hecht et al., 2004). An inverse relationship between 
urinaiy levels of isothiocyanates and breast cancer has also been reported and, once again, the 
effects were related with homozygous deletion of GSTMl or GSTTl (Fowke et al., 2003). 
The effects of dietary intake of cruciferous vegetables on reduction of cancer, however, is 
inconsistent, presumably due to GST polymorphisms in individuals (Moore et al., 2007).
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Underlying mechanisms of cancer prevention have been studied; one such mechanism is 
modulation of carcinogen bioactivation enzymes. Urinary excretion of MelQx and 2-amino-l- 
methyl-6-phenylimidazo[4,5-b]pyridine (PhP), heterocyclic amines (HAs) found in cooked 
meat, decreased during cruciferous vegetables intake, paralleled with no DNA adducts of 
PhIP in lymphocytes being detected. These results were associated with induction of CYP1A2 
activity during cruciferous vegetable consumption, as exemplified by increased caffeine 
metabolism (Murray et al., 2001). Induction of phase II enzymes, such as GST, and protection 
against oxidative DNA damage, as exemplified by reduction in the urinary excretion of 8- 
oxo-7,8-dihydro-2'-deoxyguanosine (8-oxodG), one of the mutagenic base modifications 
produced in DNA by the reaction of reactive oxygen species, has been reported following 
Brussels sprouts intake (Bogaards et al., 1994; Verhagen et al., 1995).
1.7 Cancer prevention by isothiocyanates
1.7.1 Major chemical carcinogens
1.7.1.1 Polvcvclic aromatic hvdrocarbons
Polycychc aromatic hydrocarbons (PAHs) are chemical carcinogens generated from the 
incomplete combustion of organic material. There are more than 100 chemicals in the PAH 
group containing 3 or more fused aromatic rings (Fig. 1.5). PAHs are potent inducers of both 
subfamilies of the CYPl family which induction mechanism appears to be Ah receptor- 
dependent (Shimada et a l, 2002). Moreover, the induction potential of each PAH depends on 
their molecular weight, with the heavier and more toxic molecules being the more potent 
inducers (Till et a l, 1999). Benzo(a)pyrene (BaP) is one of a large number of PAHs to which 
human are exposed mostly from cigarette and smoked and grilled food (Hecht, 2003; Larsson 
et a l, 1983). Lung is a principal target tissue for PAHs, especially BaP (Harrigan et a l, 2004). 
Lung tumourigenesis induced by BaP in A/J mice was suppressed by benzyl isothiocyanate 
(BITC), whereas PEITC was effective against a mixture of BaP and NNK, but not BaP alone 
(Hecht et a l, 2000; Sticha et a l, 2000). Both BITC and PEITC showed no significant
10
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reduction of BaP metabolism in liver microsomes of either hamsters or F344 rats (Hamilton 
and Teel, 1994), suggesting that the chemopreventive activity of ITCs against BaP is tissue 
specific. The ability of ITCs to inhibit PAH-induced CYP450 expression has been 
investigated. It was revealed that sulforaphane (SFN) and its analogues inhibited CYP1A2 to 
a greater extent than CYPlAl, and their distinctive inhibition potency indicated that the 
substituent plays an important role in chemopreventive activity (Skupinska et al., 2009a); 
similar observations have been made by other workers (Erkoc and Erkoc, 2005).
Figure 1.5 Benzo(a)pyrene structure.
1.7.1.2 Heterocvclic amines
Heterocyclic amines (HAs) are carcinogens generated during the cooking of meat and fish as 
a result of the condensation of creatinine with amino acids. Many studies reported the 
presence of HAs in various foods. However, grilled chicken contains relatively higher amount 
than other grilled products such as beef, pork, salmon and hamburger, being 14,300 ng/lOOg 
(Kataoka et al., 2002; Murray et al., 1993; Sinha et al., 1995; 1998). One such HA is IQ, 
which has been demonstrated as a liver carcinogen in animal models such as monkey 
(Adamson et al., 1990a; 1990b). It was first listed as a human carcinogen in 2002, based on 
sufficient evidence of carcinogenicity (10th Report on Carcinogens, 2003).
The underlying carcinogenicity mechanism oflQ  is believed to be related to its bioactivation
through CYP1A2 which leads to the formation of DNA-adducts of IQ (Snyderwine et al.
11
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2002). Correspondingly, inhibition of IQ-induced mutagenesis by PEITC has been 
demonstrated which was attributed, in part, to inhibition of CYPl A l and 1A2 (Hamilton and 
Teel, 1996). In the case of sulforaphane, modest inhibition of IQ-induced mutagenesis by rat 
hver post-mitochondrial preparations involved direct inhibition of CYP1A2 enzyme activity 
(Yoxall et al., 2005). Moreover, Brussels sprouts and garden cress juices have been 
demonstrated to suppress IQ-induced DNA-damage and preneoplastic lesions in the colon and 
hver of rats, and these were paralleled with induction of uridine diphospho- 
glucuronosyltmnsferase (UDPGT), indicating that UDPGT is also one of the enzymes 
involved in the suppression of IQ carcinogenicity (Steinkellner et al., 2001a).
1.7.2 Chemoprevention by isothiocyanates in animal studies
The comparative chemopreventive potency between glucosinotales and isothiocyanates has 
not been clearly established. Even though an inverse relationship between glucosinolate 
intake and cancer development has been demonstrated in many studies, the chemopreventive 
effects may be attributed, at least to some extent, to their breakdown products rather than the 
parent glucosinolates. There is also evidence that the intact glucosinolate from broccoli was 
not active m modulating xenobiotic-metabolising enzymes, and incubation with myrosinase to 
promote degradation of the glucosinolates to ITCs was necessitated for CYP450 enzymes to 
be modulated (Vang et al., 2001). Furthermore, some studies demonstrated that glucosinolates 
also have adverse effects by inducing DNA damage, which may develop to cancerous cells 
(Conaway et al., 1999; lARC, 2004; Robbins et al., 2005).
The anticarcinogenic bioactivity of various isothiocyanates has been demonstrated in various 
animal models such as rats, mice and hamsters, and in different target tissues such as lung, 
oesophagus, liver, colon (Wiseman, 2005), mammary gland and forestomach (Manesh and 
Kuttan, 2005). There are large but unexplained potency differences among the various
12
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isothiocyanates. Incidence of colon tumours in rats receiving methylaxozymethanol was 
reduced to 53% following treatment with BITC before and during exposure to the carcinogen 
(Sugie et al., 1994). Treatment with BITC also reduced 7,12-dimethylbenz(a)anthracene 
(DMBA)-induced rat mammary tumour formation even when administered after DMBA 
(Wattenberg, I98I), and inhibited rat bladder cancer following simultaneous exposure to N- 
butyl-JV-(4-hydroxybutyl)nitrosamine (BBN) (Okazaki et al., 2002). However, administration 
of BITC after treatment with BBN was found, in contrast, to promote urinaiy bladder 
carcinogenesis (Hirose et al., 1998). In mice, BITC reduced BaP- and A-nitrosodiethylamine- 
induced forestomach tumours (Wattenberg, 1987). Prior and conclurent treatment with 6- 
phenylhexyl isothiocyanate, a longer alkyl chain isothiocyanate, resulted in reduction of 
NNK-induced lung tumour incidence in rat (Hecht et al., I996a;1996b). Moreover, the same 
isothiocyanate suppressed bladder tumour multiplicity following treatment of rats with BBN 
(Nishikawa et al., 2003). Sulforaphane, an alkyl isothiocyanate, was shown to inhibit 
mammary tumours in rat when administered before exposure to DMBA (Zhang and Talalay, 
1994). Further studies revealed its ability to suppress BaP-induced forestomach mrnours in 
mice (Fahey et al., 2002). This was associated with induction of phase II enzymes, since the 
chemopreventive effect of sulforaphane was abolished in animals with deleted nuclear factor 
E2-related factor 2 (Nrf2) gene (see Section 1.9). Comparing the protective potency among 
aiylalkyl isothiocyanates on oesophagus tumourigenesis caused by N- 
nitrosomethylbenzylamine (NMBA), revealed a rank order for inhibition of 3-phenylpropyl 
isothiocyanate > PEITC > BITC (Morse et al., 1997; Wilkinson et al., 1995). In the case of 
NNK-induced pulmonaiy tumourigenesis, the inhibition potency of individual isothiocyanates 
was similar being 6-pheneylhexyl- > 5-phenylpentyl- = 4-phenylbutyl- = 3-phenylpropyl- > 
phenethyl isothiocyanate (Morse et al., 1991; Stoner and Morse, 1997). These observations 
insinuate structure-activity relationships which are discussed in Section 1.8 (vide infra).
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1.8 Cancer prevention by phenethyl isothiocyanate
PEITC is one of the most extensively studied aromatic ITCs because of its high potency 
against a wide variety of cancers, such as lung (Hecht et al., 1995; Mi et al., 2007), breast, 
oesophagus, forestomach, pancreas, prostate and colon as well as leukaemia (Hu et al., 2003; 
Johnson et al., 2004; Ogawa et al., 1998; Telang et al., 2009). In addition, no toxicity has been 
observed in animal models at anticarcinogenic or even higher doses (Hecht, 1995). The 
protection effects of isothiocyanates may be specific, depending on target tissue, nature of 
carcinogens, dose regime and length, and timing of exposure. For example, prevention of 
tumour formation caused by NMBA in the oesophagus of Fischer rats was inhibited when the 
animals were fed diets supplemented with PEITC for 25 weeks, only before or concurrent 
with exposure to the carcinogen (Stoner et al., 1991). On the other hand, total number of 
aberrant crypt foci in Fischer rats was suppressed by PEITC when administered either before 
or after dosing with azoxymethane (Chung et al., 2000). Moreover, the fact that PEITC 
inhibited tumour formation following NNK but not BaP treatment as determined in mouse 
lung and skin (Adam-Rodwell et al., 1993; Lin et al., 1993) supports the carcinogen- 
dependent specificity. Similarly, BITC, the structurally related isothiocyanate, was shown to 
inhibit BaP- (Lin et al., 1993; Wattenberg, 1987) but not NNK-induced tumourigenesis in 
mouse lung (Morse et al., 1989). In addition, the protective effect o f BITC against BaP 
carcinogenicity was tissue-specific as, in contrast to lung, protection was unattained in 
forestomach and skin (Lin et al., 1993; Wattenberg, 1987). The chemopreventive activity of 
PEITC towards the tohacco-specific carcinogen NNK, which is believed to be involved in the 
development of lung cancer in smokers (Rivenson et al., 1988), in various tissues and species 
has been well established (Hecht et al., 1996b; Morse et al., 1991; 1989; Smith et al., 1990; 
1996; Staretz et al., 1997). Further studies indicated that the antitumour function of PEITC 
against NNK was mediated by the isothiocyanate itself rather than its W-acetylcysteine 
metaholite (Chung et al., 1996). PEITC also suppressed forestomach and lung tumours in 
mouse as well as rat mammaiy tumourigenesis caused by DMBA (Futakuchi et al., 1998;
14
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Wattenberg, 1981). When compared to BITC, PEITC was a more effective inhibitor of NNK- 
induced tumourigenesis, and this was linked to its stronger mechanism-based inhibition 
towards CYP2A6 and 2A13, the major enzymes involved in NNK metabolism (von Weymam 
et al., 2006). The enhanced inhibitory potency of PEITC, having the longer alkyl chains, is 
probably related to the increased lipophilicity associated with the increasing alkyl chain 
length, hence competitive interaction with cytochrome P450 enzymes is more facile (Guo et 
al., 1993; Smith et al., 1990). However, a decline in chemopreventive potency occurred when 
the length was extended from Ce to Cg as demonstrated in less inhibitory activity of PEITC to 
CYPlAl, 2B1 (Conaway et al., 1996) and CYP2E1 (Wang et al., 1995) activity in rat 
microsomes showing that other factors are included. This is believed to reflect the specificity 
of the CYP450-binding site to the shape and size of substrate (Wang et al., 1995); the 
presence of the phenyl ring in PEITC enables this isothiocyanate to inhibit CYPlAl activity 
since the binding site of CYPlAl is highly specific to aromatic compounds such as PAHs 
(loannides and Parke, 1990). Given that humans are exposed to a variety of carcinogens, it 
may be advisable that intake of a mixture of ITCs may afford higher degree of 
chemoprevention in different tissues and against different chemical carcinogens.
1.9 Possible mechanisms of the anticarcinogenic action of phenethyl isothiocyanate
Protective mechanisms of dietary anticarcinogenic compounds occur in all steps of multi­
stage of carcinogenesis. The so called ‘blocking agents’ prevent procarcinogens from reacting 
with cntical targets such as DNA by modulating phase I and phase II enzyme systems. This 
mechanism is likely to occur when the compound is administered before or concurrently with 
the chemical carcinogen. However, at post-initiation, the compounds that impair the progress 
of mutant cells to neoplasia are termed ‘suppressing agents’, where the compounds modulate 
growth-promoting signaling pathways, cell cycle arrest and induction of apoptosis through 
various mechanisms, leading to a lower tumour incidence (Wattenberg, 1996).
15
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Likewise, ITCs exert their cancer prevention effect at a variety of levels, one of the most 
prominent mechanisms being the favorable modification of biotransformation enzyme 
systems by inducing phase II enzymes, blocking carcinogen activation by inhibiting certain 
phase I enzymes, and to a lesser extent by stimulating apoptosis of damaged cells (Lampe and 
Peterson, 2002; Robbins et ah, 2005).
Effect of phenethvl isothiocvanate on cvtochrome P450 enzvm es
As already discussed, a major mechanism of ITCs involves suppression of reactive metabolite 
generation and, therefore, a decrease in DNA adduct formation. Most chemical carcinogens, 
known as procarcinogens, require metabolic activation, primarily catalysed by cytochromes 
P450, before exerting their carcinogenic effects. Many ITCs are known to either directly 
inhibit (competitive or mechanism-based inhibition) or down-regulate CYP450 enzymes 
depending on the CYP450 isoform. Down-regulation mechanisms by ITCs have not been 
fully described to date. However, it has been established that suppression of CYP450 such as 
CYPlAl and 1A2, may occur at both pre- and post-transcriptional levels, i.e. by enhancing 
mRNA degradation which can occur as a result of induction of interferon, an RNase inducer, 
when the cells are exposed, for example, to ionising radiation (Clave et ah, 1997; Delaporte 
and Renton, 1997). Inhibition of CYP2E1 by PEITC appears to be the result of pre- 
transcriptional modulation, as exemplified by a decrease in the mRNA levels of CYP2E1 
(Morimoto et ah, 1995). On the other hand, a number of studies have demonstrated the direct 
inhibition mechanisms of ITCs towards CYP450. The mechanism-based inhibition of 
CYP450 is characterised by loss of CYP450 catalytic activity as a result of binding of the 
reactive intermediate, the metabolite of substrate generated from bioactivation by the CYP450 
enzyme, to the cytochrome P450 enzymes. Unlike competitive inhibition where the reaction 
is reversible, mechanism-based inhibition represents a strong inhibition in which the activity 
is not regained, and synthesis of new enzyme is necessitated.
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In a study of the inhibition mechanism indicated that PEITC inhibited purified human
CYP1A2 and 2A6 in a competitive fashion, and non-competitive inhibition was shown in the
case of CYP2C9, 2C19, 2D6 and 2E1, whereas a mixed-type of inhibitions was observed in
the case of CYP3A4 (Nakajima et al., 2001). Similar competitive inhibition of PEITC
towards purified human CYP1A2 has been reported and believed to responsible for a decrease
in NNK metabolism (Smith et al., 1996). In rats in vitro, PEITC suppressed CYPlAl, 1A2
and 2B1 activity in various induced rat microsomes (Conaway et al., 1996; Thapliyal and
Maru, 2001). Following treatment of rats with ethanol, PEITC has been reported to be a
potent inhibitor of CYP2E1 (Lindros et al., 1995). The effects of ITCs on CYP450 in vivo
appear to be inconsistent, depending on experimental conditions, nature of ITC, treatment
regime and the target tissue (Zhang and Talalay, 1994). For example, a single oral dose of
PEITC (1 mmol/kg) resulted in inhibition of CYP2E1 activity (Ishizaki et al., 1990) whereas
the same enzyme was enhanced following exposure to PEITC for a longer period (Smith et 
al., 1993).
Effect of phenethvl isothiocvanate on phase II enzvm es
Induction of phase II enzymes in most cases leads to enhanced reduction of the biological 
activity of many carcinogens. PEITC treatment inhibited the formation of DNA adducts of IQ 
m rat hver and plasma, as well as of PhIP in various tissues, as a result of enhanced activities 
of GST, sulphotransferase and NQOl (Dingley et al., 2003). Although the inhibitory activity 
of CYP450 by ITCs is strongly structure-dependent, as already discussed, a study of nine 
isothiocyanates that differed in their chemical structures showed no difference in phase II 
enzyme induction, e.g. NQOl and GST in mouse liver (Zhang and Talalay, 1998). However, 
PEITC has been shown to be a tissue-specific inducer of phase II enzymes. Treatment with 
PEITC induced NQOl and GST activities in rat liver, whereas these enzymes in the lung and 
nasal mucosa remained unaffected (Conaway et al., 2002). Induction of NQOl and GST was 
also observed in the pancreas of male F344 rats following administration of PEITC, but to a
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lesser extent thanin liver (Wallig et al., 1998). It has been demonstrated that supplementation
of diets with PEITC promoted chemoprevention effects in the digestive tract of rats by 
increasing GSTtt activity and GSH content, whereas in the liver GSTa and GSTp were 
elevated (van Lieshout et al., 1996). Phase II enzyme induction was found to be regulated by 
intracellular levels of ITCs which are facilitated by their interaction with glutathione (Zhang,
2000). Moreover, the interaction of ITCs with glutathione leads to depletion of glutathione 
and triggers apoptosis of cancer cells (Franco et al., 2007).
Modulation of xenobiotic-metabolising enzymes by glucosinolate derivatives depends largely 
on their structures. Distinctive regulation caused by indoles and ITCs has been demonstrated 
(Fig. 1.6). Indole-3-carbinol (13 C), bifunctional inducer, induces both phase I and phase II 
enzymes such as CYPlAl/2, NQOl and GSTa through the xenobiotic response element 
(XRE) by the binding of I3C to the aryl hydrocarbon receptor (AhR), leading to translocation 
of the AhR complex to the nucleus and interaction with XRE in the gene promoter. In 
contrast, ITCs typically offer monofunctional induction by activation of only phase II genes 
through the antioxidant response element (ARE) (Lampe and Peterson, 2002; Lynn et al., 
2006) and the transcription factor, nuclear factor E2-related factor 2 (Nrf2), which is bound to 
the Kelch-hke ECH associated protein 1 (Keapl) in the cytoplasm. ITCs dissociate Keapl 
from Nrf2 by interaction with the highly reactive sulphhydryl groups in the ATP-binding 
domain present in Reap I (Myzak and Dashwood, 2006). This interaction allows Nrf2 to 
translocate to the nucleus and mediates expression of phase II genes via interaction with the 
ARE (Keum et al., 2003; Lee and Surh, 2005; Xu et al., 2006).
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Figure 1.6 Regulation of xenobiotic-metabolising enzymes by glucosinolate breakdown 
products (Lampe and Peterson, 2002).
Effect of phenethvl isothiocvanate on apoptosis
Induction of apoptosis underlines one of the chemopreventive mechanisms of PEITC as 
demonstrated previously in human leukaemia HL60 cells (Xu and Thomalley, 2001). The 
molecular mechanisms of the activation process are likely to be complex and are only partly 
understood (Zhang, 2004). The trigger for apoptosis is believed to involve DNA damage 
formation, covalent binding to proteins or oxidative stress (Mi et al., 2007). The major route 
of PEITC metabolism is enzymatic or non-enzymatic conjugation with thiol groups of GSH. 
These reactions are rapid and reversible, but they may lead to a temporary decrease in cellular 
cysteinyl thiol groups that provides an oxidative trigger for apoptosis (Xu and Thomalley,
2001). Irreparable DNA damage has been reported as one of the molecular effects in the 
induction of apoptosis (Sheikh et al., 2000). PEITC enhanced DNA damage by induction of 
growth arrest and DNA damage-inducible genes (GADD) (Powolny et al., 2003). Finally, 
interaction of PEITC with intracellular macromolecules such as tubulin proteins has been 
proposed as one of the mechanism of apoptosis induction (Mi et al., 2007). Induction of 
activating caspases is an additional underlying mechanism responsible for apoptotic
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induction. The effect on particular activating caspases has been shown to be tissue specific 
(Tang and Zhang, 2004). For example, PEITC induced apoptosis through a caspase-3 in 
human cervical cancer cells (Yu et al., 1998), caspase-3 and -8 in human leukaemia cells (Xu 
Thomalley, 2001), whereas a caspase-9 and -3 dependent mechanism in ovarian cancer 
cells was observed (Satyan et al., 2006). Satyan and colleagues also reported that PEITC 
enhanced suppression of anti-apoptotic Bcl-2 and induction of pro-apoptotic Bax levels. 
PEITC triggers induction of caspase-9 by damaging mitochondria in cultured human bladder 
cancer cells (Tang and Zhang, 2005). However, the efficacy of apoptosis induction is 
inconsistent among ITCs and depends on the individual ITC lipophilicity (Tang and Zhang, 
2005). PEITC was a more effective apoptosis inducer compared with SFN in human lung 
cancer cells (Mi et al., 2007). Similarly, BITC and PEITC showed a stronger apoptosis 
induction than SFN in human bladder cancer cell lines (Tang and Zhang, 2005). A possible 
underlying mechanism of this feature is that reactivity of PEITC towards intracellular proteins 
is higher than for sulforaphane (Mi et al., 2007). Moreover, the induction of apoptosis by 
ITCs is selective, in that it is more toxic to cancer cells than normal cells, but the mechanism 
of this differentiation effect is not well understood.
Effect of phenethvl isothiocvanate on cell proliferation
Inhibition of cell proliferation associated with cell cycle arrest by PEITC is considered as 
another anticancer mechanism. An almost complete growth inhibition of Caco-2 cancer cells 
by PEITC has been reported which, however, had no adverse effect on cell viability 
throughout a 48-hr of incubation (Visanji et al., 2004). Studies to elucidate the mechanisms 
undertaken in human prostate cancer cells revealed that PEITC suppressed nuclear factor 
kappa B (NF-kB) growth factor transcription and Bcl-XL anti-apoptotic protein (Xu et al., 
2005). Induction of the growth arrest mechanism by PEITC leading to activation of DNA 
damage checkpoint and, consequently, cell cycle arrest of colon cancer cells has been
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described (Visanji et al., 2004). This isothiocyanate also suppressed unscheduled DNA 
synthesis in the hamster buccal pouch mucosa exposed to NMBA (Soit et al., 2003). 
Interestingly, a more potent effect was observed when PEITC was replaced by its metabolite 
PEITC-NAC in human hepatoma cancer cells (Hwang and Lee, 2006).
Effect of phenethvl isothiocvanate on phase III transporters
In general, phase I and phase II enzymes play central roles in the biotransformation, 
metabolism, elimination and detoxification, of xenobiotics introduced into the human body 
whereas phase III transport is as important, since it involves carrying of xenobiotics or of 
their metabolites towards excretion (Petzinger and Geyer, 2006). Phase III transporters, for 
example, P-glycoprotein (P-gp), multidrug resistance-associated proteins (MRPs), and 
organic anion transporting polypeptide 2 (0ATP2) are expressed in many tissues such as 
liver, intestine, kidney and brain (Xu et al., 2005). Suppression of P-gp or MRP transport by 
chemotherapeutic agents such as ITCs is believed to prolong and increase the anticancer 
potency of these compounds. It has been reported that accumulation of PEITC in human 
pancreatic carcinoma cell line increased in the presence of the MRP inhibitor MK571, 
suggesting that PEITC is a substrate for MRP (Hu and Morris, 2004). Similarly, the ability of 
PEITC to inhibit P-gp-mediated efflux of drugs has been reported (Tseng et al., 2002). 
However, it was demonstrated in subsequent studies that MRP2, and not P-gp, is responsible 
for the transport of PEITC (Ji and Morris, 2005), suggesting that another mechanism may 
account for the inhibitory effect of PEITC towards P-gp.
1.10 Toxicity of isothiocyanates
ITCs may cause toxicity, both in vivo and in vitro. Short chain length isothiocyanates such as 
allyl isothiocyanate (AITC) have been demonstrated to cause bladder cancer in male rats 
(Dunnick et al., 1982). In rats treated with AITC (40 mg/kg) for 4 weeks, the isothiocyanate 
gave rise to renal dysfunction as exemplified by an increase in urinaiy excretion of aspartate
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urineanimo-transferase, reduction in urine volume and a change in the specific gravity of uri 
(Lewerenz et al., 1988). The same researchers also reported toxicity for BITC in rats treated 
with high dose (50-200 mg/kg) for 4 weeks, causing reduction of weight gain in a dose- 
dependent manner, renal dysfunction and increase in the weight of many organs (Lewerenz et 
al., 1992). In the case of PEITC, no adverse effects were observed following administration of 
a diet supplemented with PEITC (0.75-6 pmole/g diet) for 13 weeks to F344 rats (Morse et 
al., 1989). Nevertheless, genotoxicity at high concentrations of PEITC has been reported in 
the Ames test employing Salmonella typhimurium, DNA damage in Escherichia Coli and 
micronucleus assay in HepG2 cells (Kassie and Knasmuller, 2000).
L ll  Pharmacokinetics and bioavailability of phenethyl isothiocyanate
In order to understand the mechanism of the chemopreventive action of isothiocyanates,
bioavailability and pharmacokinetic studies were undertaken by several laboratories. The fate
of glucosinolates very much depends on the adopted cooking process (Johnson and
Williamson, 2003). Raw cruciferous vegetable intake leads to further degradation of
glucosinolates inside the oropharyngeal or small intestine by plant myrosinase or may
eventually undergo hydrolysis by bacterial myrosinase in the colon. The degradation products
will then be excreted into faeces or may be partly absorbed into the bloodstream (Krul et al.,
2002). In the case of cooked vegetables, only bacterial myrosinase will bring about the
degradation process, so that the body is exposed mostly to glucosinolates. Accordingly,
urinary excretion of biomarker metabolites of ITCs was higher in humans that consumed raw
vegetables compared with cooked vegetables (Getahun and Chung, 1999). In the case of
isothiocyanates, they are absorbed from the small bowel and colon and the rate of absorption
from gastro-intestinal tract (GIT) to bloodstream and organs depends largely on their 
lipophilicity.
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The mercapturic acid pathway is the major route of ITC metabolism (Brusewitz et al., 1977; 
Chung et al., 1992; Mennicke et al., 1987). Although all types of ITC metabolites, i.e. ITC- 
cysteinylglycine, ITC-cysteine and mercapturate have been found in urine, such as following 
administration of sulforaphane (Al Janobi et al., 2006), metabolism is subject to species 
differences; a cyclic mercaptopyruvic acid conjugate was demonstrated as the major urinary 
metabolite of PEITC in mouse (Eklind et al., 1990), whereas following gluconasturtiin 
administration to humans the V-acetylcysteine conjugate was the most important metabolite 
(Chung et al., 1992). After metabolism, distribution of ITCs through the plasma membrane 
cannot occur in the glutathione conjugate form. Thus dissociation of ITC conjugates to the 
parent compounds is the rate limiting step of both their import or export from cells. About 9- 
15% of ITC conjugates was converted to free ITCs within 15 min when incubated with rat 
hepatocytes in the buffer (pH 7.4), depending on the individual structure of ITCs (Bruggeman 
et al., 1986).
The chemoprevention of ITCs is species- and tissue-dependent (Guo et al., 1992). 
Correspondingly, bioavailability of ITCs in the target organs may be an important key in 
determining their protection potency. For example, a synthetic homologue 6-phenylhexyl 
isothiocyanate (PHITC) was a more potent inhibitor of tumour development in lung than 
other tissues in A/J mice and F344 rats compared with PEITC due to its higher effective 
concentration in these organ (Conaway et al., 1999); this is possibly related to the higher 
lipophilicity of PHITC associated with the slower rate of elimination. Species differences in 
ITC bioavailability and, therefore, in their effectiveness has been described, presumably due 
to distinct pattern of XMEs, and tissue disposition and metabolism of ITCs in the different 
species (Chung et al., 1996).
In our laboratory, determination of plasma concentrations of SFN in Wistar albino rats 
revealed a rapid absorption and 82% absolute bioavailability after an oral dose of 2.8
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|imole/kg which, however, decreased with increasing dose, similar to the half-life and volume 
of distribution (Hanlon et al., 2008a). PEITC (19 nM) was detected in the plasma of human 
volunteers 3 hr after consumption of 200 g raw broccoli (Song et al., 2005) whereas plasma 
concentration of PEITC (928 nM) in human volunteer was detected following consumption of 
100 g watercress (Ji and Morris, 2003). In studies conducted in rats, PEITC was rapidly 
absorbed with peak plasma occurring at 0.4 and 2 hr following oral doses of 10 and 100 
pmole/kg, and oral bioavailability of PEITC was 115% and 93%, respectively (Ji and Morris, 
2005). However, these studies employed doses higher than human daily intake. In order to 
evaluate the pharmacokinetic characteristics of PEITC from a therapeutic point of view, 
pharmacokinetic studies following repeated administration are pivotal and remain to be 
investigated.
1 .1 2  Precision-cut tissue slices in the study of the regulation of xenobiotic-metabolising 
enzymes
The tissue slicing technique was first established in 1923, and in 1980 the Krumdieck sheer 
was developed, enabling widespread use of this technique for various purposes such as 
investigations into xenobiotic-metabolism, mechanism of toxicity, organ specificity (Catania 
et al., 2001; Harrigan et al., 2004; Olinga et al., 2001; Price et al., 1996), enzyme regulation 
(Pushparajah et al., 2008b) and enzyme-mediated toxicity (Lake et al., 1999; van de et al., 
2005). Slices have been prepared from a number of tissues including liver, kidney (Parrish et 
al., 1998) and lung (Pushparajah et al., 2007), and from a number of species, e.g. rat, (Lake et 
al., 1996), human, dog (Connors et al., 1996), guinea pig, monkey (Price et al., 1996), deer 
and cattle (Sivapathasundaram et al., 2004). Cryopreservation of tissue slices has been 
demonstrated as a feasible method to alleviate the scarcity of tissue (De Graaf et al., 2007; De 
Kanter et al., 1998; Fisher et al., 1993). Optimum slicing method in terms of suitable 
incubation medium, and slice thickness and diameter has been studied (Fisher et al., 1995; 
Parrish et al., 1995). Certainly, precision-cut tissue slice is a well-developed in vitro system. It
24
Chapter 1: Introduction
mimics features of the whole tissue and has a number of advantages over other in vitro 
systems, specifically isolated cell culture, i.e. maintaining the functional heterogeneity and 
cellular communication and interactions of the parent tissue (Toutain et al., 1998). Moreover, 
this system has been reported as a suitable model for investigation of xenobiotic-metabolising 
enzymes as exemplified by the stability of enzyme activities during culture period such as 
phase II enzymes (epoxide hydrolase, GST and glutathione reductase) which apparently were 
more stable than cytochrome P450 enzymes (CYPlAl, 1A2 and 2B1), in rat liver slices 
(Hashemi et al., 1999b; Hashemi et al., 2000).
Precision-cut slices have been successfully employed to establish modulation of cytochrome 
P450 and phase II enzymes by aliphatic isothiocyanates, such as sulforaphane and erucin, in 
rat liver and lung (Hanlon et al., 2008c; 2009a) as well as in human liver (Hanlon et al., 
2008b).
1.13 Project objectives
The objectives of current project are:
1. To ascertain whether PEITC influences xenobiotic-metabolising enzymes in various rat 
tissues and its impact in the bioactivation of chemical carcinogens.
2. To compare the ability of PEITC to modulate xenobiotic-metabolising enzymes in human 
and rat liver utilising precision-cut slices, and investigate underlying mechanisms.
3. To evaluate possible mechanisms of the chemopreventive effect of PEITC.
4. To set up and validate an LC-MS method for the determination of plasma concentrations of 
PEITC in rats treated with low doses.
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5. To determine the pharmacokinetic characteristics and absolute bioavailability of PEITC in 
rats following repeated intake.
26
Chapter 2: Materials and Methods
CHAPTER 2
Materials and methods
27
Chapter 2: Materials and Methods
2.1 MATERIALS
Abeam, Cambridge, U.K.
Rat anti-CYP3A and anti-quinone reductase (NQOl) primary antibodies 
ABGene, Epsom, Surrey, U.K.
Absolute™ QPCR ROX MIX, Absolute QPCR seal and Thermo-fast 96 detection plates
Ambion, W arrington, U.K.
RNAlater®-ICE
Amersham Life Sciences, Bucks, U.K.
ECL kit for Western blot immunodetection, Hybond-P polyvinylidene difluoride membrane and 
mini camera
BD Biochemicals, Oxford, U.K.
Bacto agar, 7-benzyloxyquinoline, 7-hydroxyquinoline and rat anti-CYPlBl and anti-CYP2B 
primary antibodies
Bio-Rad, Hertfordshire, U.K;
Aerylamide (40%), bis-acrylamide and Bio-Rad dye reagent 
Calbiochem, Lutterworth, U.K.
Rat anti-CYPlAl, anti-CYPlA2, anti-GSTAl-1, anti-GSTM 1-1 and anti-GSTPl-1 primary 
antibodies
Fischer Scientific, Leicestershire, U.K.
Acetonitrile (HPLC grade)
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Fluka, Bunchs SG, Switzerland
4-Chloro-7 -nitrobenzofuran
Gibco-Invitrogen Life Sciences, Paisley, U.K.
Dithiothreitol, DNase stop solution, dNTP mix (dATP, dCTP, dOTP and dTTP), Earle’s balance 
salt solution (EBSS), foetal calf serum, gentamicin, random hexamers, RNase-ffee water, RNase 
OUT, RPMI-1640 culture medium, RT buffer and Superscript II reverse transcriptase
Helena Biosciences, Gateshead, U.K.
12-Well plate
LKT Laboratories Inc., Minnesota, U.S.A.
Phenethyl isothiocyanate
Macherey-nagel GmbH & Co. KG., Diiren, Germany
Nucleospin® RNAII
Melford Laboratories Ltd., Ipswich, Suffolk, U.K.
Agarose, NADP and NADPH
Midwest Research Institute, Kansas, U.S.A.
Benzo(a)pyrene-4,5-epoxide and benzo(a)pyrene-4,5 -dihydrodiol
Moleknla, Dorset, U.K.
Hydroxypropyl-p-cyclodextrin
MWG, Ebersberg, Germany
Rat CYPlAl, CYP1A2, GYP IB 1, NQOl and 18*S rRNA primers and probes
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Phenomenex, Macclesfield Cheshire, U.K.
Synergi 4 micron minibore column (150x2 mm)
Premier Beverages, U.K.
Marvel dried skimmed milk powder
Promega, Southampton, U.K.
DNase buffer, DNase stop solution and RNase-free DNase 
Sigma-Aldrich, Dorset, U.K.
Ammonium persulphate, anti-goat, anti-mouse and anti-rabbit secondary antibodies, 
benzo(a)pyrene, bovine serum albumin, l-chloro-2,4-dinitrobenzene, D-glucose anhydrous, 
1,2-dichloro-4-nitrobenzene, D-saccharic acid, EDTA, 7-ethoxycoumarin, ethoxyresorufin, 
FAD, P-glucuronidase, glucose-6-phosphate dehydrogenase, glycerol, hydrocortisone 21- 
hemisuccinate sodium salt, 7-hydroxycoumarin, L-methionine, methoxyresorufm, p- 
mercaptoethanol, MOPS, MTT, Orange G dye, pentoxyresorufin, phenethyl isocyanate, 
phosphate buffer solution, Polaroid film, pyronin Y, reduced glutathione, resorufm, sodium 
hydrosulfite, sodium dodecyl sulphate (SDS), sulphatase, A.AW'W'-tetramethylethylenediamine 
and Tris base
Sarstedt, North Carolina, U.S.A.
96-Well plate
Toronto Research Chemicals Inc., North York, Canada
2-Amino-3 -methylimidazo [4,5-/] quinoline
Rat anti-epoxide hydrolase primary antibody was generously provided by Dr. Micheal Arand 
(University of Zurich, Zurich, Switzerland).
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2.2 METHODS
2.2.1 Rat husbandry
Male Wistar albino rats (200-250 g) were obtained from B & K Universal Ltd. (Hull, East 
Yorkshire, U.K.) and subjected to a 12-hr light-dark cycles in an animal care facility at 22±2 °C 
and 30-40% humidity. On arrival, rats were allowed to acclimatise for at least 24 hr before use. 
A maximum of four and a minimum of two rats were housed per cage. Food and water were 
provided ad libitum.
2.2.2 Preparation and culture of rat liver slices
Animals were killed by cervical dislocation and livers were immediately removed and put into 
slicing medium, ice-cold oxygenated EBSS solution containing 25 mM D-glucose. Liver slices 
(250-300 pm) thickness regulation, were produced using a Krumdieek tissue sheer (Alabama 
Research and Development Corp., Munford, AL, U.S.A) as shown in Figure 2.1. The sheer was 
filled up with ice-cold slicing medium. A hand-held core maker was used to achieve uniform 
tissue core (0.8 cm diametre). Slices were cultured in 12-well plates, each well containing 1.5 
ml of culture medium. To the culture medium, RPMI (1640) supplemented with 1 pM insulin, 
0.1 mM hydrocortisone 21-hemisuccinate sodium salt, 0.5 mM L-methionine, 5% foetal calf 
serum (FCS) and 50 pg/ml gentamicin, liver slices were placed 1 slice per well. The well plates 
were placed on a rotating shaker (105 rpm) (Stuart, Barloworld Scientific Ltd., Staffordshire, 
U.K.) in a humidified incubator, maintained at a temperature of 37 and in an atmosphere of 
95%02/5% CO2.
Liver slices were pre-incubated for 30 min and then briefly washed with 0.154 M KCl 
containing 50 mM Tris-HCl buffer, pH 7.4, prior to being transferred to fresh medium 
containing either 0.1% v/v DMSO as a vehicle control or the same volume containing the test 
compound, and incubated for 24 hr. Note that the final volume of DMSO did not exceed 0.5% 
as it can be toxic to the slice (Grondin et al., 2008). At the end of the incubation period, once
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again slices were washed with the buffer as described above. Using the hand-held homogeniser 
(NLD710HD power drill, Performance Power Tool, Chandlers Ford, U.K.), the slices were 
homogenised in the same buffer. Homogenate was finally stored at -80 °C until use. The 
metabolic viability of precision-cut liver slices was validated using 7-ethoxycoumarin as the 
model substrate (Hashemi et al., 1999).
2.2.2.1 Determination o f 7-ethoxycoumarin metabolism
The substrate 7-ethoxycoumarin (7-EC) was used to assess liver slice viability. Rat liver slices 
were incubated in 7-EC, dissolved in DMSO, at a final concentration of 50 pM. Slices and 
media were collected at each time point (0, 1, 2, 3, 4 and 6 hr), and formation of the 7-EC 
metabolites, i.e. free 7-hydroxycoumarin (7-HC), and its sulphate and glucuronide conjugates, 
was determined in the media. An aliquot of the medium (100 pi), was ineubated with 50 pi of 
0.5 M sodium acetate buffer (pH 5.0) or the same buffer containing either sulphatase (250 
U/ml), or p-glucuronidase (5000 U/ml), for 16 hr at 37 °C in a shaking water bath. Post 
incubation, 100 pi of an aliquot was mixed with 900 pi sodium acetate buffer in chloroform- 
resistant tubes. To each tube, 4 M HCl (250 pi) was added followed by 6 ml chloroform, and 
extraction into the organic layer was carried out for 30 min using 360° vertical rotator (Stuart 
Scientific , Essex, U.K.); 5 ml of the chloroform layer was removed and extracted with 3 ml of 
0.5 M glycine-NaOH, pH 10.5 for a further 30 min. The aqueous layer was used to determine 
7-EC metabolites by fiuorimetry (Cary Eclipse, Varian fiuorimeter), with the excitation and 
emission wavelengths set at 3 80 and 452 nm respectively, and both slit widths 
set at 5 nm. Each analysis was carried out in triplicate. Protein eontent of each liver slice was 
determined in all cases (see Section 2.2.2.3). 7-HC (0- 5 nM) was used as a standard and was 
carried through the same procedure.
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(c)
(b)
Figure 2.1 Preparation o f precision-cut tissue slice. The sheer (a) was kept at 4 °C for at
least 24 hr before use. All the parts were swabbed with 70% ethanol before assembly and the 
sheer was then filled with ice-cold oxygenated EBSS solution. Rat liver (b) was put into ice- 
cold oxygenated EBSS solution and cores were generated using a hand-held corer (c) having a 
diametre of 0.8 cm (d). Precision-cut liver slices were cultured in 12-well incubation plate 
containing 1.5 ml of supplemented RPMI medium (e). Finally, the plates were incubated in a 
humidified incubator at 37 °C on a rotating shaker (f).
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2.2.2.2 Preparation o f liver subfractions
Homogenate was prepared by pooling 10 slices in 1 ml of 0.154 M KCl containing 50 mM Tris- 
HCl, pH 7.4, the homogenising buffer. The microsomal supernatant (S9) was prepared by 
differential centrifugation at 9000 xg (Eppendorf, Hamburg, Germany) for 20 min at 4 °C. 
Supernatant was subsequently collected and stored at -80 °C until required. Fully thawed S9 
was used for further centrifugation at 105,000 xg for 45 min at 4 °C in a Beckman L7-65 
ultracentrifuge using a Ti.70.1 rotor. Supernatant and precipitated pellet were collected and 
microsomal pallet was resuspended to the same volume of S9 in homogenising buffer. Assays 
on the microsomal fractions were carried out on the same day in order to avoid loss of activity; 
on the other hand, cytosolic fractions were stored for a short period of time at -80 °C prior to 
analysis.
Fractions from whole tissue were prepared in the same way, except in the homogenate 
preparation procedure. Fresh or completely thawed tissue was briefly washed in homogenising 
buffer and then dabbed briefly to remove excess water. Subsequently, ice-cold homogenising 
buffer was added to achieve the final percentage of homogenate required: 25% (w/v) for liver 
89 or 50% (w/v) for lung and kidney 89. The tissues were scissor-minced prior to 
homogenisation, and microsomal and cytosolic fractions prepared as described for the slices.
2.2.23 Protein determination
Protein content was determined in both fractions utilising the protein-dye binding method 
(Bradford, 1976). Appropriate concentrations were obtained by dilution of microsomal (30 
times for sliees or 50 times for whole tissue) or cytosolic (50 times for slices or 80 times for 
whole tissue) fractions using 0.5 M NaOH prior to 10 pi of each sample being mixed in 96-well 
plates with 200 pi of diluted Bio-Rad dye reagent (1 to 5) in water. The blue colour of the dye- 
protein complex was allowed to develop for 5 min, and absorbance was read at 595 nm. A range 
of bovine serum albumin (B8A) standards (0-500 pg/ml) were conducted through the same 
procedure. Both sample and standard analyses were carried out in triplicate.
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2.2.2.4 Lactate dehydrogenase (LDH) leakage
Release of lactate dehydrogenase (LDH) was used as a marker for studying the cytotoxicity of 
PEITC in precision-cut tissue culture (Decker and Lohmann-Matthes, 1988). In the current 
study, LDH was measured using a cytotoxic detection kit '^"  ^ (Roche Diagnostic, Germany), 
according to the manufacturer’s instructions. Following a 24-hr incubation of liver slices with a 
range of PEITC concentrations, an aliquot (50 pi) of culture media or slice homogenate (1 slice 
per 1.5 ml of 50 mM phosphate buffered saline (PBS), pH 7.4) were used for analysis.
The following reagents were added to a 96-well plate:
Sample 50 pi
Phosphate buffer (50 mM, pH 7.4) 100 pi
Reaction mixture* 50 pi
* The mixture comprised 11.25 ml of dye and 0.25 ml of catalyst.
On completion of a 10-min incubation at room temperature, the reaction was terminated by 
addition of 25 pi stop solution, and absorbance was read at 492 nm using an ELISA reader. 
LDH released into the culture medium as percentage total LDH was calculated (% release = 
(LDH in medium/total LDH) x 100 where total LDH = LDH in medium + LDH in slice 
homogenate).
2.2.3 Determination of CYP450 activities
2.2.3.1 Ethoxy-, methoxy- and pentoxyresorufin O- dealky las es
Fluorimetric measurement of the 0-deethylation of ethoxyresorufin to resorufm was carried out 
as a marker for CYPlAl activity (Burke and Mayer, 1974). CYP1A2 and CYP2B1 activities 
were monitored using methoxyresorufin O-demethylase (MROD) (Nerurkar et al., 1993) and 
pentoxyresorufin O-depentylase (PROD) respectively (Lubet et al., 1985). On a Perkin-Elmer 
LS-5 luminescence spectrophotometer, excitation and emission wavelengths of 571 and 585 nm 
and slit widths at 10 nm and 2.5 nm respectively, were set.
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The following reagents were added into a cuvette:
0.1 M Tris-HCl buffer, pH 7.8 1.85 ml
Microsomal suspension^ 0.10 ml
0.1 mM Ethoxyresorufin^ 0.01ml
“ For liver slices, 10 slices were pooled in 1 ml whereas for whole tissues, 25% (w/v) for liver or 
50% (w/v) for lung and kidney microsomal preparation were used.
 ^ 0.1 mM Methoxyresorufm or 0.1 mM pentoxyresorufin were also used, all substrates being 
dissolved in 70% ethanol.
The reaction was initiated by the addition of 0.01 ml of 50 mM NADPH in 1% NaHCOg. The 
mixture was immediately mixed well by gentle inversion prior to placing in the cell holder, the 
reaction was followed for 10 min at 37 °C. In the kinetic mode, a slope was obtained for the 
reaction. A standard curve was constructed using 5 pi aliquots of 0.01 mM resorufm (in 70% 
ethanol) in 2 ml of 0.1 M Tris-HCl buffer, pH 7.8.
2.2.3.2 Benzyloxyquinoline 7-dealkylase
7-Benzyloxyquinoline (7-BQ) was used as a model substrate to assess CYP3A activity as it 
showed the highest degree of selectivity for the CYP3A subfamily (Stresser et al., 2002). The 
non-fluorescent 7-BQ is dealkylated by rat CYP3A1/3A2 or human CYP3A4 to the fluorescent 
metabolite, 7-hydroxyquinoline (7-HQ). Fluorimetric measurement of the production of 7-HQ 
was carried out as described previously (Stresser et al., 2000). Generation of NADPH is 
achieved by addition of glucose-6 -phosphate and NADP+ in the presence of glucose-6 - 
phosphate dehydrogenase. Excitation and emission wavelengths were set at 410 and 538 nm 
respectively, and both slit widths at 5 nm in a Perkin-Elmer LS-5 luminescence 
spectrophotometer. Each analysis was performed in triplicate.
The following reagents were added to a cuvette:
0.1 M Sodium phosphate buffer, pH 7.4 1 .75 ml
Microsomal suspension* 0.10 ml
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0.4 U/ml Glucose-6 -phosphate dehydrogenase 0.10 ml
3.3 mM Glucose-6-phosphate 0.05 ml
40 mM 7-BQ 0.01 ml
* For liver sliees, 10 slices were pooled in 1 ml whereas for whole tissues, 25% (w/v) for liver 
or 50% (w/v) for lung and kidney microsomal preparation were used.
The reaction was started immediately by addition of 0.01 ml of 1.3 mM NADP"  ^and carried out 
for 5 min at 37 °C; the slope of the kinetic reaction was recorded. A standard curve was 
constructed using 5 pi aliquots of 10 pM 7-HQ in 2 ml of 0.1 M sodium phosphate buffer, pH 
7.4. Each analysis was performed in triplicate.
2.2.3.3 p-Nitrophenol hydroxylase
;?-Nitrophenol hydroxylation has been widely used as a specific probe for mierosomal CYP2E1. 
The rate of 4-nitrocatechol production was spectrophotometrically measured in UV-visible 
range at 536 nm. 4-Nitrocatechol (0-0.5 mM) was prepared in 0.2 M potassium phosphate 
buffer, pH 6.8  and used as a standard. Both test samples (microsomal suspension from whole 
liver) and standards were put through the same procedure as described previously (Chang et al., 
1998; Reinke and Moyer, 1985).
To the incubation tubes, the following reagents were added:
Blank Sample/standard
0.2 M Potassium phosphate buffer, pH 6.8 0.75 ml 0.65 ml
1 mM Ascorbic acid (freshly made) 0.10 ml 0.10 ml
1 mM /7-Nitrophenol 0.10 ml 0.10  ml
0-0.5 mM 4-Nitrocatechol _ 0.10 ml
Mierosomal suspension (25%, w/v) 0.10  ml 0.10  ml
Samples and standards were incubated at 37 °C in a shaking water bath for 3 min. To sample 
tubes only, 0.1 ml of 10 mM NADPH in 1% NaHCOg was added. All the tubes were
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subsequently incubated for another 30 min following addition of 0.5 ml of 0.6 M perchloric 
acid. The reaction mixtures were then centrifuged at 2000 xg for 10 min. Prior to measurement 
of absorbance, 1 ml aliquot of the supernatant was mixed with 0.1 ml of 10 M NaOH. Each 
assay was carried out in triplicate.
2.2.4 Determination of phase II activities
2.2.4.1 Epoxide hydrolase
Epoxides are formed by CYP450 oxygenation of the double bond or aromatic ring molecules 
generating a highly strained ring which adducts to protein or DNA. Therefore, epoxide 
hydrolase is considered as an important detoxifying enzyme for epoxide. A fluorimetric assay 
was used to determine microsomal epoxide hydrolase activity (Dansette et ah, 1979). A Perkin- 
Elmer LS-5 luminescence spectrophotometer, set at excitation and emission wavelengths of 310 
and 385 nm with slit widths at 5 and 2.5 nm, respectively, was used.
The following reagents were added into a cuvette:
0.015 M Tris-HCl buffer, pH 8.7 1.90 ml
Microsomal suspension* 0.10 ml
2 mM Benzo(a)pyrene 4,5-epoxide in acetonitrile 0.01 ml
* For liver slices, 10 slices were pooled in 1 ml whereas for whole tissues, 25% (w/v) for liver 
or 50% (w/v) for lung and kidney microsomal preparation were used.
The reaction was started immediately by the addition of the microsomal suspension and 
monitored for 4 min at 37 °C; the slope of the kinetic reaction was recorded. A standard curve 
was constructed using 2 pi aliquots of 2 mM benzo(a)pyrene-4,5-/ra«.y-dihydrodiol (dissolved in 
acetonitrile) in 2 ml of 0.015 M Tris-HCl buffer, pH 8.7. Each analysis was performed in 
triplicate.
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2.2.4.2 Glutathione-S-transferase
Glutathione-5-transferases (GSTs) are soluble enzymes residing in the cytosolic fraction, and 
catalyse the detoxication of highly electrophilic chemicals by conjugation with endogenous 
glutathione. Different chemical probes were used to determine the activity of different GST 
isoforms: l-chloro-2,4-dinitrobenzene (CDNB), 1,2-dichloro-4-nitrobenzene (DCNB) and 4- 
chloro-7-nitrobenzofuran (NBD-Cl), using a published procedure (Habig et al., 1974).
CDNB and DCNB
In a cuvette, the following reagents were added:
Sample Reference
0.1 M Potassium phosphate buffer, pH 7.5 0.95 ml 1.00 ml
Cytosolic fraction^ 0.05 ml
25 mM CDNB or DCNB in 70% ethanol 0.05 ml 0.05 ml
Reduced glutathione^ 0.25 ml 0.25 ml
 ^For liver slices, 10 slices were pooled in 1 ml whereas for whole tissues, 25% (w/v) for liver or 
50% (w/v) for lung and kidney cytosol preparation were used.
 ^5 mM Reduced glutathione for CDNB or 25 mM for DCNB.
The absorption wavelengths were 340 nm for CDNB and 345 nm for DCNB.
NBD-Cl
In a cuvette, the following reagents were added:
Sample Reference
0.1 M Sodium phosphate buffer, pH 7.5 1.225 ml 1.235 ml
(containing 5 mM reduced glutathione)
Cytosolic fraction* 0.100 ml
4 mM NBD-Cl in 70% ethanol 0.075 ml 0.075 ml
* For liver slices, 10 slices were pooled in 1 ml whereas for whole tissues, 25% (w/v) for liver 
or 50% (w/v) for lung and kidney cytosol preparation were used. Increase in absorption was 
monitored at 419 nm.
In each assay, using different substrate, the buffer was maintained at 37 °C and the reaction 
mixture was well mixed by gentle inversion prior to the reaction was monitored at different
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wavelength for over 1 min. The activity was calculated using the molar extinction coefficients 
of 8.5, 9.6 and 14.5 mM'^cm'* for CDNB, DCNB (Habig et al., 1974) and NBD-Cl (Ricci et al., 
1994), respectively. Each determination was carried out in triplicate.
2.2.4.3 Quinone reductase
Quinone reductase (NQOl) is a major anticarcinogenic enzyme that facilitates the hydration of 
quinones to generate hydroquinones that further conjugate with glucuronic acid or sulphate and 
are excreted from the body. Determination of NQOl activity was based on a previous published 
method (Prohaska and Santamaria, 1988). Menadiol reduces 3-(4,5-dimethylthiazol-2-yl)-2,5- 
diphenyl tetrazoliumbromide (MTT) to the blue formazan, which can be measured over a broad 
range of wavelengths (550-640 nm).
In a cuvette, the following reagents were added:
25 mM Tris-HCl containing 0.083 % Tween 20 0.800 ml
100 mM MTT in ethanol 0.006 ml
50 mM NADPH in 1% NaHCO] 0.006 ml
Cytosolic fraction* 0.050 ml
*For liver slices, 10 slices were pooled in 1 ml whereas for whole tissues, 25% (w/v) for liver or 
50% (w/v) for lung and kidney cytosol preparation were used.
The reaction was initiated by the addition of 6.0 pi of 10 mM menadione, and production of 
formazan was determined at 610 nm using a Kontron spectrophotometer. NQOl activity was 
calculated from the initial rate of reaction, using the molar extinction coefficient of 11.3 mM'' 
cm ' (Prohaska and Santamaria, 1988). Each determination was carried out in triplicate.
2.2.4.4 Glutathione reductase
Glutathione reductase is an important enzyme that protects against oxidative damage by 
maintaining intracellular glutathione in the reduced state. The assay was carried out according to 
a published method (Carlberg and Mannervik, 1975).
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In a cuvette, the following reagents were added:
0.1 M Sodium phosphate buffer, pH 7.5 containing 0.1% EDTA 0.500 ml
0.3 mM FAD in water 0.025 ml
17.5 mM Oxidised glutathione in water 0.050 ml
Cytosolie fraction* 0.150 ml
* For liver slices, 10 sliees were pooled in 1 ml whereas for whole tissues, 25% (w/v) for liver
or 50% (w/v) for lung and kidney cytosol preparation were used.
The reaction was commenced by the addition of 50 pi of 2 mM NADPH in 1% NaHCOg. The 
formation of reduced glutathione was monitored at 334 nm in a Kontron spectrophotometer. 
Activity was calculated from the initial rate of reaction, using the molar extinction coefficient of
4.3 mM cm (Carlberg and Mannervik, 1975) and protein content. Each sample was analysed 
in triplicate.
2.2.5 Total glutathione concentration
Total glutathione was determined by monitoring the rate of reduction of 5,5'-dithiobis (2- 
nitrobenzoic acid), DTNB, recorded spectrophotometrically, at a wavelength of 412 nm 
(Akerboom and Sies, 1981).
Cytosolic fraction from whole tissue (25% (w/v) for liver or 50% (w/v) for lung or kidney), or 
tissue slices (10 slices per 1 ml cytosol) was prepared. To 0.1 ml of cytosol, an equal volume of 
2 M perchloric acid containing 4 mM EDTA was added. The pH was adjusted to 7.0 by addition 
of 0.1 ml 2 M potassium hydroxide containing 0.3 M MOPS. In order to remove the protein, 
the mixture was then eentrifuged at 3000 xg for 1 min. Oxidised glutathione (0-0.1 mM) was 
used as standard, and was put through the same procedure as the test samples.
In a cuvette, the following reagents were added:
0.1 M Potassium phosphate buffer, pH 7.0 containing 25 mM EDTA 0.85 ml
4 mg/ml NADPH in 0.1% NaHCO] 0.05 ml
41
Chapter 2: Materials and Methods
6 U/ml Glutathione reductase 0.02 ml
Standard/sample 0.10  ml
The reaction was initiated by the addition of 3.8 mM of 0.1 ml DTNB in 0.1% NaHCOj. The 
rate of formation of 5-thio-2-nitrobenzoate (TNB) was followed at 412 nm using a Kontron 
spectrophotometer.
2.2.6 Total cytochrome P450 content
Total cytochrome P450 content was determined as described previously (Omura and Sato, 
1964). An aliquot of 0.5 ml of hepatic microsomes 25% (w/v) was mixed with 2.5 ml of 0.1 M 
potassium phosphate buffer, pH 7.6. Sodium dithionite (about 1 mg/ml) was added in order to 
reduce the haem group o f the cytochrome P450. The mixture was then divided into two 
cuvettes, one serving as reference, and a baseline was run between 400 to 500 nm using a 
Kontron spectrophotometer. The sample cuvette was saturated with CO (a rate of about 1 
bubble per second for 20  seconds), and the spectrum between 400-500 nm was recorded.
Cytochrome P450 content was calculated using the molar extinction coefficient of 91 mM 
(Omura and Sato, 1964). Each determination was carried out in triplicate.
'em''
2.2.7 Western blot analysis
Westem blot analysis was used to determine the presence and relative abundance of individual 
protein as described earlier (Towbin et al., 1979). Dodecyl sulphate gel was used to separate 
polypeptides based on their size and shape. Immobilised polypeptides on the gel were then 
transferred to polyvinylidene difluoride membrane by electrophoresis. In order to reduce non­
specific protein interactions between the membrane and the antibody, the membrane was 
blocked with excess protein and then a specific primary antibody was used to bind to specific 
polypeptides. Finally, a second antibody directed against the first antibody was applied. The 
specific protein was then detected by the peroxidase reaction product. Molecular weight 
markers were used to define proteins of interest.
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2.2.7.1 Preparation o f SDS-polyacrylamide gels
All equipment used for gel preparation were carefully washed with reverse osmosis (RO) water 
to reduce any possibilities of residual impurity. Using a gel sandwich kit, a pair of short and 
spacer plates that were clipped together onto a vertical stand, a resolving gel was prepared as 
follows:
Milli-Q grade water 5.430 ml
Resolving gel buffer* 4  5qO ^ 1
Aerylamide (40%, w/v) 5 620 ml
5 z5-acrylamide (2%, w/v) 2.950 ml
A(/V;/Y',A'-Tetramethylethylenediamine (TEMED) 0.018 ml
Freshly prepared ammonium persulphate solution (10%, w/v) 0.180 ml
*The resolving gel buffer consisted of 1.5 M Tris-HCl, pH 8.8 containing 0.4% (w/v) sodium 
dodecyl sulphate (SDS).
To the gel sandwich, the resolving gel mixture was poured up to an appropriate height. Milli-Q 
water was then used to fill up the sandwich to ensure the gel remains smooth prevent it from 
drying. The gel was allowed to solidify for 10 min, and the water was then drained off. Using a 
filter paper, exeess water was removed. A stacking gel was prepared as follows:
Milli-Q grade water 7 15 ml
Stacking gel buffer* 2 50 ml
Aerylamide (40%, w/v) q -75
5w-acrylamide (2 %, w/v) 0.40 ml
A,7V;A'',A''-Tetramethylethylenediamme(TEMED) q.qI ^1
Freshly prepared ammonium persulphate solution ( 10%, w/v) 0.05 ml
♦The stacking gel buffer was prepared using 0.5 M Tris-HCl. pH 6.8 containing 0.4% (w/v) 
sodium dodecyl sulphate (SDS).
43
Chapter 2: Materials and Methods
Once the stacking gel was well mixed, it was poured on the gel sandwich, on top of the 
solidified resolving gel. The 8-well comb was carefully placed into the gel and care was taken to 
avoid the formation of bubbles; the gel was allowed to set for 30 min. The comb was removed 
and the gel was transferred to the electrode mount, which was placed into an electrode tank 
containing diluted running buffer (1 to 5) in milli-Q grade water. The running buffer comprised 
15.15 g Tris base, 72 g glycine and 5 g SDS in total volume of 1 litre.
2.2.7.2 Preparation o f samples
Protein content in the microsomal or cytosolic fractions from whole tissue or tissue slices was 
determined. Equal concentrations of protein in all samples was prepared by dilution with PBS, 
pH 7.5. An equal volume of the loading buffer was prepared freshly, and added to the protein. 
Loading buffer was prepared as follows:
Milli-Q grade water 4.80 ml
0.5 M Tris-HCl, pH 6.8 1.20 ml
Glycerol 0.96 ml
SDS ( 10%, w/v) 0.40 ml
P-Mercaptoethanol 0.48 ml
Pyronin Y (0.05%, w/v) 0.60 ml
In order to unfold the polypeptide structure, the protein mixtures were heated in a heating block 
at 95 °C for 5 min, and subsequently centrifuged at 3000 xg for 1 min. In the well, 10-30 pi of 
sample was loaded depending on the enzyme studied. The gel was run for 90 min at constant 
current of 40 mA and voltage at 120 V. Once the pink dye of the loading buffer reached the base 
of the plate, the gel was removed from the electrophoresis mount and was transferred to a 
polyvinylidene difluoride membrane.
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2.2.7.3 Transfer o f protein from gel to polyvinylidene difluoride membrane 
The proteins were transferred from gel to the membrane in order to be accessible to the 
antibody. Transfer buffer, a mixture of 16 mM Tris-HCl, 120 mM glycine and methanol (20%, 
v/v), was prepared and 1 litre was added into the electrophoresis tank. The gel was removed 
from the electrophoresis mount, and gently attached to a polyvinylidene difluoride membrane 
that was pre-wetted in methanol for 5 min, and subsequently immersed into the transfer buffer 
for 2-5 min. Blotting paper was added over the gel and the membrane, and subsequently the 
blotting paper was covered with scotchbrite pad. Note that 2 pieces of blotting paper were 
needed on each side and they should not be larger than the gel as that would allow the current an 
alternate route, hence making transfer inefficient. The smooth surface of a glass rod was lightly 
run across the entire surface to avoid air bubbles being formed between the gel and the 
membrane. A set of gels was placed in the cassette and transferred to the electrophoresis tank. A 
constant current of 100 mA and a voltage of 120 V for over 15 hr were used to horizontally 
transfer the proteins from the gel to the polyvinylidene difluoride membrane. Figure 2.2 shows a 
schematic representation of the gel stacking.
Black electrode (-ve) side
Scotchbrite pad
Blotting paper x2
Gel
Polyvinylidene dilluoridc membrane
Blotting paper x2
Scotchbrite pad
Red electrode (+ve) side
Figure 2.2 Schematic representation of the gel stacking procedure.
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2.2.7.4 Detection and visualisation
The membrane was transferred to a universal tube (50 ml). It should be pointed out that the 
protein side resided inside the tube in order to be fully exposed to the detection reagents, which 
were added consecutively. The following reagents (10 ml of each) were put in the tube:
•  Membrane blockins for 1 hr
Blocking reagent composed of 7.5% (w/v) Marvel milk powder in Tris-bufferred saline (TBS) 
pH 7.6 containing 0.1% (v/v) of Tween-20 (TBS-tween).
•  Wash
Membrane was washed with TBS-Tween 3 times (for 10, 5 and 5 min respectively).
•  Primary antibodv incubation for 1 hr
Membrane was incubated with the primary antibody diluted in 1% (w/v) Marvel milk powder in 
TBS-Tween.
•  Wash
Membrane was washed with TBS-Tween 3 times (for 10, 5 and 5 min respectively).
•  Secondary antibodv incubation for 1 hr
Membrane was incubated with the appropriate secondary antibody diluted in 1% (w/v) Marvel 
milk powder in TBS-Tween.
•  Wash
Membrane was washed with TBS-Tween 3 times (for 10, 5 and 5 min respectively).
The membrane was subsequently transferred to a flat plate, protein side facing upwards. 
Detecting reagents labelled A (1ml) and B (0.05ml) were mixed and pipetted over the entire 
membrane prior to incubation for 5 min. Using a mini camera kit, apoprotein bands were 
detected by placing the protein side against the base of the camera, taking care to avoid bubbles. 
Finally, the membrane was exposed to a Polaroid film for various times to achieve a well- 
defined band, which was then quantified by densitometry using the GeneTool software 
(Syngene Cooperation, Cambridge, U.K.).
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2.2.8 Ames mutagenicity test
The mutation assay was performed according to the published method (Maron and Ames, 
1983). The test uses amino acid-dependent strains of Salmonella typhimurium in which the 
bacteria lack the ability to synthesise the essential amino acid, histidine. Consequently, these 
bacteria can only grow in a medium supplemented with histidine. Back mutation, i.e. reversion 
of DNA to the original sequences in the presence of test compound, allows the bacteria growth 
to resume in a medium defieient in histidine. Moreover, the standard tester strains also contain 
other mutations that increase their ability to detect mutagens. At least, a doubling number of 
spontaneous reversion rate and a coneentration-dependent effect are the criteria for a positive 
mutagenic response.
2.2,8.1 Confirmation o f the bacterial tester strain (YG1024) characteristics 
Histidine requirement
To the surface of bottom agar plate, 2 ml of top agar containing 0.1 ml of 0.1 M L-histidine and 
0.5 mM biotin was poured and allowed to solidify. Fresh culture was streaked across the plate 
using a flamed loop and the plates were incubated overnight in an oven at 37 °C. The same 
procedure was repeated in the absence of histidine. Bacteria growth was anticipated in 
histidine/biotin plates while no growth was expected in control.
Presence o f the rfa mutation
Partial loss of the lipopolysaccharide barrier increases permeability of large compounds that 
would otherwise unable to penetrate the cell wall. Sensitivity to crystal violet was carried out to 
assess rfa mutation, a characteristic of the standard bacterial strains. Fresh culture (0.1 ml) was 
added into 2  ml of top agar, supplemented with 0.5 mM L-histidine and 0.5 mM biotin, and then 
vortex-mixed prior to pouring onto solidified bottom agar. The plates were allowed to solidify 
and then were centrally embedded with a sterile filter paper (1 cm diameter), to which 10 pi of 1 
mg/ml solution of crystal violet was added. The plates were incubated for 48 hr at 37 °C in an
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oven. A clear zone of inhibition around the disc indicated the presence of the rfa mutation as 
crystal violet can diffuse into the bacteria leading to death.
Presence ofR-factor
The presence of the ampicillin-resistance factor was also assessed since it is unstable and can be 
lost from the bacteria. The R factor plasmid makes strains more responsive to a variety of 
mutagens, and it carries an ampicillin resistance gene, so that ampicillin resistance indicates that 
the strains retain the plasmid. An aliquot (0.1 ml) of freshly grown bacterial was added into 2 ml 
of top agar containing 0.5 mM biotin and 0.5 mM histidine, and then vortex-mixed prior to 
pouring on to solidified bottom agar. The plates were allowed to solidify and then were centrally 
embedded with a sterile filter paper (1 cm diameter), to which 10 pi of 8 mg/ml ampicillin 
solution in 0.02M NaOH was added. The plates were incubated for 48 hr at 37 °C in an oven. In 
the presence of the plasmid there should be no clear zone of inhibition around the disc.
Bacterial viability testing
Serial dilution of freshly grown bacterial strain YG1024 was conducted using nutrient broth, 
until a final dilution of 1.10 was achieved. Subsequently, 0.1 ml of diluted culture was added 
into 2 ml top agar supplemented with 0.5 mM L-histidine and 0.5 mM biotin and then poured 
onto bottom agar. After the plates solidified, they were incubated at 37°C for 48 hours in an 
oven and the number of colonies counted using a Gallenkamp colony counter.
2.2.8.2 Preparation o f the media 
Toy a2 ar
To 250 ml of RO water, 1.5 g of agar No 1 (0.6 %) and 1.25 g of NaCl (0.5 %) were added. The 
mixture was sterilised by autoclaving under pressure (15 Ib/in^) at 121 °C for 15 min. Sterile 
top agar was then stored at 4 °C, and was placed in a microwave oven to melt when required. 
The temperature of top agar was maintained at 45-50 °C in a water bath while being used.
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Bottom a2 ar
Bottom agar was prepared and plated up in petri dishes, whieh were stored at 4 °C until 
required. Bacto agar (15 g) was added into RO water (930 ml), and the mixture was subjected to 
sterilisation by autoclaving under pressure (15 Ib/in^) at 121 °C for 15 min. Subsequently, 20 ml 
of Vogel-Bonner (VB) salt and 50 ml of 40% (w/v) of D-glucose were added into the warm 
sterile solution of bottom agar. The mixture was mixed carefully, poured into petri dishes and 
allowed to solidify.
Vosel-Bonner medium E  (5Ox VB salt)
To prepare VB salt the following reagents were mixed:
RO water 670 ml
Magnesium sulphate (MgS0 4 .7H2 0 ) 10 g
Citric acid monohydrate 100 g
Potassium phosphate, dibasic (anhydrous) (K 2 HPO 4 ) 500 g
Sodium ammonium phosphate (NaNH4HP0 4 .4H2 0 ) 175 g
The salts were completely dissolved by placing on a heating plate in the presence of magnetic 
stirrer, and then mixture was autoclaved.
Nutrient broth preparation
To 1 litre of RO water, 25 g of nutrient broth was dissolved. The solution was then poured into 
20-ml glass bottles and autoclaved. Sterile broth was kept at 4°C until required.
2.2.8.3 Preparation o f bacterial culture
Fresh cultures of YG1024 were prepared from frozen permanents. Using a flamed loop, frozen 
permanent was scraped from the surface and inoculated into sterile nutrient broth (10 ml) 
containing ampicillin in 0.02 M NaOH (50 pg/ml). The inoculated nutrient broth was then 
incubated for 11-14 hr in a shaking water bath at 37 °C. The nutrient broth was wrapped with
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aluminium foil throughout the experiment to protect it from direct fluorescent light. After 
incubation, the fresh culture was removed from the incubator and kept at room temperature 
while being used.
Frozen permanents were prepared in the same way; however, after incubation, DMSO was 
added (90 pl/ml nutrient broth) to act as a cryoprotectant. The fresh culture was then stored at - 
80 °C.
2.2.8.4 Spontaneous reversion rates
Spontaneous reversion rate was determined in each experiment and expressed as the number of 
spontaneous revertants per plate. It was determined in the presence of DMSO, the vehicle used 
for IQ.
2.2.8.5 Preparation o f Aroclor 1254-inducedS9
Aroclor 1254 was administered to rats (500 mg/ kg) intraperitonially. On the 5* day after 
administration, rats were killed, livers were removed immediately and put into ice-cold 0.154 M 
KCl. S9 from whole liver was then prepared as described in Section 2.2.1.2 and stored at -80 °C 
until required.
2.2.8.6 Test system
To sterile tubes, the following reagents were added:
Top agar containing 0.5 mM biotin and 0.5 mM histidine (45-50 °C) 2.0 ml
Fresh bacteria culture 0.1 ml
Test compound or vehicle 0.1 ml
Fresh metabolic activation system (S9 mix) 0.5 ml
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The mixtures were then vortexed and plated immediately onto bottom agar, when the agar
solidified the plates were inverted and incubated at 37 °C for 72 hr in an oven. Colonies were
counted using a Gallenkamp colony counter.
2.2.8.7 Metabolic activation system (S9 mix)
The metabolic activation system was prepared as follows:
0.33 M Potassium chloride 10 %
Liver S9 (25%, w/v) 10%
0.08 M Magnesium chloride 10 %
Cofactor solution 20 %
NADP+ (20 pmol/ml) and glucose -6 - phosphate (25 pmol/ml)
0.2 M Potassium phosphate buffer 50 %
2.2.9 Determination of mRNA levels in liver slices
Quantification of mRNA levels was accomplished by using reverse transcription (RT) real time- 
PCR (RT-PCR). The first step, reverse transcription, converts mRNA into eomplementary DNA 
(cDNA) that is then amplified by real-time PCR. The real-time PCR technique is widely used, 
replacing the traditional PCR which is less sensitive and accurate, and also more laborious. RT- 
PCR allows amplification of minimal nucleic acid segments to generate a huge number of exact 
copies of DNA which may be detected by fluorescence.
2.2.9.1 RNA Extraction
Slices were prepared as described in Section 2.2.2. Optimum incubation time was established 
and subsequently used to study the effect of PEITC on the mRNA levels of the genes of interest; 
three slices per replication were used (n=3). In each experiment, all slices were obtained from 
the same animal to avoid inter-individual variation. At the end of the incubation period, slices 
were washed thoroughly to remove residual test media, and rapidly frozen utilising liquid 
nitrogen, prior to storage at -80 °C. RNAlater ice was used for long- term storage, 0.3ml per
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three slices, to protect RNA from degradation. The slices were thawed at -20 °C for 24 hr prior 
to homogenisation utilising UVed hand-held micropestles. RNA extraction was carried out 
according to NucleoSpin® RNA II, total RNA isolation, system. All apparatus and solutions 
were RNase-free to minimise degradation of RNA. Finally, pure RNA was eluted by RNase- 
free water and stored at -20 °C prior to quantification.
2.2.9.2 RNA quality determination
Purity of RNA is essential for investigation of gene expression. To assess purity, a ratio of 
absorbances at 260 to 280 nm was determined using a spectrophotometer (Nanodrop; LabTech, 
East Sussex, U.K.); a ratio >1.8 indicated acceptable RNA purity. Moreover, a second check 
was carried out involving electrophoresis analysis. RNA extract aliquots (2pl) were mixed with 
Orange G dye (5 pi) and loaded onto 1% agarose gel containing 5 pg/ml ethidium bromide in Ix 
TAB, a mixture of 40 mM Tris base, 40 mM acetic acid and 1 mM EDTA. On the gel, RNA 
migrates according to size and the 285' and 185" rRNA bands were visualized by ethidium- 
bromide staining. Sharp ribosomal bands at 285" and 185' were expected, and a 285': 185' ratio 
greater than 2.0 was considered to denote high quality intact RNA (Vendrely et al., 1968). 
Nanodrop was also used to determine the concentration of RNA (ng/ml).
2.2.9.3 DNase I  treatment
Since the method is very sensitive and will amplify any contaminating genomic DNA, 
elimination of DNA is indispensable. Concentration of RNA was calculated, and 5 pg was put 
through the DNase I treatment prior to cDNA synthesis. The reaction mixture for the DNase I 
treatment eomprised 2 pi of lOx DNase buffer, and 2 pi of enzyme, RNase-free DNase I. 
RNase-free water was added to make up the total volume to 20 pi; however, this also included 2 
pi of DNase stop solution (20mM EGTA, pH 8.0) which was added at the end of the incubation 
of these mixtures at 37 °C for 30 min in an oven. After addition of the DNase stop solution, the
52
Chapter 2: Materials and Methods
mixture was incubated once again at 65°C for 10 min in the pettier thermal cycler (MJ Research 
PCT-225) to inactivate the DNase.
2.2.9.4 cDNA synthesis
cDNA synthesis was further carried out by mixing 1 pg (4pl) of DNased RNA with 5 pi of 
RNase-free water, 1.5 pi of 10 mM dNTPs, and 1.5 pi of 150 ng/pl random hexamers. The 
mixtures were incubated at 65 C for 5 min in pettier thermal cycler and cooled down on ice for 
at least 2 min.
In the mean time, the RT mix (RT+) was prepared as a bulk mix. The mixture for one RNA 
sample involved addition of 0.75 pi of RNase-free water, 4 pi of 5x RT buffer, 2 pi of 0.1 M 
DTT, 1 pi of 40 U/pl RNase OUT RNase inhibitor, and 0.25 pi of 200 U/pl Superscript II 
reverse transcriptase. A bulk mix for control RT mix (RT-) was also prepared as described 
above by omitting addition of RNase OUT and Superscript II reverse transcriptase. Any 
amplification of the control will indicate the presence of a residual contaminating genomic DNA 
in the RNA sample preparation. To 12 pi of DNased-RNA, 8 pi of the mixture (RT+ or RT- 
mix) was added and the new mixture was incubated at 25 °C for 10 min followed with 50 min at 
42 C, and finally 15 min at 70 °C in PCR machine. The samples were stored at -20 and were 
mixed with 80 pi of RNase-free water before use.
2.2.9.5 Quantitative PCR
Primer and probe sets for rat CYPlAl, 1A2, IB l and NQOl genes were designed using Primer 
Express® version 2 (Applied Biosystems, Warrington, U.K.). A housekeeping gene, 185 rRNA, 
was used as an internal standard in order to normalise gene quantification. Dual label probe 
was labelled with the reporter dye (6 -FAM) at the 5'-end. The 3'-end was labelled with the 
TAMRA quencher. Custom oligonucleotide sequences of the primers and probes are as follows:
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CYPlAl
5' primer : GCCTTCACATCAGCCACAGA 
3' primer : TTGTGACTCTAACCACCCAGAATC 
Probe : TGGCCGTCACCACATTCTGCCTT
CYP1A2
5' primer : AAGCGCCGGTGCATTG 
3' primer : TGCAGGAGGTAGGCTAAGAAG 
Probe ; CCCGGCCAAGTGGGAAGTCTTCC
CYPIBI
5' primer : TTCAGCTGTTCAAACGAAGCA 
3’ primer : TCCCAAAGTTGAAAGCTTACGTTA 
Probe : CGAGTTATGAGGGAGAAAAAGGTTTGCCA
NQOl
5 'primer : GAGGTTCAAGAGGAGCAGAAAAAG 
3 'primer : GTTGTCGGCTGGAATGGACTT 
Probe : TTTGGCCTTTCTGTGGGCCATCA
185 rRNA
5' primer : CGGCTACCACATCCAAGGAA 
3' primer : GCTGGAATTACCGCGGCT 
Probe : TGCTGGACACAGACTTGCCCTC
Probes and primers were diluted to the appropriate concentrations using O.lx TAE. Bulk mix 
was prepared for a number of genomic standards and cDNA of RNA samples (from RT+)
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including its individual control (from RT-); the volumes given below were used for one RNA
sample:
Forward primer (10 pmol/pl stock) 1.0 pi
Reverse primer (10 pmol/pl stock) 1.0 pi
Probe (5 pmol/pl stock) 0.5 pi
RNase-free water 5.0 pi
Taqman® Universal PCR MasterMix 12.5 pi
To each well of the 96-well plate, 20 pi of bulk mix and 5 pi of cDNA or genomic standard 
were added. The samples were assayed in triplicate, whereas genomic standards were analysed 
in duplicate. The reaction plate was well sealed with an optical adhesive cover, and then spun 
using a centrifuge (Eppendorf, Centrifuge 5810, Hamburg, Germany) at 1000 xg for 2 min prior 
to loading onto the ABI Prism 7000 sequences detection system (Applied Biosystem, 
Warrington, U.K.) as shown in Figure 2.3. Using real-time PCR, gene expression and quantity 
(number of copies) were determined. Cycle by cycle fluorescent detection of accumulated PCR 
product was performed under the thermo cycler settings indicates in table 2 .1.
Table 2.1 Thermal cycling conditions for quantitative PCR.
Stage Temperature (°C) Time Cycles
1 50 2 minutes 1
2 95 10 minutes 1
95 15 seconds
3 40
60 1 minute
A threshold cycle (Ct) was then set in the exponential phase of the amplification to obtain the 
most accurate reading. The rate at which the cycle number reached the established threshold
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determined the quantity of DNA present in each sample; the earlier the threshold was achieved 
indicates the more DNA.
2.2.9.6 Genomic DNA standard
Absolute PCR quantification can be achieved using a standard curve constructed by amplifying 
known amounts of target DNA. Rat genomic DNA standard was prepared and serial dilution 
was performed to provide a stock solution of 0 to 10^  single strand per 5 pi using O.lx TAE. The 
stock solution was kept at -20  °C for long-term storage.
Figure 2.3 The ABI Prism 7000 sequences detection system (Applied Biosystem, 
Warrington, U.K.).
2.2.10 Statistical analysis
The Student’s t-test was employed to evaluate statistically significant differences between 
control and treated groups. A p-value was calculated and statistical significance is achieved 
when probability (p) is less than 0.05.
56
Chapter 3: PEITC-modulated hepatic xenobiotic-metabolising enzymes
CHAPTER 3
PEITC-modulated xenobiotic-metabolising 
enzymes in rat and human hepatic precision-cut
slices
57
Chapter 3: PEITC-modulated hepatic xenobiotic-metabolising enzymes
3.1 Introduction
Carcinogenesis is a multi-stage process of cancer development having three well-defined 
stages, namely initiation, promotion and progression. ITCs have attracted a lot of interest since 
it became evident that their chemopreventive mechanisms involve suppression of 
carcinogenesis at every stage (lARC, 2004; Nishikawa et al., 1999). Many biologically active 
ITCs are likely to influence the initiation stage by modulating the metabolic conversion of pro­
carcinogens to their DNA-reactive intermediates or by facilitating their detoxification (Hecht, 
1999; Nishikawa et al., 1999). Xenobiotic, including carcinogen, metabolism occurs in two 
distinct phases. During phase I reactive intermediate(s) of the carcinogen may be produced, 
most frequently generated by oxidation, which subsequently may be neutralised by 
conjugation reactions, catalysed by phase II enzymes, or interact covalently with cellular 
proteins, RNA and DNA leading to toxicity/earcinogenicity (Schoket et al., 2001). Many 
studies have revealed that suppression of activity or down regulation of phase I enzymes 
promotes cancer prevention (von Weymam et al., 2006). On the other hand, induction of phase 
II enzymes represents a promising strategy for defence against eancer (Mandlekar et al., 2006). 
For instance, the chemopreventive effects of fiavonoids have been attributed to inhibition of 
cytochrome P450 enzymes such as CYPlAl/2, 2E1 and 3A4, as well as stimulation of phase 
II detoxifying enzymes, such as UDPGT, GST and NQOl (Moon et al., 2006). Moreover, 
human deficiencies in phase II enzymes activity, specifically GST, have been identified ancf 
associated with increased colon cancer risk (Wilkinson and Clapper, 1997). Therefore, 
modulation of xenobiotic-metabolising enzymes by PEITC may contribute to its 
anticarcinogenic effect and merits thorough investigation.
Precision-cut tissue slice is a well-developed in vitro system and employed by many 
researchers because it mimics features of the whole tissue (Buettner et al., 2005; De Graaf et 
al., 2007; Hanlon et al., 2008b; Hashemi et al., 1999; 2000; Lake et al., 1997; Moronvalle- 
Halley et al., 2005; Pushparajah et al., 2007; Umachandran et al., 2004; 2006; Vickers, 2008).
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Tissue slices resemble an organ mini-model where metabolic activity of all tissue cell types 
and tissue architecture are preserved (Vickers, 2008). This in vitro technique has been used 
intensively for studying drug metabolism, toxicity and chemical transport, demonstrating good 
correlations with the corresponding parameters measured in vivo (De Graaf et al., 2007; 
Drahushuk et al., 1996; Olinga et al., 2001). Moreover, it has been successfully used with 
different tissues as well as animal species, including rat (Hashemi et al., 1999) and human 
liver (Hanlon et al., 2008a; Pushparajah et al., 2008b). The objective of the current study was 
to investigate the effect of PEITC on xenobiotic-metabolising enzymes in rat and human 
hepatic precision-cut slices.
3.2 Methods
3.2.1 Effect of PEITC on xenobiotic-metabolising enzymes in rat and human liver slices
Fresh human livers that could not be used for transplantation purposes were obtained from the 
UK Human Tissue Bank (The Innovation Center, Leicester, U.K.). The liver sections were 
transported to the university in cold University of Wisconsin (UW) preservation solution on 
ice, about 8-12 hr after removal from the Donors. Prior to use, the UW solution was decanted 
and the liver sections were washed carefully with culture medium. All Donors were of 
Caucasian origin, and further information for each individual is provided in Table 3.1.
As described in Section 2.2.2, rat and human liver slices were prepared using a Krumdieck 
sheer and incubated in culture medium containing PEITC (0.5-50 pM) or the corresponding 
volume of DMSO for 24 hr. At the end of the incubation period, slices were removed and 
microsomal and cytosolic fractions were prepared by differential centrifugation (see Section 
2.2.2.2). In the microsomal fraction, EROD, MROD and PROD were determined as described 
in Section 2.2.3.1 and BOD and epoxide hydrolase as described in Sections 2.2.3.2 and 2.2.4.1 
respectively. Cytosolic GSTs were monitored using as accepting substrates CDNB, DCNB
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and NBD-Cl; NQOl, glutathione reductase, and total glutathione levels were determined in 
the cytosolic fraction (see Sections 22.4.2-2.2.4.4 and 2.2.5, respectively). Finally, total 
protein concentration and expression of enzymes at the protein level using Western 
immunoblotting were determined as described in Sections 2.2.2.3 and 2.2.7 respectively. 
Leakage of LDH in the culture medium was determined in order to evaluate the cytotoxicity of 
PEITC in the tissue eultures (Section 2.2.2.4). The metabolic viability of the tissue slices was 
assessed by measuring 7-ethoxycoumarin (7-EC) metabolism as the model substrate (see 
Section 2.2.2.1).
Table 3.1 Liver Donor information.
Information Donor 1 Donor 2 Donor 3 Donor 4
Age (yr) 26 54 67 64
Gender Male Female Female Male
Cause of death Head injury Intracranial
bleed
Hypoxic brain 
iniury
Head injury
Medical
history
Schizophrenia Unremarkable Diabetic, 
Diet control, 
Hyperlipidaemia
Depression, High 
cholesterol. 
Inguinal hernia 
(2007), Gastric 
ulcer (2008)
Drug history Unremarkable Unremarkable Unremarkable Simvastatin,
Ranitidine,
Paracetamol,
Amlodepine,
Cefotaxime,
Metoclopramide,
Bisoprolol
Life style 
history
Binge drinker. 
Ecstasy and 
cannabis in 
past
Unremarkable Unremarkable Unremarkable
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3.2.2 Modulation of xenobiotic-metabolising enzymes mRNA levels by PEITC in rat liver 
slices
Preparation of rat liver slices was carried out as already described (Section 2.2.2). Firstly, the 
optimum incubation period to achieve the maximum induction of mRNA transcription was 
defined; to obtain this objective slices were incubated (0-24 hr) with 1 pM PEITC and mRNA 
levels were determined. Subsequently, the optimum incubation time was applied to assess 
modulation of CYPIA, IB l and NQOl mRNA levels following incubation with various 
concentrations of PEITC. On completion of incubation, slices were removed from the medium 
and washed thoroughly with ice-cold 0.1 mM potassium phosphate buffer in 0.154 M KCL to 
remove excess medium. For each concentration three pools were prepared, each containing 
three slices. Each replicate was immersed into RNAlater ice (100 pi per slice), snapped frozen 
in liquid nitrogen and stored at -80 °C. The samples were thawed at -20 °C for at least 24 hr 
prior to RNA extraction and quantification (Sections 2.2.9.1 and 2.2.9.5). BaP (0.1 pM) was 
used as a positive control, whereas 185 rRNA served as internal control to normalise mRNA 
quantity.
3.3 Results
3.3.1 Viability of rat and human liver slices
7-EC metabolism was used as a model substrate to assess the metabolic viability of slices, as 
this substrate requires metabolism by both phase I and II enzymes. The protein content of liver 
slice homogenates retrieved from tissue cultured over the incubation period remained 
relatively constant (Fig. 3.1) and the value in rat was in the same range as demonstrated earlier 
in our laboratory. In both rat (Fig. 3.2) and human (Fig. 3.3) liver slices, the metabolism of 7- 
EC was time-dependent. The sulphate conjugate of 7-HC was the major metabolite of 7-EC in 
rat, whereas in human the glucuronide predominated. The glucuronide conjugate and free 7- 
HC were also produced by rat liver slices but at lower levels. Finally, total 7-EC metabolism
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by human liver slices from Donor 4 (Fig. 3.3B) was slightly higher than that from Donor 3 
after a 4-hr incubation (Fig. 3.3A).
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Figure 3.1 Homogenate protein concentration in rat and human liver slices following 
incubation time. Rat and human liver slices were incubated in medium containing 7- 
ethoxycoumarin (50 pM). Protein content in individual slices was determined at each time 
point. Results are presented as mean ± SD where n=3 slices per time point.
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Figure 3.2 Metabolism of 7-ethoxyconmarin by precision-cut rat liver slices. Rat liver 
slices were incubated in medium containing 7-ethoxycoumarin (50 pM), and the metabolites 
present in the medium were determined at each time point. Results are presented as mean ± 
SD where n=3 slices per time point.
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3.3.2 Toxicity of PEITC in cultured rat liver slices as exemplified by LDH leakage
LDH leakage was used to evaluate the toxicity of PEITC in tissue slices. Incubation of liver 
slices in culture medium containing various PEITC concentrations (0-50 pM) for 24 hr 
revealed a statistically significant increase in LDH only at the highest concentration employed 
(Fig. 3.4).
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Figure 3.3 Metabolism of 7-ethoxycoumarin by precision-cut human Donor 3 (A) and 
Donor 4 (B) liver slices. Human liver slices were incubated in medium containing 7- 
ethoxycGumarin (50 pM), and the metabolites present in the medium were determined at each 
time point. Results are presented as mean ± SD where n=3 slices per time point.
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Figure 3.4 Toxicity of PEITC to rat liver slices. LDH leakage was measured in rat liver 
slices incubated in culture medium containing PEITC (0-50 pM) for 24 hr. Results are 
presented as mean ± SD of triplicate slices, each analysed in duplicate. *, ?<0.05.
3.3.3 Modulation of cytochrome P450 enzyme activities by PEITC in rat liver slices
Exposure of rat slices to PEITC resulted in a marked decrease in MROD activity, which was 
statistically significant at concentrations higher than 1 pM (Fig. 3.5). The decrease in activity 
was paralleled by marked concentration-dependent drop in CYP1A2 apoprotein levels (Fig.
3.6). No statistically significant changes were evident in the other enzyme activities studied. 
At the apoprotein level, however, CYP2B and CYP3A2 levels declined at the highest (50 pM) 
PEITC concentration, whereas CYPlAl levels were suppressed at concentration higher than 1 
pM.
3.3.4 Modulation of cytochrome P450 enzyme activities by PEITC in human liver slices
Human liver slices from 4 donors were incubated for 24 hr with PEITC (0-50 pM) under the 
same conditions as the rat liver slices. In Donor 4 the concentrations of PEITC employed were 
changed in order that the effects of PEITC at higher concentrations (10-40 pM) are better 
defined.
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CYPlAl expression
There were no major differences in basal EROD activity, a marker for CYPlA l, among the 4 
donors. PEITC in Donors 1 and 4 decreased at all concentrations of PEITC studied. In Donor 
3 the same decrease was manifested only at high concentrations, whereas in Donor 2 
statistically significant reduction was observed only at the concentrations 1 and 5 pM (Fig.
3.7). In contrast, CYPlAl apoprotein levels were markedly increased in Donors 1 and 4, and 
modestly in Donor 3, but at the low concentrations only. No clear rise in apoprotein levels was 
seen in Donor 2, but a decrease at the highest PEITC concentration only (Fig. 3.8A).
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Figure 3.5 Effect of PEITC on cytochrome P450 enzyme activities in rat liver slices.
Liver slices were incubated in culture medium containing PEITC (0.5-50 pM) for 24 hr. 
Values are presented as mean ± SD of three replicates, each containing 10 slices/ml 
*,P<0.05.
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Figure 3.6 Effect of PEITC on cytochrome P450 apoprotein levels in rat liver slices. Liver 
slices were incubated in culture medium containing PEITC (0-50 pM) for 24 hr. Microsomal 
proteins were isolated and equal amounts were loaded on to 10% (w/v) SDS-PAGE and then 
transferred electrophoretically to Hybond-P polyvinylidene difluoride membrane. The 
immunoblot analysis was carried out by exposure to mouse anti-rat CYPlAl/2, goat anti-rat 
CYP2B or rabbit anti-rat CYP3A2 primary antibodies followed by the appropriate peroxidase- 
labelled secondary antibody. Each lane was loaded with 30 pg (CYPlAl, 2B and 3A2) or 15 
48 (CYP1A2) of total protein. Values above blots show % levels of optical density of each 
band relative to control.
CYPIA2 expression
Donor 4 was the most sensitive, with MROD activity, a substrate used for monitoring 
CYP1A2 activity, diminishing at all concentrations, whereas in Donors 1 and 3 activity was 
depressed at PEITC concentrations >5 pM (Fig. 3.9). In Donor 2, activity was suppressed only 
at the concentration range of 0.5-5 pM. Immunoblot analysis revealed a decrease in CYP1A2 
apoprotein levels in all donors, with Donors 3 and 4 being the most sensitive. However, in 
Donor 4 a rise in apoprotein levels was seen at the two lowest PEITC concentrations used 
(Fig. 3.8B). No major differences in basal MROD activity were observed among the 4 donors.
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Figure 3.7 Effect of PEITC on EROD activity in human liver slices. Liver slices were 
incubated in culture medium supplemented with PEITC (0.5-50 pM in Donors 1, 2 and 3, and 
0.5-40 pM in Donor 4) for 24 hr. Values are presented as mean ± SD of three replicates, each 
containing 10 slices/ml. *, P<0.05; **, P<0.01; ***, P<0.001.
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Figure 3.8 Effect of PEITC on CY PlA l (A) and CYP1A2 (B) apoprotein levels in human 
liver slices. Liver slices were incubated in medium supplemented with PEITC (0.5-50 pM in 
Donors 1, 2 and 3, and 0.5-40 pM in Donor 4) for 24 hr. Microsomal proteins were isolated 
and equal amounts (30 pg for CYPlAl or 15 pg for CYP1A2) protein were loaded on to 10% 
(w/v) SDS-PAGE and then transferred electrophoretically to Hybond-P polyvinylidene 
difluoride membrane. The immunoblot analysis was carried out by exposure to mouse anti­
human CYPlAl or CYP1A2 primary antibodies followed by peroxidase-labelled anti-mouse 
IgO . Values above blots show % levels of optical density of each band relative to control.
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Figure 3.9 Effect of PEITC on MROD activity in human liver slices. Liver slices were 
incubated in culture medium supplemented with PEITC (0.5-50 pM in Donors 1, 2 and 3, and 
0.5-40 pM in Donor 4) for 24 hr. Values are presented as mean ± SD of three replicates, each 
containing 10 slices/ml. *, P<0.05; **, P<0.01; ***, P<0.001.
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CYPIBI expression
CYPIBI activity was not assessed due to lack of a suitable chemical probe. Western blot 
analysis revealed a rise in CYPIBI apoprotein at all PEITC concentrations, except at the 
highest, in Donor 2 and to a lesser extent in Donor 4. In contrast, suppression was observed at 
all PEITC concentrations in Donor 3, whereas no influence was observed in Donor 1, except 
for a decrease at the highest concentration (Fig. 3.10A).
CYP2B6 expression
A single, well-defined band was visualised when immunoblots were probed with polyclonal 
anti-rat CYP2B1 indicating its cross-reactivity to human CYP2B6 as previously reported 
(Chang et ah, 1993; Forrester et ah, 1992; Mimura et ah, 1993) since they share 75% gene 
homology (Harleton et ah, 2004). A similar increase in CYP2B6 apoprotein in Donors 2 and 
3, and to a lesser degree in Donor 1, was observed at low concentrations of PEITC. Expression 
of CYP2B6, however, decreased at the higher concentrations of the isothiocyanate in all 
donors (Fig. 3.1 OB). 7-Benzyloxyresorufin O-dealkylase (BROD) has been used as a selective 
marker for human CYP2B6 (Nakajima et ah, 1998). However, as a result of limited sample 
availability, determination of CYP2B6 activity was not carried out and analysis was 
concentrated on the more important CYPlAl/2 and CYP3A4 enzyme.
CYP3A4 expression
The activity of CYP3A4 in human liver slices was determined using BOD as a marker. There 
was substantial variation in the basal activities, with Donor 4 displaying the highest activity, 
which could reflect, at least partly, drug intake. Clear inhibition of activity was seen in the 
liver from Donor 4, but no major concentration-dependent effects were observed in the case of 
the other donors (Fig. 3.11). In contrast, a marked increase in CYP3A4 apoprotein levels was 
observed in Donor 4 and to a lesser extent in the other donors (Fig. 3.12). Maximum induction 
appears to have occurred at a concentration of about 5-10 pM.
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Figure 3.10 Effect of PEITC on CYPIBI (A) and CYP2B6 (B) apoprotein levels in 
human liver slices. Liver slices were incubated in medium supplemented with PEITC (0.5-50 
pM in Donors 1, 2 and 3, and 0.5-40 pM in Donor 4) for 24 hr. Microsomal proteins were 
isolated and equal amounts (30 pg) of protein were loaded on to 10% (w/v) SDS-PAGE and 
then transferred electrophoretically to Hybond-P polyvinylidene difluoride membrane. The 
immunoblot analysis was carried out by exposure to rabbit anti-rat CYPIBI or goat anti-rat 
CYP2B1 primary antibodies followed by peroxidase-labelled secondary antibody. Values 
above blots show % levels of optical density of each band relative to control.
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Figure 3.11 Effect of PEITC on BOD activity in human liver slices. Liver slices were 
incubated in culture medium supplemented with PEITC (0.5-50 pM) in Donors 1, 2 and 3, and 
0.5-40 pM in Donor 4) for 24 hr. Values are presented as mean ± SD of three replicates, each 
containing 10 slices/ml.*, ?<0.05; **, P<0.01; ***, P<0.001.
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Figure 3.12 Effect of PEITC on CYP3A4 apoprotein levels in human liver slices. Liver 
slices were incubated in medium supplemented with PEITC (0.5-50 pM in Donors 1, 2 and 3, 
and 0.5-40 pM in Donor 4) for 24 hr. Microsomal proteins were isolated and equal amounts 
(30 pg) of protein were loaded on to 10% (w/v) SDS-PAGE and then transferred 
electrophoretically to Hybond-P polyvinylidene difluoride membrane. The immunoblot 
analysis was carried out by exposure to rabbit anti-human CYP3A4 primary antibody followed 
by peroxidase-labelled anti-rabbit IgG. Values above blots show % levels of optical density of 
each band relative to control.
3.3.5 Modulation of phase II enzyme activities and glutathione concentration by PEITC 
in rat liver slices
In general, exposure of rat liver slices to PEITC led to a rise in GST activity, measured using 
CDNB, DCNB and NBD-Cl as substrates (Fig. 3.13), quinone reductase and total glutathione 
levels at the lower concentrations employed (0.5-10 pM) (Fig. 3.14). The activities of 
glutathione reductase and epoxide hydrolase were not influenced by the PEITC treatment. 
Nevertheless, marked suppression was observed at the highest PEITC concentrations studied, 
particularly in the case of GST (CDNB) and NQOl (Figs. 3.13 and 3.14). Western blot 
analysis displayed major increase of NQOl protein levels at the low PEITC concentrations 
(Fig. 3.15). In parallel with the intense decrease in activity, expression of NQOl at the highest
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PEITC concentration was undetectable. Epoxide hydrolase protein levels modestly increased 
whereas no major changes in GST protein levels were seen, except for a drop in GSTp levels 
at the higher concentrations (Fig. 3.15).
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Figure 3.13 Effect of PEITC on GST activities in rat liver slices. Liver slices were 
incubated in culture medium containing PEITC (0.5-50 pM) for 24 hr. Values are presented as 
mean ± SD of three replicates, each containing 10 slices/ml. *, P<0.05; **, P<0.01.
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Figure 3.14 Effect of PEITC on phase II enzyme activities and glutathione concentration 
in rat liver slices. Liver slices were incubated in culture medium containing PEITC (0.5-50 
pM) for 24 hr. Values are presented as mean ± SD of three replicates, each containing 10 
slices/ml. *, P<0.05; **, P<0.01; ***, P<0.001.
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Figure 3.15 Effect of PEITC on phase II enzymes protein levels in rat liver slices. Liver 
slices were incubated in culture medium containing PEITC (0-50 pM) for 24 hr. Cytosolic or 
microsomal (in the case of epoxide hydrolase) proteins were isolated and equal amounts were 
loaded on to 10% (w/v) SDS-PAGE and then transferred electrophoretically to Hybond-P 
polyvinylidene difluoride membrane. The immunoblot analysis was carried out by exposure to 
rabbit anti-rat GSTAl-1, GSTMl-1, NQOl or epoxide hydrolase primary antibodies followed 
by the appropriate peroxidase-labelled secondary antibody. Each lane was loaded with 30 pg 
(NQOl and epoxide hydrolase) or 15 pg (GSTAl-1 and GSTMl-1) of total protein. Values 
above blots show % levels of optical density of each band relative to control.
3.3.6 Modulation of phase II enzyme activities and glutathione concentration by PEITC 
in human liver slices
Glutathione S-transferase (NBD-Cl) expression
Exposure of human liver slices to PEITC did not cause consistent effects on GST activity as 
determined using NBD-Cl as a substrate, in the four donors (Fig. 3.16). While enhancement of 
activity in Donors 1, 3 and 4 appeared to occur at high PEITC concentrations, suppression at 
low concentration (0.5-5 pM) was observed in Donor 2 (Fig. 3.16). Basal activities did not 
differ markedly among the 4 donors. Immunoblot analysis revealed induction of protein levels 
in all donors with Donor 4 being the most susceptible (Fig. 3.17).
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Figure 3.16 ^ fect of PEITC on GST (NBD-Cl) activity in human liver slices. L.ver slices 
were incubated m culture medium supplemented with PEITC (0.5-50 pM in Donors 1, 2 and 
, and 0,5-40 pM in Donor 4) for 24 hr. GST activity was determined using NBD-Cl as the
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Figure 3.17 Effect of PEITC on GSTa protein levels in human liver slices. Liver slices 
were incubated in medium supplemented with PEITC (0.5-50 pM in Donors 1, 2 and 3, and 
0.5-40 pM in Donor 4) for 24 hr. Cytosolic proteins were isolated and equal amounts (15 pg) 
of protein were loaded on to 10% (w/v) SDS-PAGE and then transferred electrophoretically to 
Hybond-P polyvinylidene difluoride membrane. The immunoblot analysis was carried out by 
exposure to rabbit anti-human GSTAl-1 primary antibody followed by peroxidase-labelled 
anti-rabbit IgG. Values above blots show % levels of optical density of each band relative to 
control.
Glutathione S-transferase (CDNB) expression
When GST activity was assessed using the broad substrate CDNB, no rise in activity was 
observed in any of the four donors. However, in Donors 1, 2 and 3, loss of activity was seen at 
some of the PEITC concentrations studied, but consistent effects were observed only in the 
case of Donor 2 (Fig. 3.18). A marked variation in activity was evident, with Donor 4 
displaying the lowest.
Glutathione S-transferase (DCNB) expression
Cytosolic GST activity, employing DCNB as a chemical substrate, was undetectable in human 
liver slices. However, the corresponding GSTp protein levels rose at low PEITC
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concentrations specifically at 0.5 pM in Donors 2, 3 and 4 while a decline at high 
concentrations was observed in all donors, except in Donor 3 (Fig. 3.19A).
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Figure 3.18 Effect of PEITC on GST (CDNB) activity in human liver slices. Liver slices 
were incubated in culture medium supplemented with PEITC (0.5-50 pM in Donors 1, 2 and 
3, and 0.5-40 pM in Donor 4) for 24 hr. GST activity was assessed using CDNB as 
substrate.Values are means presented as mean ± SD of three replicates, each containing 10 
slice/ml. *, P<0.05.
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Figure 3.19 Effect of PEITC on GSTp (A) and GST;r (B) protein levels in human liver 
slices. Liver slices were incubated in medium supplemented with PEITC (0.5-50 pM in 
Donors 1, 2 and 3, and 0.5-40 pM in Donor 4) for 24 hr. Cytosolic proteins were isolated and 
equal amounts (15 pg) of protein were loaded on to 10% (w/v) SDS-PAGE and then 
transferred electrophoretically to Hybond-P polyvinylidene difluoride membrane. The 
immunoblot analysis was carried out by exposure to either rabbit anti-human GSTMl-1 or P l- 
1 primary antibody followed by peroxidase-labelled anti-rabbit IgG. Values above blots show 
% levels of optical density of each band relative to control.
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Glutathione S-transferase (GSTit) expression
Figure 3.19B shows expression of GSTtt in human liver slices exposed to PEITC. Similar 
observations were made in protein expression as in GSTp. A rise in protein levels was seen at 
the 0.5 pM PEITC concentration in Donors 2 and 3 but levels dropped below control values at 
the highest PEITC concentration in all donors.
NQOl expression
Considerable inter-individual difference in the basal levels of activities was observed. 
Treatment with PEITC led to a differential response in the four livers, with the one consistent 
effect being a suppression of activity in Donor 1, whereas a statistically significant rise in 
activity was seen in Donor 4 at the 20 pM level of PEITC exposure (Fig. 3.20). At protein 
level, NQOl decreased in the liver of all donors, at all PEITC concentrations, except in the 
case of Donor 4 where a marked rise was displayed (Fig. 3.21).
Glutathione reductase activity
Glutathione reductase activity decreased in all donors, with Donor 1 being the most sensitive 
(Fig. 3.22). No marked difference in basal activity was noted in the 4 donors.
Total glutathione level
PEITC treatment did not influence glutathione level in Donors 1 and 2. A significant increase 
at low concentrations followed by a marked drop at the highest PEITC concentration 
employed were observed in Donor 3 whereas the reverse picture was exhibited by Donor 4 
(Fig. 3.23). Difference in basal concentrations among the four donors was very pronounced. It 
is of interest that rise in levels was noted in the two donors with the higher glutathione 
concentrations.
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Figure 3.20 Effect of PEITC on NQOl activity in human liver slices. Liver slices were 
incubated in culture medium supplemented with PEITC (0.5-50 pM in Donors 1, 2 and 3, and 
0.5-40 pM in Donor 4) for 24 hr. Values are presented as mean ± SD of three replicates, each 
containing 10 slices/ml. *, P<0.05.
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Figure 3.21 Effect of PEITC on NQOl protein levels in human liver slices. Liver slices 
were incubated in medium supplemented with PEITC (0.5-50 pM in Donors 1, 2 and 3, and 
0.5-40 pM in Donor 4) for 24 hr. Cytosolic proteins were isolated and equal amounts (30 pg) 
of protein were loaded on to 10% (w/v) SDS-PAGE and then transferred electrophoretically to 
Hybond-P polyvinylidene difluoride membrane. The immunoblot analysis was carried out by 
exposure to rabbit anti-human NQOl primary antibody followed by peroxidase-labelled anti- 
rabbit IgG. Values above blots show % levels of optical density of each band relative to 
control.
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Figure 3.22 Effect of PEITC on glutathione reductase activity in human liver slices.
Liver slices were incubated in culture medium supplemented with PEITC (0.5-50 pM in 
Donors 1, 2 and 3, and 0.5-40 pM in Donor 4) for 24 hr. Values are presented as mean ± SD 
of three replicates, each containing 10 slices/ml. *, P<0.05.
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Figure 3.23 Effect of PEITC on total glutathione levels in human liver slices. Liver slices 
were incubated in culture medium supplemented with PEITC (0.5-50 pM in Donors 1, 2 and 
3, and 0.5-40 pM in Donor 4) for 24 hr. Values are presented as mean ± SD of three 
replicates, each containing 10 slices/ml. *, P<0.05; **, P<0.01; ***, P<0.001.
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3.3.7 Modulation of CYPl and NQOl mRNA levels in rat liver slices by PEITC
3.3.7.1 Time course study o f mRNA induction
Liver slices were incubated with PEITC for various periods of time prior to CYP1A2 and 
NQOl mRNA levels being determined using real-time polymerase chain reaction (PGR); 185 
rRNA was used to normalise the mRNA number of copies. Induction of CYP1A2 and NQOl 
mRNA levels was observed only after an 8-hr of incubation (Fig. 3.24).
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Figure 3.24 Effect of incubation time on CYP1A2 and NQOl mRNA levels. Liver slices 
were incubated in culture medium containing I pM PEITC for various incubation periods (0- 
24 hr). The levels of mRNA were determined and normalised with respect to 185 rRNA. 
Values are presented as mean ± SD of three replicates, each containing 3 slices. *, P<0.05.
3.3.7.2 Effect o f PEITC on CYPl and NQOl mRNA levels in rat liver slices
Liver slices were incubated in culture medium containing a range of PEITC concentrations (0- 
40 pM) for 8 hr and mRNA was then extracted and quantified. PEITC failed to influence 
CYPl A and IB l mRNA levels at all PEITC concentrations. The levels of NQOl mRNA 
expression were, however, increased moderately at concentrations > 10 pM (Fig. 3.25).
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Figure 3.25 Effect of PEITC on C Y PlA l, CYP1A2, CYPIBI and NQOl mRNA levels in 
rat liver slices. Liver slices were incubated in culture medium supplemented with PEITC 
(0.5-40 pM) or 0.1 pM BaP for 24 hr. Total RNA was extracted from tissue slices and the 
mRNA levels of CYPl A I, CYP1A2, CYPIBI and NQOl were quantified by quantitative RT- 
PCR methodology (TaqMan); mRNA levels were normalised with respect to 185 rRNA. 
Values are presented as mean ± SD of three replicates, each containing 3 slices. *, P<0.05; **, 
P<0.01; ***, P<0.001.
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3.4 Discussion
It is logical to consider that ITCs may have the potential to function as cancer 
chemopreventive agents by modifying carcinogen metabolism via inhibition of phase I and/or 
induction of phase II enzymes, and this hypothesis still remains to be tested for individual 
ITCs and their glucosinolate precursors (Hecht et ah, 1999). Glucoraphanin, the precursor of 
sulforaphane, for example, markedly induced CYPlAl/2, CYP3A and CYP2E1 activities in 
Sprague-Dawley rat liver, accompanied with a paralleled rise in the apoprotein and mRNA 
levels (Perocco et ah, 2006). This findings raise the possibility that long-term administration 
of glucoraphanin could actually pose a potential health hazard as these cytochrome P450 
enzymes are extensively involved in the bioactivation of carcinogens (Drahushuk et ah, 1998; 
Stresser et ah, 2000). In addition, CYPl A apoprotein levels induction is not welcome in the 
pharmaceutical industry and if it occurs during drug development, the further development of 
the drug may be terminated for induction may lead to toxicity (Nebert et ah, 2004). Therefore, 
the balance of modulation of XMEs is an important key to evaluate safety and/or advantages 
of anticarcinogenic compounds. In contrast, in study conducted in precision-cut tissue slices, 
sulforaphane, the isothiocyanate derived from glucoraphanin, had no effect on rat CYP450 
activities in either lung or liver (Hanlon et ah, 2009; 2008a).
The ability of PEITC to modulate cytochrome P450 and phase II activities was investigated in 
vitro using precision-cut liver slices. Optimum incubation conditions, such as a 24-hr 
incubation, to achieve maximum cytochrome P450 induction have previously been established 
(Pushparajah et ah, 2007).
3.4.1 Viability of rat and human liver slices
7-EC is a model substrate for monitoring metabolic viability. To ensure the viability of slices 
used throughout the in vitro study, the rate of 7-EC metabolism was assessed both in rat and 
human liver slices. 7-Hydroxycoumarin (7-HC), the product of oxidation, is formed mainly
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by CYPl A and, to a lesser extent, by CYP2B and 2E1 (Kuhn et ah, 1998; Yamazaki et ah, 
1999), and is then further conjugated with D-glucuronic acid and sulphate to generate 7-HC 
glucuronide and 7-HC sulphate respectively. Thus, this substrate allows the simultaneous 
monitoring of cytochrome P450 and phase II conjugation reaction.
In rat, time-dependent metabolism of 7-EC was observed, with 7-HC sulphate being the major 
metabolite followed by 7-HC glucuronide and free 7-HC, comparable to previous published 
studies emanating from this and other laboratories (Ball et ah, 1996; Hashemi et ah, 1999). 
The total metabolites generated were similar to those previously reported (Hashemi et ah, 
1999). In contrast to rat, the major product of 7-EC metabolism in human liver slices was the 
glucuronide conjugate in agreement to previous studies (Walsh et ah, 1995). Comparing the 
two liver samples studied, 7-EC metabolism in human Donor 4 was doubled that of Donor 3. 
This may represent a difference in CYPIA activities since CYPlAl and 1A2 are the major 
enzymes catalysing 7-EC metabolism (Kuhn et ah, 1998; Yamazaki et ah, 1999). However, no 
marked difference in basal CYPIA activities could be observed in the two donors as 
exemplified by the EROD and MROD activities. Hence higher of CYP2B and/or 2E1 
activities in Donor 4 may be responsible for this difference, but they were not determined in 
the current study. Many other factors contribute to inter-individual variability including 
environmental and dietary exposure to chemicals (Pelkonen et ah, 2008), the nature of the 
disease (Vavilin et ah, 2002), gender (Shimada et ah, 1994) and genetic polymorphism 
(Chowbay et ah, 2005; frigelman-Sundberg et ah, 1999).
Nevertheless, a loss of enzyme activities or induction was evident at high PEITC 
concentrations employed in rat liver slices. This was accompanied by a marked decrease in 
GST (CDNB) activity and glutathione concentration, presumably because glutathione 
conjugation, catalysed by GSTs is a major route of isothiocyanate metabolism (Conaway et 
ah, 2002). The cysteinyl thiol group of glutathione is an important site of thiocarbamoylation 
of PEITC, the reaction leading to decrease in intracellular GSH and GSSG levels which
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triggers induction of apoptosis and cytotoxicity (Xu and Thomalley, 2001). Moreover, toxicity 
of PEITC to rat liver slices monitored using LDH leakage into the media, confirmed that 
PEITC at the highest concentration of 50 pM, displayed mild toxicity to cultured rat liver 
slices. Although the basal LDH leakage in rat liver slices following 24 hr incubation was about 
50%, evaluation of 7-EC metabolism indicated that the slices were metabolically viable, for at 
least 6 hr. Indeed, there is no relationship between slice viability and LDH leakage (Barr et ah, 
1991a;1991b).
3.4.2 Modulation of cytochrome P450 enzymes by PEITC in rat and human liver slices
Rat and human liver slices were incubated with PEITC. The highest concentration of PEITC 
employed in this study was based on toxicity studies in rat liver slices assessed by LDH 
leakage (see Section 3.4.1). Modulation of cytochrome P450 enzymes was monitored using 
the dealkylations of ethoxy- (Burke and Mayer, 1974), methoxy- (Burke and Mayer, 1983), 
pentoxyresorufm (Lubet et ah, 1985) and 7-benzyloxyquinoline (Stresser et ah, 2002), as 
markers for microsomal CYPlAl, 1A2, 2B and 3A2/4, respectively. In all cases, 
determination of enzyme activities was supported by immunological studies.
Cytochrome P450 enzyme activities in rat liver slices were not influenced by exposure to 
PEITC, at the range of concentrations studied, the only exception being MROD which was 
decreased; the decrease in activity was accompanied by a marked decline in apoprotein levels 
of CYP1A2, indicating that the drop in activity is due to decreased enzyme availability. A 
similar inactivation of this enzymes has also been observed by other isothiocyanates (Hanlon 
et ah, 2008a, Yoxall et ah, 2005). This raises the question why CYP1A2 is more sensitive to 
ITCs, specifically PEITC, compared with other cytochrome P450 enzymes; a possible 
explanation is that CYP1A2 may be the enzyme responsible for the formation of the metabolic 
species that interacts with cytochrome (Lee, 1996). A marked decrease in CYPlAl 
apoprotein, at the highest PEITC concentration, was in disagreement with unchanged EROD
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activity. Studies on specificity of ethoxyresorufm revealed that, in control rat liver 
microsomes, the dééthylation of ethoxyresorufm is primarily mediated by CYP2C6 (36%) 
(Burke et ah, 1994), and to a lesser extent CYP2C11 (24%) and lA l (23%) (Chovan et ah, 
2007). Consequently, EROD activity in untreated slices was more likely to be catalysed by 
cytochrome P450 enzymes other than CYPlAl, and that these enzymes were not influenced 
by PEITC. Finally, at the highest concentration of PEITC studied, i.e. 50 pM, a decrease in 
CYP2B and CYP3A2 expression, that has also been reported for other isothiocyanates in the 
same system, was observed and is believed to be due to depletion of glutathione that occurs at 
this high isothiocyanate concentration (Hanlon et ah, 2008b; 2009; 2008a).
Human liver slices have been used extensively to achieve many objectives including 
xenobiotic toxicity and drug metabolism (Olinga et ah, 2008; Persson et ah, 2006; Plazar et 
ah, 2007; Pushparajah et ah, 2008a; 2008b; van de Bovenkamp et ah, 2008). They have also 
been used in our laboratory to investigate xenobiotic-metabolising enzyme modulation by the 
aliphatic isothiocyanates, sulforaphane and erucin (Hanlon et ah, 2008a). The same approach 
was used in the present studies with PEITC.
In contrast to observations made with sulforaphane and erucin conducted in only two donors 
where no change on cytochrome P450 activities was noted (Hanlon et ah, 2008a), treatment of 
human liver slices with PEITC promisingly impaired EROD activity; however, in two of the 
four donors, CYPlAl apoprotein levels rose moderately. These observations denote that 
CYPlAl expression was up-regulated but the enzyme was not catalytically competent 
suggesting that PEITC may be an inhibitor of human CYPlAl, and this aspect will be 
discussed later in Chapter 4. Moreover, MROD activity decreased in all donors, concomitant 
with a drop in apoprotein levels, except that in one donor induction at low PEITC 
concentrations was noted. Indeed, PEITC is an established potent suicide inhibitor of CYPl A2 
presented in human liver microsomes (Nakajima et ah, 2001). Similarly, Smith and co­
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workers revealed competitive inhibition of human CYP1A2, as exemplified by MROD 
activity (Smith et ah, 1996). Observations made in the present study revealed a promising 
selective inhibitory action of PEITC on CYP1A2, in both rat and human, implying that 
CYP1A2 may be involved in PEITC metabolism, thus explaining its sensitivity to CYP1A2. 
Lee (1996) reported that the enzymes in rat liver microsomes responsible for metabolism of 
the structurally related BITC were induced by Aroclor 1254, a potent CYPl and 2B inducer 
(Gorrod et ah, 1993), and to a lesser extent phénobarbital (Lee, 1996), providing indirect 
evidence that CYP1A2 may be an important catalyst of PEITC oxidative metabolism. In 
addition, in studies conducted to evaluate the impact of individual CYP450 enzymes on 
PEITC metabolism (see Chapter 4), liver slices from rats induced with selective inducers of 
CYP450 enzyme were incubated with PEITC, and its time-dependent disappearance was 
determined by LC-MS. In these studies, slices from rats treated with the CYPIA inducer (3- 
naphthoflavone (Meunier et ah, 2000) did not accelerate the disappearance of the substrate. 
This would indicate that CYP1A2 has no major role in the metabolism of PEITC or, more 
likely, that CYP-modulated metabolism is not a major route of metabolism compared with 
glutathione conjugation, the principal metabolic pathway of isothiocyanates (Conaway et ah, 
2002). On the other hand, previous studies carried out in human hepatic microsomes indicated 
that PEITC was the most potent inhibitor of CYP2B6 compared to CYPlAl and 1A2 
(Nakajima et ah, 2001; Thapliyal and Maru, 2001). It may be inferred that CYP2B6 is a 
superior catalyst for PEITC biotransformation, in comparison with other CYP450 enzymes. 
However, although CYP2B6 may be the major catalyst of PEITC metabolism compared with 
CYP1A2, it should be emphasised that CYP2B6 is a very minor form of CYP450 in human 
liver, and CYPIA enzymes are present at relatively higher concentrations (Shimada et ah, 
1994) and thus responsible for the PEITC oxidation in human microsomes.
CYP3A4 has been of interest as it is the predominant cytochrome P450 enzyme in the human 
liver and intestine (Code et ah, 1997), and is involved in the metabolism of most of drugs
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introduced to the body. Previous studies demonstrated that sulforaphane inhibited CYP3A4 
activity and suppressed CYP3A4 mRNA expression in both human and rat hepatocyte primary 
cultures (Maheo et ah, 1997; Zhou et ah, 2007). In the present study, BOD activity was 
suppressed by PEITC but only in two of the donors, although elevation of apoprotein levels 
was observed in all donors. Mixed-type, competitive and non-competitive, inhibition action of 
PEITC on CYP3A4 has been demonstrated in human hepatocytes (Nakajima et ah, 2001).
Western blot analysis showed that apoprotein levels of CYP2B6 were modestly enhanced at 
low concentrations of PEITC in three of the donors. Bearing in mind the low initial 
concentration of CYP2B6 in human liver, the increase in apoprotein levels, even if translated 
into a similar rise in activity, is unlikely to have a major effect on xenobiotic metabolism. 
Yamano and colleagues reported profound variation, from non-detectable to high levels, in 
CYP2B mRNA levels determined in isolated human liver. They claimed that the 
heterogeneous expression was due to a defective gene present in human or that the gene is 
differently regulated or induced (Yamano et ah, 1989). PEITC is a potent non-competitive 
inhibitor of human CYP2B6 when determined in microsomes using benzyloxyresorufm O- 
dealkylase as a marker (Nakajima et ah, 2001). Nonetheless, determination of CYP2B6 
activity was not carried out in this study due to sample quantity limitation. Thus, a definitive 
conclusion on the effect of PEITC on CYP2B6 activity cannot be reached. Likewise, CYPIBI 
expression was moderately induced, however, the response was not consistent among all 
donors. Nevertheless, CYPIBI is not a major hepatic enzyme and is essentially an 
extrahepatic enzyme (Chang et ah, 2003; Li et ah, 2000; McFadyen and Murray, 2008). 
Furthermore, sequence variants in CYPIBI gene may also affect its regulation and function 
(Chang et ah, 2003) and may be responsible for the heterogeneous PEITC response among 
individuals.
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Collectively, even though PCR analysis showed induction of transcription levels of CYPlAl/2 
in cultured human hepatocytes exposure to PEITC (Goosen et ah, 2000; Gross-Steinmeyer et 
ah, 2004), the present study showed that, at the activity and protein level, PEITC impaired 
CYP1A2 in both rat and human slices. In general, CYP450 inhibition was more pronounced in 
human liver compared with rat. Suppression of CYP1A2 activity, occurred at concentrations 
that may be attained through dietary intake. Bearing in mind the pivotal role of CYP1A2 in the 
metabolism of human carcinogens such as heterocyclic and aromatic amines (Boobis et ah, 
1994; Hammons et ah, 1997; Tureshy et ah, 2002), this is a feasible mechanisms of its 
chemopreventive action.
3.4.3 Modulation of phase II enzyme activities and glutathione level by PEITC in rat and 
human liver slices
It is believed that high phase II enzyme activities and high intracellular levels of glutathione 
are favourable for cancer prevention. Glutathione 5-transferases are an important group of 
detoxification phase II enzymes. They enhance excretion of xenobiotics, by catalysing their 
conjugation reactions to cellular glutathione, thus the ability of PEITC to elevate GST 
expression is a crucial factor to implicate its chemopreventive action. In the current study, 
treatment of rat liver slices with PEITC elevated GSTa and p, determined as accepting 
substrates NBD-Cl and DCNB respectively, albeit only at low PEITC concentrations. No 
major changes in GST protein levels were observed except for a drop in GSTp at the higher 
PEITC concentrations. Moreover, a marked rise in both GST assessed using CDNB as 
substrate and to a lesser extent total glutathione level was also observed at low PEITC 
concentration and they were, however, subsequently dropped at high PEITC concentration. 
The decrease of GST (CDNB) and glutathione level at high concentration of PEITC was 
presumed to be due to cytotoxicity of PEITC, hence loss of enzyme activities or induction at 
high PEITC concentrations occurred. Indeed, associations among cellular glutathione 
concentration, isothiocyanate accumulation and the efficacy of ITCs to modulated XMEs have
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been previously studied. It was established that high cellular glutathione concentration was 
proportionate to the increase in ITC accumulation, which subsequently generated induction of 
ARE (antioxidant response element ) -mediated phase II enzymes gene (Kim et ah, 2003) or 
rendered the stimulation of cytochrome P450 enzymes inhibition (Conaway et ah, 2001). In 
other words, depletion of glutathione levels infers induction of phase II enzymes expression. 
However, exposure of HepG2-C8 cells to non-toxic levels of sulforaphane revealed a drop in 
glutathione levels during the first 4 hr, which was restored up to 2.2-fold after 24 hr (Kim et 
ah, 2003), implying that ARE induction would occur during the early hours of glutathione 
depletion.
Quinone reductase, an important enzyme involved detoxification of xenobiotic, preventing the 
formation of the semiquinone radical and the generation of destructive ROS, was determined 
using MTT as substrate (Prohaska and Santamaria, 1988). Among ITCs, sulforaphane is 
believed to be the most potent inducer of NQOl (Myzak and Dashwood, 2006). Treatment of 
rats with erucin and sulforaphane increased both activity and protein levels of NQOl in liver, 
lung (Hanlon et ah, 2008b), duodenum, forestomach, and especially urinary bladder (Munday 
and Munday, 2004). In the present study, marked induction was observed in rat liver slices, 
but only at the 1 pM PEITC concentration, concomitant with a pronounced elevation of the 
protein levels. The activity and enzyme expression subsequently fell at higher concentrations 
of PEITC, especially a t>  10 pM. Similarly, induction of NQOl in human bladder cancer cells 
by PEITC following 24 hr exposure appeared to decrease at concentrations > 7.5 pM and was 
paralleled by loss of its anticarcinogenic activities (Tang and Zhang, 2004). This was claimed 
to be due to, once again, cytotoxicity of ITCs at high concentration. Epoxide hydrolase and 
glutathione reductase were not influenced by PEITC which the aliphatic isothiocyanate 
sulforaphane also revealed the similar result in epoxide hydrolase activity (Yoxall et ah, 
2005).
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The mechanism of gene induction of phase II enzymes remains unclear. It was believed that 
induction of phase II enzymes by ITCs is mediated by AhR. Nevertheless, ARE through the 
ARE-binding protein, including Nrfl, 2 and 3, is recognised as being important in the 
regulation of some phase II enzymes such as NQOl, UDPGT and GSTs (Bonnesen et ah, 
2001).
In contrast to rat, only modest effects in phase II enzymes were observed in human liver slices 
exposed to PEITC, and marked variation was evident in the 4 human livers. When CDNB was 
used as substrate, no rise in activity was noted, but when NBD-Cl was used, an increase in 
activity, preferentially modulated by GSTa, was evident in three of the donors, and was 
paralleled by a rise in enzyme protein levels. It may be consequently inferred that the effects 
of PEITC on the GST enzyme system are isoform-specific, selectivly increasing the levels of 
some isoforms. At the protein level, no major effect was observed in GSTp and tt, but levels 
dropped markedly at the higher concentrations. These findings are of particular interest since 
GSTp (Lampe and Peterson, 2002) and GSTtt (Zhang, 2001) have been reported to play an 
important role in the metabolism of ITCs. ITCs are effective substrates of GSTs so that a 
decrease in these particular isoforms probably results in longer exposure time of ITCs in the 
body. Polymorphisms in human GSTs, e.g. pancreas (Coles et ah, 2000) and lung (Nakajima 
et ah, 1995) have been reported. Each individual genotype plays a different role in ITC 
metabolism, hence many researchers are now focussing on the relationship between 
polymorphisms associated with reduced GST activity and increase in the chemopreventive 
effects of cruciferous vegetables (Epplein et ah, 2009; Lampe and Peterson, 2002). Moreover, 
the difference in GST modulation by PEITC between rat and human liver slices also suggests 
a species-specific response to PEITC, but a larger number of human livers need to be 
investigated before a firm conclusion can be drawn.
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The induction of NQOl activity in human cultured prostate cells treated with sulforaphane 
(Brooks et ah, 2001) and in various tissues such as liver, lung and kidney following AITC 
administration to rats has been reported (Munday and Munday, 2002). In the case of PEITC, 
an 11-fold rise in NQOl mRNA at 25 pM PEITC was reported in PEITC-exposed primary 
human hepatocyte culture (Gross-Steinmeyer et ah, 2004). The four human livers employed in 
the present study responded differently to PEITC, in that in only liver from Donor 1 there was 
a decline in activity, whereas in the other livers there was either no or not a consistent effect. 
At protein level, however, a marked rise was seen in one donor whereas suppression in the 
levels was evident in the remaining donors. The heterogeneity in response among donors may 
be associated with individual polymorphisms. Three well-defined alleles of NQOl have been 
reported, namely NQ01*1, *2, and *3 each of which represents a functional allele, a non­
functional allele and diminished NQOl enzymic activity, respectively (Gaedigk et ah, 1998). 
The defective NQOl allele implies increased cancer risk due to lack of detoxification of 
quinones. Moreover, in Donor 2, remarkable decline in protein levels was observed at all 
PEITC concentrations indicating down-regulation of the NQOl expression by PEITC whereas 
the activity remained unchanged. It is possible that the immunodetectable protein in Donor 2 
is of the diminished NQOl activity allele, as can be seen from its relatively low activity 
compared to the others. Hence changes protein expression may not translate into detectable 
changes in activity.
PEITC had no effect on rat liver glutathione reductase in accordance with previous finding in 
F344 rats treated with the isothiocyanate (Staack et ah, 1998). In the human livers, in general, 
activity was suppressed at high concentrations of PEITC, although in Donor 1, inhibition was 
noted at lower concentrations. Total glutathione levels rose moderately in rat slices exposed to 
PEITC, as previously noted for sulforaphane and erucin (Hanlon et ah, 2008b). In human 
livers, however, a more pronounced elevation was noted, but only in two donors. It is of 
interest that the rise in glutathione levels occurred in the two donors that displayed elevated
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GSTa activity in Donors 3 and 4. It would be expected that in such individuals detoxification 
potential would be enhanced, protecting against electrophiles, and could contribute 
substantially to the chemopreventive mechanism of PEITC. Biosynthesis of glutathione is 
catalysed by two enzymes, one of which is y-glutamylcysteine synthetase, and differences in 
ability to synthesise glutathione in each individual may be associated with polymorphisms in 
this enzyme (Walsh et ah, 2001). The most pronounced variation in basal levels among the 
four donors was seen in glutathione levels. External factors especially exposure to 
environmental chemicals or medical treatment are involved in the regulation of glutathione 
synthesis and function; glutathione is a potent nucleophilic scavenger involved in maintaining 
cellular oxidation-reduction balance, hence protecting cells from many xenobiotic substances 
(Konukoglu et ah, 1997). Moreover, cellular glutathione levels has also been related to the 
immunological status of each individual (Droge and Breitkreutz, 2000).
3.4.4 Differential response of the human livers to PEITC
Considerable variation in basal activities among donors was noted in many enzymes. As far as 
phase II enzymes and glutathione levels are concerned, the basal values observed in Donors 2 
and 1 were the lowest whereas the highest was Donor 3. It may be argued that the differential 
response of the human livers to PEITC reflects, at least partly, the state of the liver when 
delivered to the university and processed. However, it should be pointed out that all livers 
were delivered 8 to 12 hr following removal from the donors. Nevertheless, it is unlikely that 
the condition of the livers on arrival was markedly different, since in the most cases basal 
cytochrome P450 and phase II enzyme activities did not differ markedly among the four liver 
samples so as to denote deterioration of the sample. Moreover, the lowest and highest enzyme 
activities were not always observed in the same donors. The higher basal CYP3A4-mediated 
BOD activity in Donor 4 could be due to the fact that this donor was receiving medicinal 
drugs, however, none of the drugs in the drug history is an established CYP3A4 inducer. 
Moreover, the extent of inhibition of EROD, MROD and BOD was more pronounced in
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Donor 4 whereas in the same liver a marked rise in glutathione concentration and to a lesser 
extent NQOl activity were observed compared to the other human samples. Different enzyme 
regulation among individuals may be due to genetic polymorphism in enzymes induction 
regulatory factors such as AhR, the regulator of CYPl (Chen et ah, 2006; Denison and Nagy, 
2003), and Nrf2-mediated phase II induction (Ansawa et ah, 2008). Drug histoiy, exposure to 
environmental and chemicals, life style such as cigarette smoking (Willey et ah, 1997), 
excessive alcohol consumption (Badger et ah, 1993) and nature of diet such as consumption of 
fruit (Raza et ah, 1996) and vegetables (Hecht et ah, 2004), may also contribute to the inter­
individual variations.
3.4.5 Effect of PEITC on carcinogen-metabolising enzymes at the mRNA level in rat liver 
slices
The most frequent mechanism of the up-regulation of enzymes such as cytochrome P450 is 
increased transcription, although, mRNA and protein stabilisation have also been described, 
albeit less frequently. For example, regulation of CYPIA up-regulation is a consequence of 
increased gene transcription through the AhR (Whitlock, Jr., 1999). CYP1A2, however, may 
also be regulated at post-transcriptional level (Silver and Krauter, 1988) where translation of 
mRNA into protein level may be affected by stability and turnover rate of mRNA or the 
protein itself (Glickman and Ciechanover, 2002; Harrigan et ah, 2004). Consequently, the 
effect of PEITC on mRNA levels was determined to identify whether increased transcription 
was involved. Since very low CYPlAl mRNA expression has been reported in liver (Iba et 
ah, 1999), CYP1A2 and NQOl mRNA levels was used as indicators in a time-course study. 
Incubation of rat liver slices with PEITC for 8 hr led to a modest but significant rise in 
CYP1A2 and NQOl mRNA levels, which declined on longer incubation, possibly due to 
mRNA turnover. Similarly, mRNA expression of hepatic CYP1A2 from rats pretreated with 
TSU-68, CYP450 inducer, reached the maximum level after 12 hr of treatment, and then 
decreased in time-dependent manner (Kitamura et ah, 2008). An additional study was carried
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out to investigate the effect of PEITC concentrations on mRNA expression after an 8-hr 
incubation. CYPlAl/2 and CYPIBI mRNA levels were not modulated by PEITC except for a 
decrease in CYPIBI at the highest concentration of PEITC (40 pM) employed, presumably 
due to cytotoxicity as already discussed (Section 3.4.1). On the other hand, NQOl mRNA 
levels were elevated, but only modestly, at concentrations > 10 pM PEITC. Similarly, PEITC 
failed to up-regulate CYPlAl mRNA levels in human colon cells but a marked rise in NQOl 
was observed, whereas sulforaphane, on the other hand, induced both CYPlAl and NQOl 
mRNA expression (Bonnesen et al., 2001). Recent study has also reported induction ability of 
sulforaphane on CYPlAl mRNA and apoprotein levels in human and rat liver cell line 
(Anwar-Mohamed and El-Kadi, 2009). Surprisingly, this work demonstrated that increase in 
protein levels was far more pronounced than mRNA levels which possibly due to the poor 
correlation between mRNA levels and protein expression (Greenbaum et al., 2003) or 
implying that up-regualtion mechanism of CYPlAl protein is not regulated only by AhR, 
post-transcriptional regulation such as increasing mRNA stability should also be considered. 
Nonetheless, to my knowledge the effect of ITCs on post-transcriptional mechanism has never 
been reported.
3.5 Conclusions
• Exposure of rat liver slices to PEITC resulted in marked decrease in CYP1A2 
expression and activity; human liver slices responded in a similar way.
• GST and NQOl activities increased in rat liver slices incubated with PEITC, but only 
at low concentrations of the isothiocyanate.
• PEITC failed to modulate CYPl mRNA levels but a modest rise in gene transcription 
of NQOl was noted in rat liver slices.
• When human liver slices were incubated with PEITC, a differential response of GST 
and NQOl was seen in the liver from four donors.
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4.1 Introduction
In animal models of cancer, PEITC has been shown repeatedly to antagonise effectively the 
carcinogenicity of chemicals in many tissues (Hecht et ah, 1995; Morse et ah, 1993; Stoner et 
ah, 1991). It afforded protection against chemically-induced carcinogenesis in the lung, 
mammary gland, pancreas, colon, forestomach and oesophagus induced by 
nitrosocompounds, azoxymethane and polycyclic aromatic hydrocarbons (Chung et ah, 2000; 
Hecht et ah, 1996a; Morse et ah, 1989; Nishikawa et ah, 1996; Wattenberg et ah, 1977), 
although in some studies no benefit was seen in colon carcinogenesis induced by 
azoxymethane when the formation of aberrant crypt foci was used as biomarker (Plate and 
Gallaher, 2006). Of interest is the observation that the mercapturate of PEITC, an important 
metabolite, retains its anticarcinogenic activity (Chung, 2001).
PEITC elicits its anticarcinogenic effects by blocking initiation (Zhang, 2004) and suppresses 
post-initiation processes of tumour growth by inducing apoptosis and modulating the cell 
cycle (Conaway et ah, 2005; Myzak et ah, 2004; Xu and Thomalley, 2001). Of the various 
anticarcinogenic mechanisms of isothiocyanates, protecting against DNA damage and, thus, 
suppression of initiation (Boysen et ah, 2003) is of major importance. This may be achieved 
by reducing the availability of the genotoxic products of chemical carcinogens by preventing 
their generation, as a result of inhibition of their cytochrome P450-mediated bioactivation 
(Moreno et ah, 2001; Morris et ah, 2004; Nakajima et ah, 2001; Stoner et ah, 1991; Talalay 
and Fahey, 2001), and/or by stimulating their detoxication, through induction of enzyme 
systems such as the glutathione ^transferases and quinone reductase (Hecht et ah, 2000). 
However, the effects of isothiocyanates at this stage are complex since they may depend on 
animal species (Hanlon et ah, 2008b), target tissue (Staretz et ah, 1997; van Lieshout et ah, 
1996), nature of isothiocyanate (Hecht et ah, 2000), dose regimen (Hanlon, 2009) and 
treatment protocol (Pintao et ah, 1995).
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Utilising precision-cut liver slices, the ability of PEITC to modulate xenobiotic-metabolising 
enzymes in human and rat liver has been established (Chapter 3) and thus demonstrated its 
possibility to function as a chemopreventive agent. It is essential to investigate if XMEs 
respond similarly to PEITC in animal models in vivo, especially following exposure to low 
doses that stimulate human dietary intake.
The principal objective of the present study was to evaluate in rats the effect of intake of 
PEITC, employing dietary levels of exposure, on XME systems such as cytochromes P450, 
NQOl and GSTs. Although studies concerned with the effects of PEITC on such enzyme 
systems have been previously reported, these employed rather high doses (Guo et al., 1992; 
Plate and Gallaher, 2006; van Lieshout et al., 1996; Wallig et al., 1998). Moreover, 
modulation of XMEs was investigated in different tissues, e.g. liver, lung and kidney, as the 
liver is the principal site of the bioactivation of carcinogens, lung is a major target tissue of 
isothiocyanates, and the kidney is an important site of isothiocyanate metabolism (Eklind et 
al., 1990).
4.2 Methods
4.2.1 Animal treatment
After a week’s acclimatisation, rats (180 ± 20 g) were randomly allocated into 4 groups of 5 
rats each. Animal doses were chosen so that the Low dose corresponds to the average human 
daily intake of glucosinolates in United Kingdom (75 mg/person/day or 1.07 mg/kg bw) 
(Sones et al., 1984). Three groups were administered diets supplemented with 0.06 (Low 
dose), 0.6 (Medium dose) and 6.0 (High dose) pmole PEITC/g diet whereas one group served 
as control; animals were maintained on these diets for 14 days. At the end of the treatment 
period, rats were killed and livers, lungs and kidneys were removed. Tissue samples were 
immediately frozen in liquid nitrogen and stored at -80 ®C until required. S9 of liver (25% 
,w/v), lung and kidney (50%, w/v), in 0.154 M KCl containing 50 mM Tris-HCl (pH 7.4),
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were prepared prior to microsomal and cytosolic separation by differential centrifugation 
(Section 2.2.2.2).
4.2.2 Modulation of xenobiotic-metabolising enzymes by PEITC
In the microsomal fraction, EROD, MROD and PROD activities were determined as 
described in Section 2.2.3.1 and BOD,/7-nitrophenol hydroxylase and epoxide hydrolase as 
described in Sections 2.2.3.2, 2.2.3.3 and 2.2.4.1 respectively. In the cytosolic fraction, 
glutathione ^'-transferases monitored using as accepting substrates CDNB, DCNB and NBD- 
Cl, NQOl, glutathione reductase, and total glutathione levels were assessed (see Sections 
2.2.4.2-2.2.2.4 and 2.2.5 respectively). Total cytochrome P450 content in the liver was also 
determined as described in Section 2.2.6 (Omura and Sato, 1964). Finally, total protein 
concentration and expression levels of enzymes using Western immunoblotting were 
determined as described in Sections 2.2.2.3 and 2.2.7 respectively.
4.2.3 Inactivation mechanism of CYP450 by PEITC
4.2.3.1 Inhibition o f hepatic GYP I A I in rat and human
Studies were undertaken to elucidate the inhibition mechanisms of PEITC and its 
metabolite(s) on EROD activity in rat and human liver. In rats, Aroclor 1254 was used to treat 
the animal as it is a strong inducer of the CYPIA subfamily (Nims et al., 1992). Rats were 
treated with a single intraperitoneal dose of Aroclor 1254 (500 mg/kg), and animals were 
killed on the 5 day following administration, and the livers were immediately removed. In 
the human study, control liver retrieved from the UK Human Tissue Bank (The Innovation 
Center, Leicester, U.K.) was utilised.
4.2.3.2 Inhibition o f rat pulmonary CYP2B
Similarly, a further study was performed to evaluate the effect of PEITC on PROD activity in 
rat lung. S9 from animals induced with phénobarbital, a strong inducer of the CYP2B
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subfamily (Daiman et al., 1983), was prepared. Single daily intraperitoneal doses of 
phénobarbital (100 mg/kg) were given to the rats for 3 consecutive days, the animals being 
killed 24 hr after the last administration; lungs were immediately removed.
4.2.3.3 Preparation o f micros omes
Following Sections 4.2.3.1 and 4.2.3.2, rat (25%, w/v) and human (50%, w/v) liver as well as 
rat lung S9 (50%, w/v) were prepared and stored at -80 °C until use (Section 2.2.2.2). 
Microsomal preparations were used to directly monitor EROD or PROD activities or to 
generate PEITC-metabolite(s) by pre-incubation with PEITC at 37 ^C in the presence of 
NADPH; subsequently modulation of EROD and PROD activities by PEITC or metabolite(s), 
was evaluated.
4.2.3.4 Mechanism-based inactivation study
A number of criteria were applied in order to characterise the mechanism-based inactivation 
characteristics of PEITC (Hollenberg et al., 2008); these include correlation with PEITC 
concentration and pre-incubation time, NADPH requirement and effect of the nucleophilic 
scavengers GSH. Finally, the effect of PEITC on total cytochrome P450 content was 
evaluated before and after pre-incubation of PEITC in the presence of NADPH for various 
periods of time (see Section 2.2.6).
4.2.3.5 Characterisation o f enzyme inhibition
Characterisation of enzyme inhibition was carried out employing Michaelis-Menten kinetics 
and Lineweaver-Burk Plots. Subsequently, using GraphPad Software, the Michaelis-Menten 
constant Km and the maximal velocity Vmax were calculated, and apparent inhibition 
constant Ki was derived using the following equations:
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[Km] [I] Competitive inhibition
Kmapp-Km
Ki -  [Vmaxapp] [I] Non-competitive inhibition
Vmax
Km and Vmax values were determined in the absence of PEITC, whereas the Kmapp and
Vmaxapp were determined in the presence of the isothiocyanate; I is the concentration of 
PEITC.
4.2.4 Modulation of IQ metabolism
To ascertain whether long-term administration of PEITC influences the bioactivation of pro­
carcinogen, the heterocyclic amine IQ was used as the model carcinogen, and its mutagenicity 
was determined using the Ames test, in the presence of an activation system containing 10 % 
(v/v) of 25% (w/v) hepatic S9 isolated from the liver of rats pretreated with PEITC (Maron 
and Ames, 1983). The Salmonella typhimurium O-acetylase over-expressing YG1024 
bacterial strain was employed (see Section 2.2.8).
4.2.5 Metabolism of PEITC by rat and human liver slices
Groups of three rats were treated with different cytochrome P450 inducers. In groups 1 and 2, 
drinking water was supplemented with 0.1% w/v phénobarbital or isoniazid (equivalent to 
100 mg/kg) for 10 days; groups 3 and 4 were given p-naphthoflavone (25 mg/kg) or 
dexamethasone (100 mg/kg), both dissolved in com oil by intraperitonial injection and gastric 
gavage respectively for 3 consecutive days, and animals were killed 24 hr later. Livers were 
rapidly excised and liver slices from each rat (n=3) were individually prepared as described in 
Section 2.2.2, and incubated with 5 pM PEITC for different time periods (0-8 hr). On 
completion of the incubation, slices were removed from culture media prior to storage at -80 
°C for further analysis. In the human study, liver slices from Donor 4 were used.
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The effect of specific CYP450 enzyme inducers on PEITC metabolism, as exemplified by 
PEITC disappearance over the incubation period, was investigated. The collected media from 
each time point were centrifuged at 3000 xg for 5 min to remove any impurity prior to 60 pi 
of medium being spiked with deuterated PEITC (at a final concentration 1.5 pM) and 
subjected to liquid extraction and derivatisation; PEITC concentration in the culture media 
was determined using LC-TOF-MS (see Sections 7.2.2 and 7.2.3).
In order to ensure that changes in metabolism are due to modulation of the CYP450 and not 
the result of increased conjugation with glutathione, GST activity, using the broad substrate 
CDNB in liver cytosol was determined (see Sections 2.2.22 and 2.2.4.2); this was supported 
by Western blot analysis using antibodies against GSTa and GSTp (Section 2.2.7). Total 
protein content of cytosol in whole liver and liver slices was determined (Section 2.2.2.3), the 
latter being used to normalise disappearance of PEITC in culture media from individual 
slices.
4.3 Results
4.3.1 Body growth
The body weight of animals was recorded throughout the treatment period. Body weight gain 
was not influenced by the PEITC treatment (Fig. 4.1), and no abnormal behaviour was noted. 
In addition, supplementation of the diets with PEITC did not perturb food consumption and 
consequently the expected dose intake of PEITC was achieved.
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Figure 4.1. Body weight changes in rats exposed to PEITC. Rats were given diets 
supplemented PEITC with 0.06 (Low dose), 0.6 (Medium dose) or 6.0 (High dose) pmole/g 
diet for 14 days, whereas another group served as control. Results are presented as mean ± SD 
of five rats.
4.3.2 Modulation of cytochrome P450 enzymes in liver and extrahepatic tissues of rats 
treated with PEITC
4.3.2.1 Modulation o f cytochrome P450 enzyme activities by PEITC in rat liver 
Administration of PEITC at Low dose significantly impaired EROD and MROD activities, 
selectively mediated by CYPlAl and 1A2 respectively (Fig. 4.2). A modest drop in activity 
was also observed in CYP2E1, as exemplified by hydroxylation of /7-nitrophenol, but at the 
two higher doses only. In contrast, PROD activity, a marker for CYP2B (Fig. 4.2) and, to a 
lesser extent BOD, a marker for CYP3A2 (Renwick et al., 2001), as well as total cytochrome 
P450 were elevated at only the High dose (Fig. 4.2). Immunoblot analysis revealed a small 
decrease in CYPlAl and 1A2 apoprotein levels at the Low dose relative to control. A marked 
dose-dependent rise in CYP1A2 levels was clearly evident at the Medium and High doses, 
and in the case of CYPlAl only at the High dose (Fig. 4.3). Apoprotein levels of CYPIBI 
were elevated at the Low dose, but the effect decreased at the higher doses. When 
microsomes were probed with antibody to CYP2B, the expression was enhanced at the 
Medium and High doses. On the other hand, CYP2E1 apoprotein levels decreased modestly
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in a concentration-dependent m anner (Fig. 4 .3 ). F inally, a m odest rise in C Y P 3A 2 apoprotein  
lev e ls  w as ob served  in the anim als exp osed  to the H igh  dose o f  PEITC (F ig. 4 .3 ).
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Figure 4.2 Effect of PEITC on cytochrome P45G enzyme activities and total cytochrome 
P450 content in rat liver. Groups of five rats were exposed to diets supplemented with 
PEITC at 0.06 (Low dose), 0.6 (Medium dose) and 6.0 (High dose) pmole/g diet for 14 days, 
whereas another group served as control. At the end of the treatment period, hepatic S9 was 
prepared and then microsomes were isolated and used to determine cytochrome P450 
activities. Results are presented as mean ± SD of five rats. * P<0 05- ** P<0 OT 
***,P<0.001.
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Figure 4.3 Effect of PEITC on cytochrome P450 apoprotein levels in rat liver. Rats were 
maintained on diets supplemented with PEITC at 0.06 (Low dose), 0.6 (Medium dose) and 
6.0 (High dose) pmole/g diet for 14 days, whereas another group served as control. Hepatic 
microsomal proteins from pooled animals were solubilised and resolved by 10% (w/v) SDS- 
PAGE before being transferred electrophoretically to polyvinylidene difluoride membrane. 
The immunoblot analysis was carried out by exposure to mouse anti-rat CYPlAl, mouse 
anti-rat CYP1A2, goat anti-rat CYP2B, CYP2E1 or rabbit anti-rat CYP3A2 and CYPIBI 
primary antibodies followed by the appropriate secondary antibody. Lanes 1, 2, 3 and 4 refer 
to Control, Low, Medium, and High dose of PEITC, respectively. Each lane was loaded with 
30 pg of total protein except in the case of CYP1A2 (15 pg). Values above blots show % 
levels of optical density of each band relative to control.
43.2.2 Modulation o f cytochrome P450 enzyme activities by PEITC in rat lung 
Administration of the High dose of PEITC led to a marked rise in both EROD activity and 
CYPlAl apoprotein levels in rat lung; PROD activity, on the other hand, was suppressed at 
the High dose (Fig. 4.4) whereas CYP2B apoprotein levels were elevated by 60% following 
Medium and High dose intake. A modest increase in CYP2E1 apoprotein levels was also 
evident in the High dose group, but CYPIBI was not influenced by PEITC treatment (Fig. 
4.5).
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Figure 4.4 Modulation of EROD and PROD activities by PEITC in rat lung. Groups of 
five rats were exposed to diets supplemented with PEITC at 0.06 (Low dose), 0.6 (Medium 
dose) and 6.0 (High dose) pmole/g diet for 14 days, whereas another group served as control. 
Results are presented as mean ± SD of five rats. *, P<0.05; **, P<0.01.
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Figure 4.5 Modulation of cytochrome P450 apoprotein levels by PEITC in rat lung. Rats 
were exposed to diets supplemented with PEITC at 0.06 (Low dose), 0.6 (Medium dose) and
6.0 (High dose) pmole/g diet for 14 days, whereas another group served as control. 
Pulmonary microsomal proteins from pooled animals were solubilised and resolved by 10% 
(w/v) SDS-PAGE before being transferred electrophoretically to polyvinylidene difluoride 
membrane. Immunoblot analysis was carried out by exposure to mouse anti-rat CYPlAl, 
goat anti-rat CYP2B, CYP2E1 or rabbit anti-rat CYPIBI primary antibodies followed by the 
appropriate peroxidase-labelled secondary antibody. Lanes 1, 2, 3 and 4 refer to Control, 
Low, Medium, and High dose of PEITC, respectively. Each lane was loaded with 30 pg of 
total protein. Values above blots show % levels of optical density of each band relative to 
control.
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4 .3 .2 3  M odulation o f  cytochrom e P 450  enzyme activities by PEITC in ra t kidney 
In the kidney, treatment with PEITC had no significant effect on EROD and PROD activities 
(Fig. 4.6). Immunodetectable CYP2E1 was not influenced by PEITC but, on the other hand, 
expression of CYP2B decreased markedly in a dose-dependent manner (Fig. 4.7). 
Dealkylation of 7-benzyloxyquinoline was undetectable in kidney and no band was 
recognised when kidney microsomes were probed with antibody to CY PIBI.
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Figure 4.6 Effect of PEITC on cytochrome P450 enzyme activities in rat kidney. Groups 
of five rats were exposed to diets supplemented with PEITC at 0.06 (Low dose), 0.6 (Medium 
dose) and 6.0 (High dose) pmole/g diet for 14 days, whereas another group served as control. 
At the end of the treatment period, S9 from kidney was prepared prior to microsomes being 
isolated and used to determine cytochrome P450 activities. Results are presented as mean ± 
SD of five rats.
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Figure 4.7 Effect of PEITC on cytochrome P450 apoprotein levels in rat kidney. Rats 
were exposed to diets supplemented with PEITC at 0.06 (Low dose), 0.6 (Medium dose) and 
6.0 (High dose) pmole/g diet for 14 days, whereas another group served as control. Kidney 
microsomal proteins from pooled animals were solubilised and resolved by SDS-PAGE 
before being transferred electrophoretically to polyvinylidene difluoride membrane. The 
immunoblot analysis was carried out by exposure to goat anti-rat CYP2B or CYP2E1 primary 
antibodies followed by the appropriate peroxidase-labelled secondary antibody. Lanes 1,2,3 
and 4 refer to Control, Low, Medium, and High dose of PEITC, respectively. Each lane was 
loaded with 30 pg of total protein. Values above blots show % levels of optical density of 
each band relative to control.
4.3.3 Phase II detoxicifation enzymes in liver and extrahepatic tissues of rats treated 
with PEITC
4.3.3.1 Modulation o f phase II  enzyme activities by PEITC in rat liver 
At all doses studied, a rise in GST activity was noted when assessed using CDNB as 
substrate, but the effect was seen at the two higher doses and only at the highest dose when 
monitored using NBD-Cl and DCNB as test substrates respectively (Fig. 4.8). A modest, but, 
statistically significant increase in glutathione reductase activity was observed, whereas total 
glutathione levels were unaffected by the treatment with PEITC (Fig. 4.9). Finally, epoxide 
hydrolase activity increased at High dose only while NQOl activity was markedly elevated at 
all doses studied (Figs. 4.8 and 4.9). Immunoblot analysis employing antibodies to GSTa and 
p revealed an increase in expression at the High dose only. Protein levels of GSTtt rose by 
70% at the Low dose but the rise was less pronounced at higher doses (Fig. 4.10). NQOl 
protein levels were markedly up-regulated at all dose levels, and a modest increase was seen 
in epoxide hydrolase activity at the High dose (Fig. 4.10).
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Figure 4.8 Effect of PEITC on phase II enzyme activities in ra t liver. Groups of five rats 
were exposed to diets supplemented with PEITC at 0.06 (Low dose), 0.6 (Medium dose) and 
6.0 (High dose) pmole/g diet for 14 days, whereas another group served as control. At the end 
of the treatment period, hepatic S9 was prepared from which cytosol and microsomes were 
isolated and used to determine phase II enzyme activities. Results are presented as mean ± SD 
of five rats. *, P<0.05; **, P<0.01; ***, P<0.001.
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Figure 4.9 Effect of PEITC on cytosolic enzyme activities and total glutathione content 
in rat liver. Groups of five rats were exposed to diets supplemented with PEITC at 0.06 (Low 
dose), 0.6 (Medium dose) and 6.0 (High dose) pmole/g diet for 14 days, whereas another 
group served as control. At the end of the treatment period, hepatic S9 was prepared and then 
cytosol was isolated and used to determine enzyme activities and total glutathione content. 
Results are presented as mean ± SD of five rats. *, P<0.05; **, P<0.01; ***, P<0.001.
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Figure 4.10 Effect of PEITC on phase II enzyme protein levels in rat liver. Rats were 
maintained on diets supplemented with PEITC at 0.06 (Low dose), 0.6 (Medium dose) and 
6.0 (High dose) pmole/g diet for 14 days, whereas another group served as control. Hepatic 
cytosolic or microsomal proteins from pooled animals were solubilised and resolved by 10% 
(w/v) SDS-PAGE before being transferred electrophoretically to polyvinylidene difluoride 
membrane. The immunoblot analysis was carried out by exposure to rabbit anti-rat GSTAl-1, 
GSTMl-1, GSTP 1-1, NQOl or epoxide hydrolase primary antibodies followed by the 
appropriate secondary antibody. Lanes 1, 2, 3 and 4 refer to Control, Low, Medium, and High 
dose of PEITC, respectively. Each lane was loaded with 30 pg (NQOl and epoxide 
hydrolase) or 15 pg (GSTAl-1, GSTMl-1 and GSTPl-1) of total protein. Values above blots 
show % levels of optical density of each band relative to control.
433 .2  Modulation o f phase II  enzyme activities by PEITC in rat lung 
PEITC treatment failed to modulate activity of GST in lung, whether CDNB or NBD-Cl was 
used as accepting substrates; similarly, epoxide hydrolase, glutathione reductase, NQOl as 
well as total glutathione concentration were unaffected (Figs. 4.11 and 4.12). No GST 
activity was detectable in the lung cytosol when DCNB served as substrate. At the protein 
level, no increase was seen in any of the enzymes studied, except for a modest rise in GSTp at 
the High dose (Fig. 4.13).
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Figure 4.11 Effect of PEITC on phase II enzyme activities in ra t lung. Groups of five rats 
were exposed to diets supplemented with PEITC at 0.06 (Low dose), 0.6 (Medium dose) and 
6.0 (High dose) pmol/g diet for 14 days, whereas another group served as control. At the end 
of the administration period, pulmonary S9 was prepared prior to cytosol and microsomes 
being isolated and used to determine phase II activities. Results are presented as mean ± SD 
of five rats.
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Figure 4.12 Effect of PEITC on cytosolic enzyme activities and total glutathione content
in rat lung. Groups of five rats were exposed to diets supplemented with PEITC at 0.06 (Low 
dose), 0.6 (Medium dose) and 6.0 (High dose) pmol/g diet for 14 days. At the end of the 
administration period, pulmonary S9 was prepared prior to cytosol being isolated and used to 
determine cytosolic enzyme activities and total glutathione content. Results are presented as 
mean ± SD of five rats.
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Figure 4.13 Effect of PEITC on phase II enzyme protein levels in rat lung. Rats were 
exposed to diets supplemented with PEITC at 0.06 (Low dose), 0.6 (Medium dose) and 6.0 
(High dose) pmole/g diet for 14 days, whereas another group served as control. Pulmonary 
cytosolic proteins from pooled animals were resolved by SDS-PAGE before being transferred 
electrophoretically to polyvinylidene difluoride membrane. The immunoblot analysis was 
carried out by exposure to rabbit anti-rat GSTAl-1, GSTMl-1, GSTP 1-1 or NQOl primary 
antibodies followed by the appropriate peroxidase-labelled secondary antibody. Lanes 1, 2, 3 
and 4 referred to Control, Low, Medium, and High dose of PEITC, respectively. Each lane 
was loaded with 30 pg (NQOl) or 15 pg (GSTAl-1, GSTMl-1 and GSTPl-I) of total 
protein. Values above blots show % levels of optical density of each band relative to control.
4.3.3.3 Modulation o f phase II enzyme activities by PEITC in rat kidney 
A marked rise was evident in NQOl and epoxide hydrolase activities in animals receiving the 
High dose of PEITC (Figs. 4.14 and 4.15). However, the same treatment failed to modulate 
GST measured by using CDNB and NBD-Cl as substrates (Fig. 4.14) as well as glutathione 
reductase activity and total glutathione content (Fig. 4.15). The activity of GST assessed 
using DCNB as a substrate was undetectable in the kidney. A marked induction of NQOl 
protein levels was noted at High dose whereas GSTp, a and n were not influenced by PEITC 
treatment (Fig. 4.16).
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Figure 4.14 Effect of PEITC on phase II enzyme activities in ra t kidney. Groups of five 
rats were exposed to diets supplemented with PEITC at 0.06 (Low dose), 0.6 (Medium dose) 
and 6.0 (High dose) pmole/g diet for 14 days, whereas another group served as control. At the 
end of the treatment period, S9 from kidney was prepared prior to cytosol and microsomes 
being isolated and used to determine phase II activity. Results are presented as mean ± SD of 
five rats.
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Figure 4.15 Effect of PEITC on cytosolic enzyme activities and total glutathione content 
in rat kidney. Groups of five rats were exposed to diets supplemented with PEITC at 0.06 
(Low dose), 0.6 (Medium dose) and 6.0 (High dose) pmole/g diet for 14 days, whereas 
another group served as control. At the end of treatment period, S9 from kidney was prepared 
prior to cytosol being isolated and used to determine cytosolic enzyme activities and total 
glutathione content. Results are presented as mean ± SD of five rats.**, P<0.01.
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Figure 4.16 Effect of PEITC on phase II enzyme protein levels in rat kidney. Rats were 
exposed to diets supplemented with PEITC at 0.06 (Low dose), 0.6 (Medium dose) and 6.0 
(High dose) pmole/g diet for 14 days, whereas another group served as control. Solubilised 
cytosolic proteins from the kidneys of pooled animals were resolved by SDS-PAGE before 
being transferred electrophoretically to polyvinylidene difluoride membrane. The immunoblot 
analysis was carried out by exposure to rabbit anti-rat GSTAl-1, GSTMl-1, GSTP 1-1 or 
NQOl primary antibodies followed by the appropriate peroxidase-labelled secondary 
antibody. Lanes 1, 2, 3 and 4 refer to Control, Low, Medium, and High dose of PEITC, 
respectively. Each lane was loaded with 30 pg (NQOl) or 15 pg (GSTAl-1, GSTMl-1 and 
GSTPl-1) of total protein. Values above blots show % levels of optical density of each band 
relative to control.
4.3.4 Modulation of IQ metabolism by PEITC
Bioactivation of heterocyclic amine IQ to mutagenic intermediates in the Ames test was 
determined in the presence of activation systems containing S9, e.g. Aroclor 1254-induced 
microsomes or microsomes isolated from PEITC-pretreated rats (Control, Low, Medium and 
High dose); Aroclor 1254-induced S9 was used as positive control. A concentration- 
dependent mutagenic response to IQ was evident in the presence of all activation systems, 
with Aroclor 1254-induced S9 being by far the most efficient (Fig. 4.17). Treatment with 
PEITC did not have a major influence on the bioactivation of IQ.
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Figure 4.17 Effect of PEITC treatment on IQ mutagenic activity. Rats were fed diets 
supplemented with PEITC at 0.06 (Low dose), 0.6 (Medium dose) and 6.0 (High dose) 
pmole/g diet for 14 days, whereas another group served as control .Mutagenic activity was 
determined in the presence of activation systems containing hepatic S9 (10% v/v) derived 
from Aroclor 1254-induced (positive control) or PEITC-pretreated rats (Control, Low, 
Medium and High dose). Salmonella typhimurium strain YG1024 and IQ (0-50 ng/plate). The 
spontaneous reversion rate of 24 ± 6 has already been subtracted. Results are presented as 
mean ± SD of triplicate plates.
4.3.5 Mechanism of CYPlAl inhibition by PEITC in rat liver
A marked rise in CYPlAl expression in rat liver at the High dose of PEITC was not 
paralleled by a similar increase EROD activity, raising the possibility that PEITC may 
function as a mechanism-based inhibitor. Modulation of EROD activity in Aroclor 1254- 
induced microsomes by PEITC was investigated, in order to test this hypothesis.
PEITC decreased EROD activity, in a concentration-dependent manner, to about 40% at the 
highest PEITC (50 pM) concentration studied (Fig. 4.18). The extent of inhibition was far 
more pronounced when a pre-incubation step was introduced where PEITC was incubated 
with microsomes in the presence of NADPH resulting in a decline of activity to about 40% at 
a concentration of only 2 pM (Fig. 419). In further studies it was established that the 
inhibition was a function of pre-incubation time with extent of inhibition increasing with pre­
incubation time (Fig. 4.20). Moreover, addition of reduced glutathione, at concentrations > 50 
pM, restored EROD activity, when no pre-incubation was performed, whereas oxidised
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glutathione failed to do so under identical conditions (Fig. 4.21). Finally, the addition of 
reduced glutathione to the reaction mixture, after a 20-min of pre-incubation, similarly re­
established EROD activity, being 80% of control when 1 mM of reduced glutathione was 
employed (Fig. 4.22).
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Figure 4.18 Effect of PEITC on EROD activity in Aroclor 1254-indnced rat liver 
microsomes. The reaction mixture comprised hepatic microsomes from Aroclor 1254-treated 
rats in the presence of PEITC (0-50 pM) and NADPH (0.25 mM), and was initiated by the 
addition of ethoxyresorufm (2.5 pM). Results are presented as mean ± SD of triplicate 
determinations. 100% Activity was 1.34 ± 0.25 nmol/min/mg protein. *, P<0.05; **, P<0.01; 
***,P<O.OOT
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Figure 4.19 Effect of PEITC on EROD activity in Aroclor 1254-induced rat microsomes 
following pre-incubation of PEITC in the presence of NADPH. The reaction mixture 
comprised hepatic microsomes from Aroclor 1254-treated rats in the presence of PEITC (0-2 
pM) and NADPH (0.25 mM), and was pre-incubated at 37 °C for 20 min. At the end of this 
period, the reaction was initiated by the addition of ethoxyresorufm (2.5 pM). Results are 
presented as mean ± SD of triplicate determinations. 100% Activity, in the absence of PEITC 
after pre-incubation, was 1.14 ± 0.02 nmol/min/mg protein. *, P<0.05; **, P<0.01; 
***,P<0.001.
125
Chapter 4: Tissue differences in the in vivo modulation o f  xenobiotic-metabolising enzymes by PEITC
^  120 n
**
80 - ***
^  60 - ***
***
40 -
20 -
0 5 10 15 20 25 30
Pre-incubation time (min)
Figure 4.20 Effect of pre-incubation time on the PEITC-mediated inhibition of EROD 
activity in Aroclor 1254-induced rat liver microsomes. Hepatic microsomes from Aroclor 
1254-treated rats fortified with 0.25 mM NADPH were pre-incubated at 37 in the presence 
(1 pM) or absence of PEITC for various periods of time. The reaction was initiated by the 
addition of ethoxyresorufin (2.5 pM). 100% Activity, in the absence of PEITC and without 
pre-incubation, was 1.39 ± 0.05 nmol/min/mg protein. Results are presented as mean ± SD of 
triplicate determinations. *, P<0.05; **, P<0.01; ***, P<0.001.
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Figure 4.21 Effect of reduced/oxidised glutathione on PEITC-mediated inhibition of 
EROD activity. The reaction mixture comprised hepatic microsomes from Aroclor 1254- 
treated rats fortified with 0.25 mM NADPH and reduced or oxidised glutathione (0-150 pM) 
in the presence of PEITC (25 pM), and was initiated by the addition of ethoxyresorufin (2.5 
pM). Results are presented as mean ± SD of triplicate determinations. 100% Activity, in the 
absence of PEITC and glutathione, was 1.26 ± 0.04 nmol/min/mg protein. *, P<0.05; 
**, P<0.01; ***, P<0.001.
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Figure 4.22 Effect of reduced/oxidised glutathione on PEITC-mediated inhibition of 
EROD activity following pre-incubation. The reaction mixture comprising hepatic 
microsomes from Aroclor 1254-treated rats, NADPH (0.25 mM) and reduced or oxidised 
glutathione (0-1000 pM) in the presence of PEITC (1 pM), was pre-incubated for 20 min at 
37 °C. After incubation, the reaction was initiated by the addition of ethoxyresorufm (2.5 
pM). The results are presented as mean ± SD of triplicate determinations. 100% Activity, in 
the absence of PEITC and glutathione without pre-incubation, was 1.48 ± 0.02 nmol/min/mg 
protein. *, P<0.05; **, P<0.01; ***, P<0.001.
43.5.1 Characterisation o f the kinetics o f PEITC-mediated EROD inhibition
To further characterise the PEITC-mediated enzyme inhibition, EROD activity in hepatic 
microsomes from Aroclor 1254-treated rats was determined at various substrate 
concentrations in the presence of two PEITC concentrations (10 or 25 pM). Michaelis- 
Menten parameters (Km and Vmax) were derived using Graphpad Software, in accordance 
with Michaelis-Menten and Lineweaver-Burk plots. PEITC was a potent competitive inhibitor 
of EROD activity (Figure 4.23) and having a Ki of 12.82 ± 2.45 pM; Km and Vmax values as 
shown in Table 4.1 A.
43.5.2 Characterisation o f the PEITC- metabolite(s)-mediated EROD inhibition
Similar analysis was carried out to characterise inhibition caused by PEITC-metabolite(s), i.e. 
following a pre-incubation period. The PEITC-metabolite(s) non-competitively impaired 
EROD activity (Fig. 4.24). The apparent Ki (0.41 ± 0.099 pM) revealed a greater inhibitoiy 
potency of the mctabolite(s) compared with parent PEITC. The Km and Vmax values are 
shown in Table 4. IB.
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Figure 4.23 Lineweaver-Burk plot of EROD activity in Aroclor 1254-induced 
microsomes in the presence of PEITC. EROD activity was determined over a range of 
ethoxyresorufm concentrations (10-2000 nM) and three different PEITC concentrations, 0, 10 
and 25 pM. The reaction mixture comprised PEITC, Aroclor 1254-induced microsomes and 
0.25 mM NADPH, and was initiated by the addition of substrate. Results are presented as 
mean ± SD of triplicate determinations.
Treatment Vmax 
(nmol/min/mg protein)
Km (pM)
Control 5.45 ±0.19 74.3 ± 10.8
PEITC 10 pM 4.71 ±0.26 125.4 ±27.7
PEITC 25 pM 5.07 ±0.19 242.0 ± 32.4
B
Treatment Vmax Km(pM)
(nmol/min/mg protein)
Control 2.12 ±0.06 63.49 ±6.8
PEITC 0.5 pM 1.45 ±0.09 62.92 ±16.4
PEITC 1 pM 1.02 ±0.10 76.17± 1.6
Table 4.1 The effect of PEITC on kinetics of PEITC- (A) and PEITC metabolite(s)- (B) 
mediated CYPlAl inhibition. EROD activity was determined over a range of 
ethoxyresorufm concentrations and three different PEITC concentrations as an inhibitor. The 
reaction mixture comprised PEITC, Aroclor 1254-induced microsomes and 50 mM NADPH, 
with or without pre-incubated at 37 °C for 30 min. Finally, the reaction was initiated by the 
addition of the substrate. Results are presented as mean ± SD of triplicate determinations.
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Figure 4.24 Lineweaver-Burk plot of EROD activity in Aroclor 1254-induced 
microsomes in the presence of PEITC-metabolite(s). EROD activity was determined over 
a range of ethoxyresorufm concentrations (10-1000 nM) and three different PEITC 
concentrations, 0, 0.5 and 1 pM, as an inhibitor. The reaction mixture comprised PEITC, 
Aroclor 1254-induced microsomes and 0.25 mM NADPH, and was pre-incubated at 37 °C for 
30 min. Finally, the reaction was initiated by the addition of the substrate. Results are 
presented as mean ± SD of triplicate determinations.
4.3.53 Binding o f PEITC to GYP 4 50
Cytochrome P450 spectra in control rat microsomes (25%, w/v) fortified with a range of 
PEITC concentrations with or without pre-incubation for 30 min at 37 °C, in the presence of 
NADPH, were recorded. P450 spectra, as exemplified by the absorption difference between 
450 and 490 nm, showed that both PEITC and its metabolite(s) diminished total cytochrome 
P450 content, but the latter was more pronounced (Fig. 4.25); the NADPH-dependent 
decrease was directly related to the duration of pre-incubation (Fig. 4.26).
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Figure 4.25 Effect of PEITC (■) and PEITC-metabolite(s) (A) on total cytochrome P450 
content. Hepatic microsomal suspension (0.5 ml), 0.25 mM NADPH and a range of PEITC 
concentrations (0-50 pM) were added into 2.5 ml of 0.1 M potassium phosphate buffer, pH 
7.6 in a cuvette. P450 spectra in the absence or presence of a pre-incubation period of 30 min 
at 37 °C were recorded. Results are presented as mean ± SD of triplicate determinations. 
100% Values with and without pre-incubation were 0.72 ± 0.03 and 0.78 ± 0.04 nmol/mg 
protein, respectively. *, P<0.05; **, P<0.01.
120 1
t  100
o
2
80
60 •
40 -
20 -
i --------
—I------------ 1---------- 1—
5 10 20
Pre-incubation time (min)
30 40
Figure 4.26 Effect of prc-incubation time on the PEITC-mediated effects on total 
cytochrome P450 content. Hepatic microsomal suspension (0.5 ml) and 0.25 mM NADPH 
were added into 2.5 ml of 0.1 M potassium phosphate buffer, pH 7.6 in a cuvette. The mixture 
was pre-incubated in the absence or presence of PEITC (25 pM) for various time periods (0- 
40 min) prior to total P450 determination. Results are presented as mean ± SD of triplicate 
determinations. 100% Value, in the absence of PEITC and without pre-incubation, was 0.69 ± 
0.02 nmol/mg protein. *, P<0.05; **, P<0.01; ***, P<0.001.
4.3.6 Mechanism of EROD inhibition by PEITC in human liver
In human liver slices, treatment with PEITC led to a decrease in EROD activity but in two of 
the four liver samples, a marked rise of apoprotein levels of CYPlAl was observed (see 
Section 3.3.4), indicating that induced CYPlAl may be catalytically incompetent, as a
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consequence of mechanism-based inactivation. Studies were undertaken, as already described 
for the rat, but using human hepatic microsomes. In the absence of a pre-incubation step, 
PEITC at the highest concentration investigated (7.5 pM) suppressed EROD activity about 
20% (Fig. 4.27). However, following a 20-minute pre-incubation, an 80% loss of activity was 
observed at PEITC concentration of only 2 pM (Fig. 4.28). The extent of inhibition was 
directly related to the pre-incubation time (Fig. 4.29).
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Figure 4.27 Effect of PEITC on EROD activity in human liver microsomes. The reaction 
mixture comprised human hepatic microsomes and PEITC (1-7.5 pM ), and reaction was 
initiated by the addition of ethoxyresorufm (0.5 pM). Results are presented as mean ± SD of 
triplicate determinations. 100% Activity was 1.45± 0.08 pmol/min/mg protein. *, P<0 05' 
**,P<0.01; ***, P<0.001.
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Figure 4.28 Effect of PEITC on EROD activity in human liver microsomes following 
pre-incubation of PEITC in the presence of NADPH. The reaction mixture comprised 
human hepatic microsomes and PEITC (0.25-2 pM), and was pre-incubated at 37 °C for 20 
min in the presence of NADPH (0.25 mM). At the end of the pre-incubation period, the 
reaction was initiated by the addition of ethoxyresorufin (0.5 pM). Results are presented as 
mean ± SD of triplicate determinations. 100% Activity, in the absence of PEITC after pre­
incubation, was 0.91 ± 0.03 pmol/min/mg protein. *, P<0.05; **, P<0.01; ***, P<0.001.
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Figure 4.29 Effect of pre-incubation time on the PEITC-mediated effects on EROD 
activity in human liver microsomes. Human hepatic microsomes fortified with 0.25 mM 
NADPH, in the absence or presence of PEITC (1 pM), were pre-incubated at 37 °C for 
various periods of time. The reaction was initiated by the addition of ethoxyresorufin (0.5 
pM). 100% Activity, in the absence of PEITC and without pre-incubation, was 1.26 ± 0.05 
pmol/min/mg protein Results are presented as mean ± SD of triplicate determinations. 
*, P<0.05; **, P<0.01; ***, P<0.001.
4.3.7 Phenethyl isocyanate (PEIC) as an inhibitor of EROD activity in rat and human 
liver microsomes.
Mechanism-based inhibition by PEITC of EROD activity implies that a generated 
metabolite(s) of the isothiocyanate irreversibly binds to CYPlAl leading to inactivation. It 
has been proposed that such metabolite, resulting from cytochrome P450 oxidation could be 
phenethyl isocyanate (PEIC) (Lee, 1994). Comparison of the inhibition potency between 
PEITC and PEIC was carried out in order to test this hypothesis. In rat, concentration- 
dependent inhibition of EROD activity by PEIC was noted, however, no profound difference 
was perceived relative to that of PEITC in the absence of pre-incubation (Fig. 4.30A). A 
similar picture emerged when human liver microsomes were used (Fig. 4.3OB).
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Figure 4.30 Effect of PEITC and PEIC on EROD activity in Aroclor 1254-induced rat 
liver microsomes (A) or control human liver microsomes (B). Microsomes were mixed 
with ethoxyresorufin (0.5 ^iM) and a range of PEITC or PEIC concentrations (0-7.5 pM). The 
reaction was directly initiated by the addition of NADPH (0.25 mM). 100% Activities in rat 
and human microsomes were 1.45 ± 0.02 nmol/min/mg protein and 1.26 ± 0.03 pmol/min/mg 
protein respectively. Results are presented as mean ± SD of triplicate determinations (the 
small SD values were within the size of the symbols). *, P<0.05; **,P<0.01; ***, P<0.001.
4.3.8 Mechanism of CYP2B inhibition by PEITC in rat lung
As already indicated, PEITC at High dose elicited a pronounced decrease in pulmonary 
PROD activity whereas CYP2B apoprotein levels increased. To address this discrepancy, 
further studies were carried out to establish the underlying mechanism. PROD activity in 
phenobarbital-induced lung microsomes was markedly inhibited by PEITC in a
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concentration-dependent manner, a 50% loss of activity was observed at PEITC concentration 
of only 0.5 pM (Fig. 4.31). When a pre-incubation step was introduced to allow metabolism 
of PEITC, the inhibition potency was not enhanced (Figs. 4.31 and 4.32). Moreover, extent of 
inhibition was not influenced by the pre-incubation period up to 30 min (Fig. 4.33).
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Figure 4.31 Effect of PEITC on PROD activity in phénobarbital indnced-Inng 
microsomes. To pulmonary microsomes derived from phénobarbital treated-rats PEITC 
(0.5-25 pM) and 0.5 pM pentoxyresorufin were added, prior to the reaction being initiated by 
the addition of 0.25 mM NADPH. 100% Activity was 69.52 ± 9.00 pmol/min/mg protein 
Results are presented as mean ± SD of triplicate determinations. *, P<0.05; **, P<0.01; 
***,P<0.001.
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Figure 4.32 Effect of PEITC on PROD activity in phénobarbital indnced-Inng 
microsomes following pre-incnbation of PEITC in the presence of NADPH. Pulmonary 
microsomes from phenobarbital-treated rats were pre-incubated in the presence of PEITC 
(0.3-2 pM) and 0.25 mM NADPH at 37 °C for 30 min. The substrate pentoxyresorufin (0.5 
pM) was added to initiate the reaction. 100% Activity, in the absence of PEITC after pre­
incubation, was 46.0 ±8 . 0  pmol/min/mg protein. Results are presented as mean ± SD of 
triplicate determinations. *, P<0.05; **, P<0.01.
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Figure 4.33 Effect of pre-incubation time on the PEITC-mediated effects on PROD 
activity in rat lung. Pulmonary microsomes from phénobarbital treated-rat fortified with 
0.25 mM NADPH and pre-incubated at 37 °C for various periods of time in the presence (0.5 
pM) or absence of PEITC. The reaction was initiated by the addition of pentoxyresorufin (0.5 
pM). 100% Activity, in the absence of PEITC and without pre-incubation, was 80.32 ± 5.36 
pmol/min/mg protein. Results are presented as mean ± SD of triplicate determinations. 
*,P<0.05; **,P<0.01.
4.3.9 Contribution of cytochrome P450 enzymes to PEITC metabolism
PEITC was subject to chemical degradation during incubation in the medium in the absence 
of any slice, and control liver slices poorly metabolised the isothiocyanate, whereas human 
slices were more effective (Figs. 4.34 and 4.35). A PEITC disappearance was more rapid in 
phénobarbital (CYP2B)-induced liver slices whereas treatment of slices with isoniazid 
(CYP2E1), (3-naphthofiavone (CYPIA) and dexamethasone (CYP3A) had no influence (Fig. 
4.34).
Since the principal pathway of PEITC metabolism involves glutathione conjugation catalysed 
by GST (Brusewitz et al., 1977; Mennicke et al., 1987), GST activity in both induced and 
control rat liver was assessed using CDNB as substrate. Treatment with the various inducers 
had no effect on GST activity (Fig. 4.36). Similarly, no major influence was evident when 
immunoblot analysis was conducted using antibodies to GSTp and GSTa (Fig. 4.37).
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Figure 4.34 Time-course of PEITC disappearance following incubation with rat liver 
slices. Precision-cut rat liver slices from control and treated rats were incubated with PEITC 
(5 (J.M) for different time periods (0-8 hours). At the end of the incubation period, PEITC was 
determined in the media by LC-MS, whereas total homogenate protein was determined in the 
homogenised slices. Results are presented as mean ± SD of three rats, with each 
determination carried out in triplicate, ttt, P<0.001.
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Figure 4.35 Time-course of PEITC disappearance following incubation with human 
liver slices. Precision-cut human liver slices or rat liver slices from control rats were 
incubated with PEITC (5 pM) for different time periods (0-8 hours). At the end of the 
incubation period, PEITC was determined in the media by LC-MS, whereas total homogenate 
protein was determined in the homogenised slices. Results are presented as mean ± SD of 
three animals in the rat studies, with each determination carried out in triplicate, and as mean 
± SD of triplicate slices in the case of the human liver.
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Figure 4.36 Effect of CYP450 inducers on GST activity in rat liver. Hepatic GST activity, 
assessed using CDNB as substrate, in the liver of rats treated with various P450 inducers was 
determined. Values are presented as mean ± SD of three rats.
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Figure 4.37 Effect of CYP450 inducers on GST protein levels in rat liver. Cytosolic 
proteins from control and induced livers were isolated and equal amount of protein (15 pg) 
was loaded on to 10% (w/v) SDS-PAGE, and then transferred electrophoretically to Hybond- 
P polyvinylidene difluoride membrane. The immunoblot analysis was carried out by exposure 
to rabbit anti-rat GSTMl-1 or GSTAl-1 primary antibodies followed by peroxidase-labelled 
anti-rabbit IgG . Values above blots show % levels of optical density of each band relative to 
control. C, B, I, P and D refer to control, P-naphthoflavone, isoniazid, phénobarbital and 
dexamethasone respectively.
4.4 Discussion
The current study investigated the in vivo modulation of xenobiotic-metabolising enzymes by 
PEITC, as this emerged as a promising ehemoprevention mechanism in the studies utilising 
precision-cut rat and human liver slices (Chapter 3). Rats were treated with diets
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supplemented with 3 different doses, 0.06 (Low dose), 0.6 (Medium dose) and 6.0 (High 
dose) pmole PEITC/g diet for 14 days. The Low dose is commensurate with human dietary 
intake of total glucosinolates, 75 mg/person/day or 1.07 mg/kg body weight for a 70 kg 
individual (Sones et al., 1984), which is equivalent to an intake of 300 g watercress, the 
principal source of PEITC, based on 100 g watercress releasing approximately 25 mg PEITC 
(Chung et al., 1992; Hecht et al., 1996b; Jiao et al., 1996). Previous studies in animal models 
have employed either a single high dose, or chronic intake of higher doses than those 
employed in the present study (Guo et al., 1992; Ishizaki et al., 1990; Manson et al., 1997; 
Smith et al., 1993).
Studies were performed in three tissues; liver was chosen being the principal site of 
bioactivation of chemical carcinogens, lung being a principal target organ of the 
chemopreventive action of isothiocyanates, especially PEITC (Hecht et al., 1995; 1999; 
1996b; 2000; Jiao et al., 1996), whereas kidney plays a major role in the metabolism of 
isothiocyanates, processing the glutathione conjugates to the corresponding mercapturates 
(Holst and Williamson, 2004; Johnson, 2007).
4.4.1 Modulation of cytochrome P450 bioactivation enzymes by PEITC in liver and 
extrahepatic tissues
It has already been reported that dietary intake oflTCs such as sulforaphane has more limited 
effects on xenobiotic-metabolising enzymes systems compared to the higher doses employed 
in many animal studies (Yoxall et al., 2005). However, in the current study, treatment of 
animals with the Low dose of PEITC showed a promising anticarcinogenic action by 
decreasing hepatic activity of EROD and MROD, accompanied with a decrease in associated 
apoprotein levels, indicating that impairment of enzyme activities was the result of low 
enzyme availability. Bearing in mind the role of CYPl in the bioactivation of chemical 
carcinogens (loannides and Parke, 1990), these findings support a role of PEITC in
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suppressing bioactivation, even at dietary doses, as previously established in human and rat 
liver slices (Chapter 3). However, the Low dose did not influence CYP450 enzymes in neither 
lung or kidney, implying that CYP450 enzymes in liver may be more sensitive to treatment 
with PEITC.
It is of interest that down-regulation of CYPIA was observed at only the Low dose and was 
accompanied by a small, though statistically non-significant, decrease in total glutathione 
concentration at the same dose. Although the molecular mechanisms of CYP450 inhibition 
have not been fully clarified, it has been demonstrated that down-regulation of CYPlAl may 
be enhanced by reactive oxygen species (ROS) through the suppression of Nuclear factor 1 
(NFI) gene promoter (Morel and Barouki, 1998), and may contribute to the CYP450 
inhibition at the Low dose. The extent of ROS accumulation in the Low dose may be higher 
than that in other two high doses due to relatively lower induction of phase II detoxicification 
enzymes and reduction of cellular GSH at this dose; however, more direct experimental 
evidence is required to support such mechanism.
In contrast, at the higher doses, PEITC did not influence hepatic EROD and MROD activities 
but a marked rise of CYPIA apoprotein levels was observed, suggesting that mechanism- 
based inhibition may be responsible for this discrepancy. At the protein levels CYPIBI is 
expressed in a tissue-specific pattern (McFadyen and Murray, 2008) with relatively high 
levels in the lung but low levels in the liver (Pushparajah et al., 2007; Walker et al., 1995), 
whereas in the mouse kidney it is only detectable at the mRNA level, at very low 
concentration (Ryu and Hodgson, 1999). CYPlBl activity was not determined due to lack of 
selective probe; however, hepatic apoprotein levels increased at the Low dose. As CYP1A2 is 
not expressed in extrahepatic tissues (Kimura et al., 1986), only CYPlAl and CYPIBI were 
investigated in the lung and kidney. In the lung, a significant rise in EROD activity following 
exposure to the High dose of PEITC, concomitant with a rise in CYPIAI/Bl apoprotein
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levels, indicating that the enhanced activity is a consequence of increased enzyme 
availability. These findings would suggest that PEITC does not function as a mechanism- 
based inhibitor in lung, presumably because the CYP-dependent metabolite(s) is either not, or 
very poorly, generated in this tissue, and the absence of CYP1A2 in lung may be the 
responsible factor. In contrast, no significant change in EROD activity was noted in the 
kidney and no immunodetectable band was observed following probing with CYPIBI 
antibodies, presumably due to its poor expression as already discussed (vide supra). Hepatic 
PROD and BOD increased concomitantly with CYP2B and CYP3A2 apoprotein levels as a 
result of treatment with PEITC. Similarly, a 7-fold rise of hepatic PROD following a single 
high dose of PEITC has been demonstrated in F344 rats (Guo et al., 1992). PROD activity in 
kidney was unaffected by the PEITC treatment indicating tissue-differences in the modulation 
of cytochrome P450 enzymes in the rat. In lung. High dose of PEITC led to a marked 
decrease in PROD activity; the apoprotein level of CYP2B was, however, not similarly 
diminished. This raises the possibility that catalytic activity of pulmonary CYP2B may be 
inhibited by PEITC and this aspect will be discussed in Section 4.4.3. In addition. High dose 
of PEITC was required to suppress PROD activity in mouse (Stoner and Morse, 1997).
PEITC has been demonstrated to function as a potent anticarcinogenic compound specifically 
in the lung of various animal species, but only when given before or concomitantly with the 
carcinogen (Nishikawa et al., 1999; 2004; 1996); in other words, blocking of the initiation 
stage of carcinogenesis. Modulation of CYP450 enzymes such as CYP2B1, one of the 
enzymes responsible for NNK bioactivation, has been established as a possible anticancer 
mechanism of PEITC in lung (Chung et ai., 1997; Conaway et al., 1996; Stoner and Morse, 
1997, Ye et al., 2007). Albeit only at the High dose, the present study also confirmed the 
ability of PEITC to impair the activity of pulmonary CYP2B. However, the same dose also 
led to a marked rise of pulmonary CYPlAl, the most active CYP isoform in the bioactivation 
of BaP (Conney, 1982; Pelkonen and Nebert, 1982). These findings support the previous
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reports that PEITC can only protect against NNK- but not BaP-induced lung tumorigenesis 
(Hecht, 1999a).
Hepatic hydroxylation of p-nitrophenol, selectively mediated by CYP2E1 (Koop et al., 1989), 
was moderately suppressed at the higher doses of PEITC. In fact, potent inhibition of hepatic 
rat CYP2E1 by PEITC has been reported in vivo (Lindros et ah, 1995), and was considered as 
a feasible strategy to use PEITC to minimise the hepatotoxicity of ethanol (McCarty, 2001). 
Pulmonary CYP2E1 apoprotein levels slightly elevated at High dose, whereas that in the 
kidney was unchanged.
4.4.2 Modulation of phase II enzymes in liver and extrahepatic tissues by PEITC
Following the Low dose administration, PEITC increased hepatic GST, when assessed using 
CDNB as accepting substrate, and glutathione reductase activities; NQOl was similarly 
elevated, paralleled with a rise in NQOl and a moderate rise in GSTtt protein levels. Clearly, 
even at dietary levels of intake detoxication enzymes may be up-regulated as a result of 
elevated enzyme levels; this contrasts with erucin and sulforaphane, both being aliphatic 
isothiocyanates where a rise in NQOl, but not GST was reported (Hanlon et ah, 2008). In the 
extrahepatic tissues studied, phase II enzymes were not influenced at this Low dose. At the 
High dose, a marked increase was observed in all hepatic activities, e.g. GSTs assessed using 
CDNB, DCNB and NBD-Cl as test substrates, NQOl and epoxide hydrolase, being the 
consequence of increased protein expression; glutathione reductase was also stimulated. 
GSTtc protein level was once again elevated but to a lesser extent compared with the Low 
dose. In lung and kidney, no activity was detectable when GST was determined using DCNB 
as substrate, presumably as a result of the poor expression of GSTp compared with the liver 
(Sherratt et ah, 2002). However, GST activity in both tissues was not influenced when either 
CDNB or NBD-Cl were used as substrates, indicating that the effects of PEITC are isoform- 
and tissue-specific in accordance to previous studies (van Lieshout et ah, 1996). Likewise,
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glutathione reductase activity in lung and kidney did not respond to PEITC treatment. On the 
other hand, epoxide hydrolase and NQOl activities in the kidney were elevated at High dose, 
whereas those in the lung were resistant to this treatment. The lack of the effect of PEITC on 
pulmonary NQOl has already been described (Guo et al., 1992). The tissue differences were 
also reflected at the protein level of quinone reductase.
In general, by contrast to liver, treatment of PEITC failed to modulate phase II enzyme 
activities determined in rat lung but inhibition of CYP2B activity was observed. These 
findings support previous reports that the inhibition of CYP450-dependent activation 
specifically CYP2B1, rather than the induction of phase II enzymes, is responsible for the 
chemopreventive effect of PEITC in rat lung (Smith et al., 1993; Yang et al., 1994).
To my knowledge, the effects of PEITC on phase II enzymes in rat kidney have never been 
reported. Nevertheless, in mice fed the structurally related isothiocyanate, BITC, GST activity 
assessed using CDNB and DCNB as substrates was enhanced, but to a lesser extent than 
quinone reductase (Benson and Barretto, 1985).
It should be noted that, the balance of activation and deactivation is pivotal in determining the 
anti-carcinogenic potency of PEITC. However, the study into the bioactivation of the 
heterocyclic amine IQ to mutagenic intermediates in the Ames test showed that the PEITC 
treatment did not have a major influence on the bioactivation of IQ. Nonetheless, activation 
systems derived from the rats administered Low dose tended to suppress mutagenic response, 
although no statistical significance was achieved. This was paralleled with a decrease in 
CYP1A2, as exemplified by MROD activity, the major enzyme catalysing the bioactivation 
of IQ (Snyderwine et al., 2002),
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4.4.3 Mechanism of hepatic CYPlAl and pulmonary CYP2B inhibition by PEITC in rat 
and human
At Medium and High doses of PEITC, hepatic EROD and MROD activities were not 
influenced despite a marked rise of CYPlAl and CYP1A2 apoprotein levels. Similar 
observations were made when human liver slices were used, but only in relation to EROD 
activity. Hence investigation of the underlying mechanism of CYPlAl inhibition was 
undertaken, and it was revealed that CYPlAl in rat and human liver was catalytically 
incompetent as a result of mechanism-based inhibition. Key findings consistent with this 
hypothesis associated with the inhibition of EROD activity was time- and NADPH- 
dependent, and was direct relationship to pre-incubation time. It may be inferred that 
unidentified reactive PEITC-metabolite(s) are generated that engage in covalent binding with 
CYPlAl, resulting in an irreversible loss in enzymatic activity (Kent et al., 2001). Similar 
findings have also been reported in rat hepatic microsomes in relation to the structurally 
related isothiocyanate, BITC (Goosen et al., 2001). Furthermore, the loss of EROD activity 
by PEITC was associated with a drop in total cytochrome P450 levels. Loss of EROD activity 
caused by PEITC and its metabolite(s) was impeded when reduced glutathione (GSH), a 
strong nucleophile, was added in the reaction mixture, presumably due to direct interaction 
between reduced GSH and both PEITC and its oxidative metabolite(s). However, a less 
pronounced recovery of activity was achieved in the presence of PEITC metabolite(s), 
possibly related to its greater inhibitory action compared with un-metabolised PEITC. In the 
case of the aliphatic isothiocyanates erucin and sulforaphane, GSH at a concentration of 50 
pM fully restored EROD activity after pre-incubation (Hanlon, 2009). However, PEITC is a 
far more potent mechanism-based inhibitor compared with erucin and sulforaphane. It would 
have been advisable to have utilised higher concentration of GSH since the cellular 
concentrations of this tripeptide may exceed 10 mM (Vina et al., 1989). Kinetic 
characteristics of rat CYPlAl inhibition by PEITC was subsequently defined using 
Michaelis-Menten and Lineweaver-Burk Plots, and it is not surprising that competitive
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inhibition by PEITC and non-competitive inhibition by PEITC-metabolite(s) were revealed. 
The Ki due to parent PEITC was higher than that of the metabolite(s), indicating that 
inhibition effect of PEITC-metabolite(s) is more potent than that of PEITC.
On the basis of studies using 2-naphthyl isothiocyanate, it has been proposed that PEIC may
be the metabolic species generated by CYP450 (Lee, 1994) that is responsible for the
inhibitory effect of PEITC. Due to the well-known very poor stability of PEIC (N. Kuhnert,
personal communication), steps were taken to minimise degradation; PEIC was maintained
under nitrogen. The corresponding concentrations of PEIC in DMSO were prepared
immediately prior to addition (1 pi) into microsomes; the mixture was well mixed and the
larger buffer volume added. However, inhibition potency of PEIC was not different from
PEITC in both rat and human liver, which is not compatible with a major metabolite acting as
the inhibitor, suggesting that PEIC may not be the principal metabolite responsible for the
mechanism-based inactivation. In both rat and human liver, PEITC competitively inhibited
the CYPlAl catalysed EROD, while PEITC-metabolite(s) showed a strong mechanism-based
inactivation by non-competitively inhibiting the enzyme. The mechanism-based inactivator
has been recommended as a potential new drug, since it would only effect the specific target
enzyme and would be convenient to use since it would need to be taken only every few days,
as the inactivated P450 enzyme has to be replaced by newly synthesised protein (Hollenberg
et al., 2008; Lee, 1994). Moreover, the inactivation effect of PEITC is more potent than we
have previously reported for the aliphatic isothiocyanates sulforaphane and erucin (Hanlon,
2009; Yoxall et al., 2005), implying an important role for the nature of the alkyl side chain.
Indeed, the rate of generation of the reactive intermediate is far higher for aromatic compared
with aliphatic isocyanates (Lee, 1996). In other words, the greater lipophilicity of the
aromatic PEITC has enhanced its inhibitory action due to its similar structure to the enzyme 
substrates {lARC, 2004 112 /id}.
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A study into the inhibition mechanism of pulmonary CYP2B by PEITC was similarly 
undertaken. Competitive inhibition was characterised, the inhibition effect being 
concentration-dependent; however, it did not require NADPH, implying that the mechanism- 
based inhibition was not occurring. Considering the involvement of pulmonary CYP2B1 in 
NNK bioactivation, the current findings support the role of PEITC towards inhibition of the 
bioactivation of this carcinogen and the underlying mechanism demonstrated in mice lung 
microsomes (Smith et al., 1990).
4.4.4 Metabolism of PEITC by human and rat liver slices
Being a potent direct inhibitor of human and rat hepatic CYPlAl and rat pulmonary CYP2B1 
suggests that PEITC possibly undergoes metabolism facilitated by CYP450 enzymes. The 
current study was carried out to test the hypothesis and identify the major CYP450 enzymes 
involved in PEITC metabolism. To some extent, PEITC concentration decreased with time in 
the absence of a slice, indicating the lack of stability of PEITC at this pH (7.4). In fact, 
previous study reported that PEITC is most stable at pH 3 and declines with increasing pH (Ji 
et al., 2005). In rat, only phenobarbital-induced liver slices were effective in catalysing 
PEITC metabolism, resulting in a loss of 85% after 8 hr incubation, whereas the 
disappearance patterns from dexamethasone-, isoniazid- and p-naphthoflavone-induced slices 
were similar to control rat. These observations indicate that the phenobarbital-inducible 
CYP2B and CYP3A are responsible for the PEITC metabolism. However, since the 
dexamethasone-induced slices were poor, similar to control rat, in metabolising PEITC, it 
may be concluded that CYP2B are the responsible enzymes, agrees with the findings that 
PEITC functioned as a competitive inhibitor of pulmonary CYP2B (Section 4.4.3). Similarly, 
a strong mechanism-based inhibition CYP2B by PEITC has been reported in rat microsomes 
(Goosen et a l 2000) and additional studies indicated that the phenobarbital-inducible CYP2B 
proteins were the most active in the oxidation of BITC, a structurally related isothiocyanate of 
PEITC (Lee, 1996). Moreover, inability of J3-naphthoflavone (CYPlA)-induced liver slices to
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enhance PEITC metabolism was consistent with previous studies demonstrating that PEITC 
was a more potent inhibitor of PROD than EROD activity when assessed in phénobarbital and 
3-methylcholanthrene-induced rat microsomes respectively (Conaway et al., 1996; Thapliyal 
and Maru, 2001), inferring that PEITC is likely to be a better substrate for CYP2B rather than 
CYPIA. Moreover, the current results indicated that CYP2E1 and CYP3A are unlikely to be 
involved in PEITC metabolism. As already discussed, conjugation with glutathione is the 
major metabolic pathway of PEITC (Brusewitz et al., 1977; Mennicke et al., 1987). 
Consequently, a parallel analysis was carried out to assess whether GST activity was 
modulated by CYP inducers and could, thus, account for increased PEITC metabolism. GST 
was not significantly different from control group, and immunoblot analysis did not reveal 
significant differences in GSTp and GSTa expressions in the treated animals. These 
observations indicate that treatment of rats with CYP450 inducers did not alter GST activity 
and, therefore, had no major impact on the modulation of PEITC metabolism. PEITC 
metabolism was effectively catalysed by human liver slices, from a single donor, whether this 
is a species difference, would require the study of more liver samples.
4.5 Conclusions
Dietary doses of PEITC modulated both cytochrome P450 and phase II enzyme 
activities in liver, lung and kidney of rats.
Effects of PEITC on carcinogen-metabolising enzyme system in rat were tissue-
specific.
In both rat and human liver, PEITC functions as a mechanism-based inhibitor of 
CYPlAl.
CYP2B is the most important CYP subfamily in PEITC metabolism in rats.
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5.1 Introduction
Human are exposed to chemical carcinogens almost on a daily basis. Major sources of these 
compounds are, for example, polycyclic aromatic hydrocarbon (PAH) derived from tobacco 
and cooked-food (Hecht, 2003), and other food-derived carcinogens such as heterocyclic 
amine (HA) and nitrosamines (Ito et al., 1991; Ohgaki et al., 1991). fri most cases 
bioactivation of chemical carcinogens is prerequisite for the formation of electrophiles which 
form DNA adducts leading to carcinogenesis. Inhibition of the enzymes responsible for the 
bioactivation of carcinogens such as CYPlAl and 1A2, the major enzymes required for PAH 
and HA bioactivation respectively (Guengerich and Shimada, 1998; Shou et al., 1996), is 
recognised as a ehemoprevention strategy (Shimada et al., 1997). Accordingly, the ability of 
glucosinolates and ITCs to prevent the formation of genotoxic metabolites through 
modulation of carcinogen-metabolising enzymes has recently attracted extensive interest 
worldwide. It has been reported that glucosinolate-rich vegetables, such as red cabbage and 
Brussels sprouts, reduced IQ-induced preneoplastic lesions in F344 rats, and this was 
accompanied by a rise in hepatic UDPGT and CYP1A2 activities (Kassie et al., 2003). 
Sulforaphane and its synthetic analogues down-regulated CYP1A2 and directly inhibited 
CYPlAl-induced activity by BaP in human cell line (Skupinska et al., 2009b).
As already described (Chapters 3 and 4), it was demonstrated in the present studies that 
PEITC inhibited cytochromes P450, such as CYP1A2 and/or CYPlAl in human and rat liver 
slices as well as in in vivo in rats, and was capable of enhancing phase II enzymes, raising the 
possibility that PEITC could limit the generation of the reactive intermediates of chemical 
carcinogens. In order to assess whether the observed changes in carcinogen-metabolising 
enzyme systems could influence the in vivo metabolism of chemical carcinogens, the 
modulation of 2-amino-3-methylimidazo[4,5-/]quinoline (IQ) metabolism by PEITC, as
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exemplified by the excretion of mutagens in urine was monitored following short- and long­
term exposure of animals to this isothiocyanate.
Chemical carcinogens such as polycyclic aromatic hydrocarbons up-regulate CYPlAl, the 
principal enzyme catalysing their bioactivation (Baird et al., 2005; Nebert et al., 2004). 
Consequently, a study was undertaken in rat and human precision-cut liver slices to establish 
whether PEITC can antagonise the benzo(a)pyrene (BaP) mediated CYPIA induction.
5.2 Methods
5.2.1 Modulation of IQ-induced urinary mutagenicity by PEITC pre-treatment
5.2.1.1 Animal pre-treatment
Male Wistar albino rats (180 ± lOg) were randomly divided into groups, each comprising four 
animals. A long-term (14 days) and a short-term (single day) exposure study were conducted 
where the ability of PEITC to influence IQ-induced mutagen excretion was investigated 
subsequent to administration of IQ. One group served as control and the remaining three 
groups were maintained on diets supplemented with 0.06 (Low dose), 0.6 (Medium dose) and
6.0 pmole/g (High dose) PEITC. Animal body weights were monitored throughout the 
treatment period. The diet was prepared weekly and stored at 5 ®C. At the end of the PEITC 
treatment period, animals were treated with a single intragastric dose of IQ (5 mg/kg) prior to 
being housed individually in metabolic cages, and urine was collected daily for three days; 
animals continued to be exposed to PEITC during the urine collection period. On completion 
of urine collection, rats were killed by cervical dislocation, livers were immediately excised, 
and post-mitochondrial fractions prepared and stored at -80 °C; subsequently microsomal and 
cytosolic fractions were prepared when required (Section 2.2.2.2). Urine was centrifuged at
3.000 xg for 5 min and supernatant was collected and stored at -80 °C prior to analysis.
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5.2.1.2 Ames mutagenicity assay
Urinary mutagenic activity was monitored using the Ames mutagenicity assay (Section 2.2.8) 
in the presence of an activation system containing 10 % (v/v) of 25% (w/v) hepatic S9 
preparations from Aroclor 1254-treated rats (see Section 4.2.3.1). Salmonella typhimurium 
YG1024 was employed as the indicator strain.
5.2.1.3 Determination o f carcinogen-metabolising enzyme activities
The activities of EROD and MROD were determined in the microsomal fraction (Section
2.2.3.1), whereas glutathione ^'-transferase activity, monitored using CDNB as the accepting 
substrate, was determined in the cytosol (Section 2.2.4.2). Protein concentration was 
determined in both fractions using bovine serum albumin as standard (Section 2.2.2.3).
5.2.2 Effect of PEITC on BaP-induced enzymes in human and rat liver slices
5.2.2.1 Tissue slices preparation
Human and rat liver slices were prepared as described (Sections 2.2.2 and 3.2) and incubated 
in media containing a range of PEITC concentrations in the presence and absence of BaP. 
Two different concentrations of BaP (0.1 and 10 pM) were applied in rat liver slices, whereas 
in human slices only 0.1 pM was used because of the limited tissue availability. After a 24-hr 
incubation, slices were removed from the medium, S9 was prepared and stored at -80 °C. 
Microsomal and cytosolic fractions were prepared by differential centrifugation (Section
2.2.2.2) when required.
5.2.2.2 Determination o f carcinogen-metabolising enzyme activities
The microsomal fraction from rat and human liver slices was used to determine EROD 
activity (Section 2.2.3.1) whereas NQOl and GST were assessed in the cytosolic fraction 
(Sections 2.2.4.2 and 2.2.4.3). Protein content and immunoblot analysis were performed using 
the procedures already described (Sections 2.2.2.3 and 2.2.7).
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5.3 Results
5.3.1 Body weight changes of rats during administration period
Figure 5.1 shows the average daily body weight gain of rats treated with PEITC- 
supplemented diet for a single or 14-day period. No marked difference in daily weight gain 
was observed between the control and treatment groups, during either treatment periods, 
indicating that PEITC supplementation did not perturb diet consumption. Moreover, 
observation of behavioural signs indicated no apparent toxicity or distress throughout the 
administration period.
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Figure 5.1 Average daily body weight gain of animals during long- and short-term 
exposure to PEITC. Rats were fed with diets supplemented with PEITC at doses equivalent 
to 0.06 (Low dose), 0.6 (Medium dose) and 6.0 (High dose) pmole/g diet for 14 days (long­
term) or 1 day (short-term), and at the end of this period all animals received a single 
intragastric dose of IQ (5 mg/kg), and continued on the PEITC diet. Animal weight was 
monitored throughout the study. Results are presented as the means ± SD of four rats.
5.3.2 Effect of long-term administration of PEITC on IQ-induced urinary mutagenicity
The urinary level of indirect-acting mutagens was determined following long-term pre­
treatment of rats with PEITC. No mutagenic activity was detectable in the urine prior to IQ 
administration. Treatment with IQ led to a marked rise in mutagenic activity; most mutagenic 
activity was excreted during the first 24 hr (Fig. 5.2). Treatment with PEITC decreased 
indirect-acting mutagenic activity at all doses employed with the highest dose being the most
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effective (Fig. 5.2). Since the bulk of the mutagenic activity was excreted within the first 24- 
hr period, the results on total mutagenicity, i.e. over 72-hr, were similar to that of the first 24- 
hr period.
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Figure 5.2 Effect of long-term administration of PEITC on IQ-mediated mutagenicity in 
rat urine. Rats were fed with diets supplemented with PEITC for 14 days at doses equivalent 
to 0.06 (Low dose), 0.6 (Medium dose) and 6.0 pmole/g (High dose), and at the end of this 
period all animals received a single intragastric dose of IQ (5 mg/kg), and continued on the 
PEITC diet. Urine was collected daily for three days, and mutagenie activity was determined 
in the Ames mutagenicity assay employing Salm onella typhimurium  strain YG1024, in the 
presence of an activation system (10% v/v) from Aroclor 1254-treated rats. The spontaneous 
reversion rate of 60 ± 10 has already been subtracted. Results are presented as mean ± SD of 
four rats, with each analysis conducted in triplicate. *, P<0.05; **, P<0.01; ***, P<0.001.
5.3.3 Effect of short-term administration of PEITC on IQ-induced urinary mutagenicity
A similar study was undertaken to elucidate the effect of a single-day exposure to PEITC on 
the IQ-induced urinary mutagenicity. Treatment of PEITC failed to influence urinary 
mutagenicity at all doses employed (Fig. 5.3).
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Figure 5.3 Effect of short-term administration of PEITC on IQ-mediated mutagenicity 
in rat urine. Rats were fed with diets supplemented with PEITC for a single day at doses 
equivalent to 0.06 (Low dose), 0.6 (Medium dose) and 6.0 pmole/g (High dose), and at the 
end of this period all animals received a single intragastric dose of IQ (5 mg/kg), and 
continued on the isothiocyanate diet. Urine was collected daily for three days, and mutagenic 
activity was determined in the Ames mutagenicity assay employing Salm onella typhimurium  
strain YG1024 and an activation system (10% v/v) from Aroclor 1254-treated rats. The 
spontaneous reversion rate of 48 ± 5 has already been subtracted. Results are presented as 
mean ± SD of four rats, with each analysis conducted in triplicate.
5.3.4 Modulation of xenobiotic-metabolising enzymes following long-term 
administration of PEITC and a single dose of IQ
Long-term pre-treatment with PEITC followed with a single dose of IQ led to a significant 
decrease of EROD activity at only the Low dose, whereas MROD activity was slightly, but 
significantly enhanced at the High dose (Fig. 5.4). No effeet was observed in GST activity 
when measured using CDNB as the model substrate. A eonsiderable rise in activity was 
noted, however, when GST was assessed using DCNB, a substrate selectively catalysed by 
GSTp (Habig et al., 1974), at the two higher doses. On the other hand, GSTa monitored using 
NBD-Cl as a substrate diminished at the Low and Medium doses (Fig. 5.5).
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Figure 5.4 Effect of long-term administration of PEITC on EROD and MROD activities 
in rat liver. Rats were fed diets supplemented with PEITC at 0.06 (Low dose), 0.6 (Medium 
dose) and 6.0 (High dose) pmole/g diet for 14 days, and at the end of this period they received 
a single intragastric dose of IQ (5 mg/kg). Three days after IQ administration, the hepatic 
dealkylations of methoxy- and ethoxyresorufin were determined in the microsomal fraction. 
Results are presented as mean ±  SD of four rats. *, P<0.05.
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Figure 5.5 Effect of long-term administration of PEITC on GSTs activities in rat liver.
Rats were fed diets supplemented with PEITC at 0.06 (Low dose), 0.6 (Medium dose) and 6.0 
(High dose) pmole/g diet for 14 days, and at the end of this period they received a single 
intragastric dose of IQ (5 mg/kg). Three days after IQ administration, GST using CDNB, 
DCNB and NBD-Cl as substrates, was determined in the cytosolic fraction. Results are 
presented as mean ± SD of four rats. *, P<0.05; **, P<0.01; ***, P<0.001.
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5.3.5 Effect of PEITC on BaP-mediated induction of carcinogen-metabolising enzyme 
systems in precision-cut rat liver slices
Figure 5.6 shows that incubation of rat liver slices with BaP at both concentrations namely 0.1 
and 10 pM, markedly enhanced EROD and, to a lesser extent NQOl, activities when 
compared to the basal activities from control group and as evidenced by the intensity of 
immunodetectable bands (Fig. 5.7); the effects are clearly dose dependent. Concurrent 
treatment of 0.1 pM BaP with PEITC led to a decrease in EROD activity at all PEITC 
concentrations, whereas at 10 pM BaP, the inhibition occurred only at concentration > 20 pM 
(Fig. 5.6). Immunoblot analysis of CYPlAl revealed that the inhibition of activity was due to 
a decrease in enzyme expression (Fig 5.7). In the case of NQOl, when rat liver slices were 
exposed to 0.1 pM BaP, PEITC caused a modest increase at 10 pM, but was markedly 
suppressed at the highest isothiocyanate concentrations (Fig. 5.6). At the protein level, at the 
low BaP concentration, synergism appears to occur at the low 10 pM PEITC concentration, 
but antagonism at the higher concentrations of PEITC (Fig. 5.7). At the 10 pM BaP, clear 
synergism was seen at the 10, and to lower extent, 30 pM concentration of PEITC, but a clear 
antagonism at the 40 pM concentration (Fig. 5.7).
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Figure 5.6 Effect of PEITC on BaP-mediated EROD, MROD and NQOl activities in rat 
liver slices. Liver slices were incubated in culture medium containing 0.1 or 10 pM BaP in 
combination with PEITC (1-50 pM) for 24 hr. Values are presented as mean ± SD of three 
replicates, each containing 10 slices/ml. *, P<0.05; **,P<0.01; ***,P<0.001 when compared 
combination treatment to BaP alone, §, P<0.05; §§,P<0.01; §§§,P<0.001 when compared all 
treatments to control slices.
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Figure 5.7 Effect of PEITC on BaP-mediated CYPlAl apoprotein and NQOl protein 
levels in rat liver slices. Liver slices were incubated in culture medium containing 0.1 or 10 
pM BaP alone or in combination with PEITC (1-50 pM) for 24 hr. Microsomal and cytosolic 
proteins were isolated and equal amounts of corresponding protein were loaded on to 10% 
(w/v) SDS-PAGE and then transferred electrophoretically to Hybond-P polyvinylidene 
difluoride membrane. The immunoblot analysis was carried out utilizing mouse anti-rat 
CYPlAl or rabbit anti-rat NQOl primary antibodies followed by the appropriate peroxidase- 
labelled secondary antibody. Each lane was loaded with 30 pg of total protein. Values above 
blots show % levels of optical density of each band relative to control.
5.3.6 Effect of PEITC on the BaP-mediated CYPIA induction in human precision-cut 
liver slices
Treatment with BaP induced EROD activity only in Donors 3 and 4 without any effect seen in 
the remaining donors. In the presence of BaP alone, EROD activity, predominantly mediated 
by CYPlAl, was not markedly different among three of the four human livers, the exception 
being in Donor 3 who displayed the highest activity. Exposure to PEITC suppressed the BaP- 
mediated EROD activity in human liver slices in Donors 2 and 4 and, to a lesser extent in 
Donor 3, whereas no effect was observed in Donor 1 (Fig. 5.8). Similar observations were
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Figure 5.8 Effect of PEITC on the BaP-lnduced EROD activity in human liver slices.
Liver slices Avere incubated in culture medium containing 0.1 pM BaP alone or in 
combination with PEITC (0.5-50 pM in Donors 1, 2 and 3, and 0.5-40 pM in Donor 4) for 24 
hr. Values are presented as mean ± SD of three replicates, each containing 10 slices/ml. 
*, P<0.05; **,P<0.01; ***,P<0.001 when compared to BaP alone, i.e. in the absence of 
PEITC. §, P<0.05; §§,P<0.01; §§§,P<0.001 when compared to control.
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made when MROD activity was determined. MROD activity in the presence of BaP alone 
was not markedly different among donors. Drop in the BaP-mediated MROD activity by 
PEITC was observed in Donors 1 and 4 and to a lesser extent in Donor 3, whereas no effect 
was observed in Donor 2 (Fig. 5.9). Apoprotein levels of CYPlAl were not determined due 
to limited sample quantity. PEITC, however, decreased the BaP-mediated rise in CYP1A2 
apoprotein levels at all concentrations in Donor 4 whereas a significant decrease was 
observed at only the highest PEITC concentrations in Donors 2 and 3 (Fig. 5.10). Moreover, 
BaP enhanced apoprotein levels of CYP1A2 in all donors but a rise in activity comparing 
with control group was evident only in Donors 1 and 4 (Figs. 5.9 and 5.10).
5.3.7 Effect of PEITC on the BaP-mediated rise in phase II enzymes in human precision- 
cut liver slices
Treatment with BaP enhanced NQOl activity only in two of the donors; however, at the 
protein level an increase was seen in all donors (Figs 5.11 and 5.12). NQOl activity in the 
presence of BaP alone was similar among the donors, except in the case of Donor 2 where it 
was lower (Fig. 5.11). Treatment with PEITC had no effect on the BaP-mediated NQOl 
activity, except in Donor 3 where there was a modest decrease which was, however, not 
concentration-dependent. PEITC elevated protein levels of the enzyme only in Donors 1 and 
4, but only in the latter case a concentration-dependent effect was evident. In Donor 4, where 
the enzyme was markedly induced by PEITC or BaP alone, incubation with a combination of 
these compounds led to an apparently synergistic effect, but only at 10 pM PEITC (Fig. 5.12). 
No such synergism was evident in the case of Donor 1, but antagonism was once again noted 
at the highest PEITC concentration. In Donors 2 and 3, who were not sensitive to PEITC 
induction, following incubation with PEITC, an antagonistic effect was generally seen but no 
consistent effects were observed (Fig. 5.12).
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Figure 5.9 Effect of PEITC on the BaP-induced MROD activity in human liver slices.
Liver slices were incubated in culture medium containing 0.1 pM BaP alone or in 
combination with PEITC (0.5-50 pM in Donors 1,2 and 3, and 0.5-40 pM in Donor 4) for 24 
hr. Values are presented as mean ± SD of three replicates, each containing 10 slices/ml. 
*,P<0.05; **,P<0.01; ***,P<0.001 when compared to BaP alone, i.e. in the absence of 
PEITC. §, P<0.05; §§,P<0.01; §§§,P<0.001 when compared to control.
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Figure 5.10 Effect of PEITC on the BaP-mediated rise in CYP1A2 apoprotein levels in 
human liver slices. Liver slices were incubated in culture medium containing 0.1 pM BaP 
alone or in eombination with PEITC (0.5-50 pM in Donors 1, 2 and 3, and 0.5-40 pM in 
Donor 4) for 24 hr. Microsomal proteins were isolated and equal amounts of corresponding 
protein were loaded on to 10% (w/v) SDS-PAGE and then transferred electrophoretically to 
Hybond-P polyvinylidene difluoride membrane. The immunoblot analysis was carried out by 
exposure to mouse anti-human CYP1A2 primary antibody followed by peroxidase-labelled 
anti-mouse IgG. Each lane was loaded with 15 pg of total protein. Values above blots show % 
levels of optical density of each band relative to control.
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Figure 5.11 Effect of PEITC on the BaP-induced NQOl activities in human liver slices.
Liver slices were incubated in culture medium containing 0.1 }xM BaP alone or in 
combination with PEITC (0.5-50 |iM in Donors 1, 2 and 3, and 0.5-40 [iM in Donor 4) for 24 
hr. Values are presented as mean ± SD of three replicates, each containing 10 slices/ml. 
*,P<0.05; **,P<0.01; ***,P<0.001 when compared to BaP alone, i.e. in the absence of 
PEITC. §, P<0.05; §§,P<0.01; §§§,P<0.001 when compared to control.
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Figure 5.12 Effect of PEITC on the BaP-mediated rise in NQOl protein levels in human 
liver slices. Liver slices were incubated in culture medium containing 0.1 \iM BaP alone or in 
combination with PEITC (0.5-50 pM in Donors 1, 2 and 3, and 0.5-40 pM in Donor 4) for 24 
hr. Cytosolic proteins were isolated and equal amounts of protein were loaded on to 10% 
(w/v) SDS-PAGE and then transferred electrophoretically to Hybond-P polyvinylidene 
difluoride membrane. The immunoblot analysis was carried out utilising rabbit anti-human 
NQOl primary antibody followed by peroxidase-labelled anti-rabbit IgG. Each lane was 
loaded with 30 pg of total protein. Values above blots show % levels of optical density of 
each band relative to control.
GST activity assessed using CDNB as a substrate was induced by BaP only in two of the 
donors, namely 3 and 4 (Fig. 5.13). GST activity was not influenced by concurrent treatment 
of BaP with PEITC in all donors.
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Figure 5.13 Effect of PEITC on the BaP-induced GST (CDNB) activity in human liver 
slices. Liver slices were incubated in culture medium containing 0.1 pM BaP alone or in 
combination with PEITC (0.5-50 pM in Donors 1,2 and 3, and 0.5-40 pM in Donor 4) for 24 
hr. Values are presented as mean ± SD of three replicates, each containing 10 slices/ml. 
*,P<0.05; **,P<0.01; ***,P<0.001 when compared to BaP alone, i.e. in the absence of 
PEITC. §, P<0.05; §§,P<0.01; §§§,P<0.001 when compared to control.
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5.4 Discussion
PEITC has the ability to protect against many chemical carcinogens in different organs of 
animal models (Morse et ah, 1989; Stoner et ah, 1991; Wattenberg, 1977; 1987). The 
potential basis of protecting mechanisms towards chemical carcinogens involves interference 
of the metabolic pathways of carcinogens by modulating enzymes, such as CYPl, which are 
associated with bioactivation (Conney, 2003; Gonzalez and Gelboin, 1994) and inducing 
phase II enzymes such as GST and NQOl (Zhang and Talalay, 1994). Following the 
experimental evidence indicating modulation of carcinogen-metabolising enzymes by PEITC 
in rat and human liver slices as well as in vivo in rat described in the previous chapters 
(Chapters 3 and 4), the present study was undertaken to elucidate the role of PEITC as an 
anticareinogen towards two distinct carcinogens namely benzo(a)pyrene (BaP) and 2-amino- 
3-methylimidazo[4,5-/]quinoline (IQ). These two carcinogens were chosen as they are 
believed to contribute to human cancer risk (Correa, 1981) as important tobacco-derived 
(Hecht and Hoffmann, 1989) and diet-derived carcinogens (Nagao et ah, 1977). Moreover, 
both compounds are known as procarcinogens, requiring CYP450-mediated activation, 
catalysed by CYPlAl in the case of BaP (Kim et ah, 1997) and CYP1A2 in the case of IQ 
(Eisenbrand and Tang, 1993; Guengerich et ah, 1994; Snyderwine et ah, 2002). The ability of 
PEITC to modulate IQ-induced urinary mutagenicity was determined using the Ames test and 
employing Salmonella typhimurium, O-acetylase over-expressing, YG1024 bacterial strain. In 
addition, the effect of PEITC towards BaP-mediated enzyme induction was assessed in rat 
and human liver slices.
5.4.1 Modulation of IQ-induced urinary mutagenicity by dietary doses of PEITC
The heterocyclic amine IQ is a potent multisite carcinogen inducing tumours in liver, colon, 
skin and small intestine (Takayama et ah, 1984). Exposure to IQ in human is inevitable as it is 
mostly found in high temperature cooked protein-rich foods, e.g. fried or grilled fish, chicken 
and meat (Hatch and Felton, 1986; Sugimura, 1988), so that it is desirable that IQ is rapidly
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eliminated from the body. The potency of isothiocyanates to assist HA detoxification is of 
interest since cruciferous vegetables are likely to be consumed along with cooked meat. The 
Ames mutagenicity assay was selected to monitor IQ metabolism, as this compound is highly 
mutagenic enabling the determination of IQ-mediated mutagenicity in rat urine. The urines 
were collected daily for up to 72 hr, as most of IQ and metabolites are excreted within these 
periods (Sjodin and Jagerstad, 1984) and, moreover, most of the mutagenicity is excreted 
within 24 hr (McArdle et al., 1999; Yoxall et al., 2004). In the Ames test, unchanged IQ 
undergoes A-hydroxylation of the exocyclic amino group, catalysed by CYP450-induced 
microsomes, followed by O-esterification mediated by Salmonella typhimurium leading to 
formation of electrophilic metabolites, such as A-sulphatoxy- and acetoxy-IQ, that break 
down spontaneously to form the nitrenium ion that interacts with DNA (Hammons et al., 
1997). The metabolic pathways of IQ are shown in Figure 5.14.
IQ was employed at a dose of 5 mg/kg that was shown in our laboratory to give a good 
mutagenic response and was on the linear part of the dose vs urinary mutagenicity (McArdle 
et al., 1999). Urinary excretion of mutagenicity due to IQ following pre-treatment of rats with 
PEITC for 14 days or a single day, was assessed. It was observed that the bulk of 
mutagenicity was excreted within 24 hr, as previously demonstrated (Barnes and Weisburger, 
1985; McArdle et al., 1999). The IQ-induced urinary mutagenicity was suppressed at all 
doses of PEITC treatment, with the High dose being the most effective, but only following 
long-term exposure. The decrease of indirect-acting mutagen in urine infers enhanced IQ 
metabolism, presumably due to modulation of the enzymes responsible for IQ metabolism. It 
has already been demonstrated that most of the mutagenicity in the urine of rats treated with 
IQ is due to un-metabolised IQ (Barnes et al., 1985); only 5% of the total dose of IQ is 
excreted in the urine unchanged (Hayatsu et al., 1987); and only a minor contribution to the 
mutagenicity is made by A-acetyl IQ and demethylated IQ (Barnes et al., 1985), the latter, 
however, is not produced in rat (Lakshmi et al., 2008). It is also pertinent to point out that the
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phenolic metabolites of amino-compounds are not subject to A-oxidation (Tong et ah, 1986), 
and the A-conjugates of IQ such as the sulphamate lack mutagenic activity (Turesky et ah, 
1986).
Long-term treatment with PEITC elevated modestly the CYP1A2 mediated MROD activity 
but only at the High dose. CYPlAl which also contributes to IQ biotransformation (Crofts et 
ah, 1998), as exemplified by EROD activity was, on the other hand, decreased at the Low 
dose. The effect on EROD activity was consistent with the results reported in Chapter 4 
where identical pre-treatment of PEITC was administered to animals; it is important to 
emphasise that IQ at the dose level employed, has no effect on CYPlAl/2 activity (Rodrigues 
et ah, 1989), so that it is extremely unlikely that it could influence CYPlAl/2 activity 
following administration of a single oral dose. It may be inferred that the increased IQ 
metabolism following exposure to PEITC is not due to change in CYPlAl/2 activity but 
involves other enzyme systems. CYPIBI, for example, has been reported to play a role in 
metabolic activation of HA (Crofts et ah, 1997). As demonstrated in Chapter 4, treatment of 
rats with PEITC enhanced CYPIBI apoprotein levels in liver. Moreover, metabolism may 
occur in extrahepatic tissue in which CYPlAl and IB 1 play more important role in that 
case (Crofts et ah, 1998). In lung, a marked rise of CYPlAl activity and apoprotein levels 
given the High dose of PEITC were observed whereas only modest effect on CYPIBI 
apoprotein levels was noted. In the case of kidney, PEITC failed to influence EROD activity, 
indicating that enhanced IQ metabolism by PEITC is unlikely to have occurred in this tissue. 
Indeed, CYP450 enzymes catalyse both activation and inactivation of IQ and different 
pathways have been reported in different species (Snyderwine et ah, 1992; Langouet et ah, 
2001).
Detoxifying phase II enzymes also play important role in IQ metabolism. Isoform-specific 
changes in GST response were revealed following treatment with PEITC where GSTp
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activity increased at the two higher doses and GSTa, on the other hand, was suppressed at the 
two low doses. No change was observed in the case of GST determined using CDNB as 
substrate. GST has been implicated in the detoxification of IQ (Kitamura et ah, 2007) by 
glutathione-dependent reduction of Y-acetoxy heterocyclic amines back to the parent 
compound (Apostolides et ah, 1997), which in human is performed by GSTAl-1 (Coles et ah, 
2001) and GSTMl (DeMarini et ah, 1997). Moreover, glutathione conjugation with N- 
hydroxy IQ or A-acetoxy IQ has been proposed as a detoxification pathway of IQ (Loretz and 
Pariza, 1984). Furthermore, the binding of A-acetoxy-PhlP, another heterocyclic amine, to the 
thiol group of GSH has been reported (Alexander et ah, 1997). The major pathway for IQ 
inactivation involves CYP1 A2-catalysed ring oxidation at the 5 position followed by 
conjugation with sulphate or glucuronic acid (Luks et ah, 1989; Inamasu et ah, 1989). The 
other major route of metabolism is direct conjugation of the exocyclic amine (McPherson et 
ah, 2001) to form A-glucuronide, sulphamate or A-acetyl catalysed once again by UDPGT, 
sulphotransferase (SULT) and A-acetyltransferase (NAT) respectively (Inamasu et ah, 1989; 
Luks et ah, 1989; Turesky et ah, 1986). However, induction of SULT may not only facilitate 
detoxification of IQ but it can also mediate activation of A-hydroxy IQ to form ultimate 
mutagen (bu-Zeid et ah, 1992; Davis et ah, 1993). Thus the ability of PEITC to modulate 
NAT, UDPGT and SULT activities is another possible mechanism that may account for the 
PEITC-enhanced IQ metabolism. However, A-acetyltransferase pathway has been reported to 
play only a minor role in IQ rat metabolism (Inamasu et ah, 1989). In addition, treatment of 
HepG2 cells with watercress juice, the principal source of PEITC, did not influence these 
activities (Lhoste et ah, 2004). Appropriate in vivo studies need to be carried out, employing 
the same dose regimes as in the current studies.
In the same urine samples, excretion of IQ metabolites was carried out concurrently by Nlin 
Arya using SPE-LC- ion trap-MS (Arya, 2009). Results revealed that treatment of animals 
with PEITC decreased unchanged IQ in a dose-dependent manner, albeit statistically
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significant only at the High dose, implying that the decrease in mutagenic response was the 
result of diminished IQ excretion, a consequence of PEITC enhanced IQ metabolism.
In control rats, the results revealed that the major metabolites of IQ were sulphamate and to a 
lesser extent A-acetyl IQ, which has previously been reported (Barnes et al., 1985; Peleran et 
al., 1987; Stormer et al., 1987; Turesky et al., 1986). Treatment with PEITC at the High dose 
significantly enhanced excretion of A-acetyl IQ from 25% up to 80% of total metabolites, 
possibly due to enhanced activity of NAT by PEITC, albeit experimental evidence is 
necessitated. 5-0-sulphate and glucuronide including A-glucuronide were also observed but at 
low levels. These results may also infer low level of A-acetoxy IQ formation since the 
presence of 5-0  glucuronide and sulphate is a biomarker for generation of this genotoxic 
metabolite (Davis et al., 1993; Frandsen et al., 2002). In addition, most of detectable 
metabolites are non-toxic and primarily generated by direct conjugation of the exocyclic 
amino group by phase II enzymes, NAT or SULT, rather than CYP450, and is in agreement 
with the observation that CYP-mediated metabolism of EROD and MROD was not markedly 
influenced. The PEITC treatment of rats led to an increase in 5-0-sulphate excretion whereas 
A-glucuronide decreased, in a dose-dependent manner, implying that PEITC may enhance the 
activity of SULT but suppress UDPGT (Arya, 2009). This contradicts previous reports that 
treatment of rats with PEITC led to a rise in UDPGT activity but SULT decreased (Dingley et 
al., 2003; Guo et al., 1992). It is relevant to point out, however, that these studies were carried 
out in F344 rats treated with an acute dose of PEITC. Regrettably, the activities of UDPGT 
and SULT were not determined in the current study and remain to be investigated. A- 
hydroxy amine, a direct mutagen (Holme et al., 1989), was not detected in the current study, 
in agreement with the fact that direct urinary mutagenicity was undetectable when urinary 
mutagenicity was determined in the absence of activation system (data not shown).
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5.4.2 Modulation of BaP-mediated enzyme induction by PEITC in human and rat liver 
slices
BaP is an important environmental carcinogen presented in cigarette smoke, industrial waste 
by-products and food (Chen et al., 2002; Hecht, 1999b). Average daily intake of BaP ranges 
from non-detectable to 22.5 pg per person per day depending on individual lifestyle 
(Massaro, 1997). The induction of enzymes by BaP is mainly to enhance its 
biotransformation, primarily by CYPl especially CYPlAl (Drahushuk et al., 1998; Roberts- 
Thomson et al., 1993; Shimada et al., 1996). Such induction is believed to enhance the 
generation of the genotoxic BaP 7,8-diol-9,10-epoxide that binds covalently to cellular DNA 
and initiates carcinogenesis (Grover and Sims, 1968; Nebert et al., 2004; Whitlock, Jr., 1999).
BaP is an avid ligand of the Ah receptor and this binding leads to up-regulation of CYP 
enzyme involved in its metabolism such as CYPlAl, CYPIBI and phase II enzyme such as 
NQOl and GST (Nebert et al., 2004; Vondracek et al., 2009). Utilising precision-cut rat and 
human liver slices the aim of the study was to determine whether PEITC can antagonise BaP- 
mediated enzyme induction, possibly by interfering with its interaction with Ah receptor. BaP 
at 0.1 pM was employed for investigating a possible antagonistic effect of PEITC, and 10 pM 
BaP was employed to achieve a maximal enzyme induction in rat liver slices, according to 
previous studies conducted in this laboratory under identical incubation conditions 
(Pushparajah et al., 2008a). EROD and NQOl activities were determined in rat liver slices 
whereas in human liver slices MROD and GST, monitored using CDNB as substrate, were 
additionally investigated.
Rat CYPlAl as exemplified by EROD activity, was induced by BaP, and PEITC was capable 
of preventing the rise in activity especially at the low concentration of BaP. Western blot 
analysis showed that this was a consequence of decrease of enzyme availability. Human 
EROD activity from only Donors 3 and 4 was susceptible to BaP treatment, and concurrent
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treatment with PEITC antagonised BaP-mediated enzyme induction. The inhibition at all 
PEITC concentrations in Donor 2 where no BaP induction was achieved, indicating that 
PEITC can also suppress basal activity as observed previously in Chapter 3 (Fig. 3.7).
MROD activity in human liver slices was moderately induced by BaP only in Donors 1 and 4 
and this induction was inhibited by PEITC at all concentrations employed. CYP1A2 
apoprotein levels, on the other hand, were markedly induced by BaP in all donors. The co­
treatment with PEITC led to a decrease in BaP-induced CYP1A2 apoprotein levels at all 
concentrations in Donor 4 whereas that in Donor 1 was resistant to this treatment, the latter 
case contradictory the observations at the activity level. A decrease in CYP1A2 apoprotein 
levels was observed at only the highest PEITC concentration in Donors 2 and 3, presumably 
due to cytotoxicity effect of PEITC as exemplified by increasing of LDH leakage (Chapter 3). 
It is relevant to note that exposure of slices to BaP at the concentrations used in the current 
study, did not influence slice viability (C. loannides, unpublished data). The discrepancy in 
induction of CYP1A2 apoprotein levels by BaP in Donors 2 and 3 but without concomitant 
increase in MROD activity may be related to a CYP1A2 variant expressing low activity 
(Murayama et al., 2004). Moreover, the decrease in MROD activity while CYP1A2 
apoprotein levels remained unchanged in Donor 1 implies mechanism-based inactivation of 
PEITC towards BaP-induced MROD activity and this resistant CYP1A2 expression may 
imply that PEITC failed to interfere the binding of BaP to Ah receptor.
Induction of CYPl is known to be regulated through the ligand-activated aryl hydrocarbon 
receptor (AhR) (Whitlock, Jr., 1999). Prior to dissociation from its ligand-binding partners, 
AhR translocates into the nucleus, subsequently binds to a specific nucleotide sequence of 
general transcription factors and initiates gene transcription of enzymes including CYPl 
(Whitlock, 1999). As a result of suppression of apoprotein levels, the antagonistic effects of
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PEITC in the current study may involve modulation of the binding of BaP by PEITC, 
although the underlying mechanism remains to be established.
The inter-individual variability in human liver from the four donors by BaP treatment was 
remarkable. Polymorphism in AhR where the different alleles have differing affinities for 
carcinogen binding and resulting in differences in induction effect have been reported (Kouri 
et al., 1974; Nebert et al., 2004) and are believed to be responsible for the different response 
of the enzymes to BaP in each individual. The higher inducibility type of CYPlAl enhanced 
susceptibility to cancer risk such as lung cancer (Kawajiri et al., 1990a; 1990b).
In the case of phase II detoxifying NQOl activity, an apparent modest synergistic effect of 
PEITC was observed in rat liver slices, albeit at the low BaP concentration only. However, 
immunoblot analysis revealed marked synergistic effect of PEITC on NQOl expression at 
both BaP concentrations. Diminishing of protein level and enzyme activity at the highest 
concentration of PEITC was observed, presumably due to toxicity of isothiocyanate as 
already discussed. In human liver slices, induction of NQOl activity by BaP was observed 
only in Donors 3 and 4. The lowest activity in the presence of BaP was seen in Donor 2, 
similar to the lowest basal activity among the other donors. A possible reason has already 
been discussed, i.e. the presence of an allele type having low activity. Treatment of slices with 
PEITC and BaP in combination modestly inhibited human NQOl activity in Donor 3, 
whereas that in other donors was unchanged. At protein level, concurrent treatment with 
PEITC suppressed the BaP-modulated NQOl expression in Donors 2 and 3 whereas that in 
Donors 1 and 4, a synergistic effect was observed, however, at only 10 pM PEITC.
Clearly, PEITC synergistically increased NQOl activity and expression in rat, but only minor 
modulation in activity was observed. In contrast, inconsistent effects were observed in human 
liver slices from the various donors, presumably due to inter-individual variation. Ability of
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PEITC to enhance phase II is thought to be through nuclear factor-E2-related factor 2 (Nrf2), 
a key regulator of ARE-mediated gene expression of phase II detoxifying enzymes (Xu et ah, 
2006). Induction mechanism by PEITC is believed to involve covalent binding of the 
isothiocyanate with the thiol groups of Keapl hence liberation of Nrf2 from Keapl leading to 
gene transcription initiation (Xu et ah, 2006).
GST is involved in the detoxification of many polycyclic aromatic hydrocarbons including 
BaP (Lamy et ah, 2008; Steinkellner et ah, 2001b), and polymorphism of this enzyme has 
been reported (Jourenkova-Mironova et ah, 1999). Activity of human GST assessed using 
CDNB as a broad substrate was elevated by BaP in only Donors 3 and 4. It has been 
demonstrated that BaP failed to modulate hepatic GST (CDNB) in vitro assessed, however, in 
only one donor (Pushparajah et ah, 2008b). In the current study, treatment with PEITC did not 
modulate BaP-mediated GST activity.
Collectively, PEITC suppressed BaP-induced CYPIA activity and apoprotein levels in rat 
liver slices and, at certain concentration, it also increased NQOl induction mediated by BaP. 
Even though both CYPIA and NQOl are known to be regulated through the same AhR- 
driven gene expression, the differential response of these enzymes may be attributed to the 
fact that induction of phase II enzyme can occur via two different pathways; in addition to 
AhR, induction of NQOl expression by BaP may be also Nrf2 dependent as demonstrated in 
mice (Hu et ah, 2006). Moreover, PEITC is more likely to induce phase II enzyme through 
Nrf2 transcription factor as already discussed (Bonnesen et ah, 2001), implying that 
synergistic increase of NQOl by BaP and PEITC is mediated through NrfZ rather than AhR. 
On the other hand, antagonistic mechanism of PEITC on CYPIA may be the result of 
interactions at the site of the AhR, preventing the binding of BaP and/or mechanism-based 
inhibition leading to loss of activity. It was demonstrated in Chapter 4 that PEITC was a 
potent mechanism-based inhibitor towards CYPlAl-mediated EROD activity, even at low
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concentrations employed in the current study. However, bearing in mind that uptake of 
PEITC by the slices may lead to lower levels, direct inhibition is unlikely. Moreover, more 
pronounced inhibition effect in mechanism-based inhibition study than the current study was 
anticipated since it was carried out in Aroclor 1254-induced microsomes.
Even though PEITC antagonised the BaP-mediated rise in hepatic CYPIA, it has been 
reported that PEITC failed to prevent BaP-induced lung tumorigenesis (Adam-Rodwell et al., 
1993; Hecht et al., 1995; 1996b; Lin et al., 1993). Although there is experimental evidence 
that the liver bioactivates BaP and the reactive intermediates are transported to the lung (Wall 
et al., 1991), it may be that in situ activation is also important. It would be worthwhile to 
determine whether interactions between BaP and PEITC are also manifested in lung slices. 
Furthermore, tissue-specific effect of PEITC on carcinogen-metabolising enzymes was 
demonstrated (Chapter 4) where the High dose of PEITC inhibited hepatic CYPlAl activity 
in a mechanism-based fashion but the same dose induced both CYPlAl apoprotein levels and 
activity in rat lung.
5.5 Conclusions
• Long-tem exposure of rats to PEITC even at dietary doses, decreased IQ-induced 
urinary mutagenicity. This was not related to changes in CYPIA and GST activities.
• In rat liver slices, PEITC antagonised the BaP-mediated rise in CYPlAl whereas at
certain concentration of PEITC an apparent synergism on BaP-mediated NQOl was noted. 
The effects of PEITC on BaP-mediated enzymes in human liver slices from four donors were 
inconsistent.
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CHAPTER 6
Development of an LC-MS method for the 
determination of PEITC in rat plasma
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6.1 Introduction
Isothiocyanates are hydrolysis products of glucosinolates, the sulphur-containing compounds 
naturally found in cruciferous vegetables, catalysed by the enzyme myrosinase (VanEtten et 
al., 1976). Glucosinolate and myrosinase are physically separated, residing in the vacuoles 
and myrosin cells of intact plant cells, respectively. The hydrolysis reaction occurs prior to 
cell rupture as a result of food preparation or consumption, so that glucosinolate and 
myrosinase come into contact, leading to conversion of the glucosinolate to its corresponding 
isothiocyanate (Conaway et al., 2002). In the human body, isothiocyanate is passively 
diffused through the cell membrane and rapidly bound to cellular glutathione (GSH) leading 
to dithiocarbamate formation; the dithiocarbamate is then exported from the cell by the 
transporter multidrug resistance protein (MRP). Subsequently, the GSH conjugate is either 
converted back to isothiocyanate that enters the cell again, or enters the mercapturic acid 
metabolic pathway to form ITC-cysteinylglycine, ITC-cysteine and ITC-A^-acetylcysteine 
(mercapturic acid) which can be excreted into the urine (Chung et al., 1992; Eklind et al., 
1990; Shapiro et al., 1998).
A number of studies have demonstrated the potential chemopreventive effects of PEITC, and
feasible mechanisms have been proposed (Hecht, 1995; Hu et al., 2003; Musk et al., 1995; Yu
et al., 1998). Consequently, clinical evaluation of this isothiocyanate is warranted. However,
for such studies to be undertaken, it is essential that the pharmacokinetic and bioavailability
characteristics of PEITC are defined so that effective dose regimes are designed. The present
study was aimed to develop a sensitive LC-MS analytical technique which is pre-requisite for
the study of the pharmacokinetic behaviour of PEITC in rats following intake of low doses, 
simulating dietary intake.
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6.2 Method development
It has been asserted that the protective effect of isothiocyanates is mediated primarily by the 
central carbon atom of the isothiocyanate moiety (lARC, 2004). Thus the differential 
reactivity of this carbon atom in particular isothiocyanates is believed to be the key for their 
diverse chemoprevention potency (Jiao et al., 1997). Isothiocyanates are highly electrophilic 
and can react with nucleophilic targets such as thiols and amines resulting in formation of 
dithiocarbamate and thiourea derivatives respectively (Thomalley, 2002). Under 
physiological condition ITCs tend to undergo thiol conjugation (Podhradsky et al., 1979), 
while the thiourea derivative is formed in a highly basic environment (Maeda et al. 1969; 
Hemandez-Triana et al. 1996).
PEITC has boiling point at 139-140 ®C. It is considerably stable in aqueous buffer at pH 7.4 
(Ji and Morris, 2005) and readily forms adducts with protein thiols (Xu and Thomalley, 
2000). The half-life of PEITC at room temperature is 56.1 hr and increases to 108 hr at 4 °C 
(Ji and Morris, 2005). The stmcture of PEITC is given in Figure 6.1.
Figure 6.1 Structure of PEITC.
Combination of the separation power of reverse phase liquid chromatography and the 
detection power of mass spectrometry can lead to the development of a suitable analytical 
technique. Through liquid chromatography, the mixture of compounds or analytes of interest, 
in high aqueous mobile phase, are captured by reverse phase HPLC column and consequently 
eluted into high organic mobile phase; the order of elution is based on the hydrophobic 
characteristic of the compounds. At the end of this step, the compounds are separated; in the
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second part, these compounds are introduced into the mass spectrometer where the molecules 
undergo fragmentation and ionisation, enabling identification and quantitation of the 
compounds to be achieved (Cazes, 2005). Electrospray ionisation (ESI) was used as an ion 
source in the current study. Liquid mobile phase containing analytes of interest is pumped 
through a small capillary and dispersed into the nitrogen gas stream. At the end of the spray 
needle, small protonated droplets, facilitated by the formic acid fortification in the mobile 
phase, are formed inside a high voltage vacuum chamber. Subsequent to liquid evaporation, 
the solvent droplets reach a certain diameter where the number of charges exceeds the number 
that can be held by surface tension force, causing a series of highly charged fine droplets to be 
expelled, electrospray, ending with charged molecules (ions) in the gas phase (Villas-Boas et 
al., 2007). The ions then travel through the high vacuum operation of time of flight (TOE), the 
mass analyser firstly developed in 1991 (Dodonov et al., 1991), where the velocity reached by 
an ion is inversely proportional to its mass. However, since the motion and separation of ions 
is based on electrical or magnetic fields inside the analyser, the mass-to-charge ratio {m/z) is 
taken into account (Chaurand et al., 2005).
6.2.1 Optimisation of liquid chromatography (LC) conditions
Liquid chromatography analysis was carried out using a Waters Alliance 2695 equipped with 
an inline degasser, a temperature controlled autosampler (4 to 40°C) and a thermostatically 
controlled column compartment (5 to 65°C). A CIS reverse phase column (particle size 4pm, 
dimensions 150 x 2.1 mm) from Phenomenex was selected since the CIS side chain is 
suitable for the separation of small hydrophobic molecules such as PEITC. Using UV 
detection at 234 nm, a mobile phase of 65% acetonitrile:35% water, and an isocratic flow of 
0.2 ml/min the retention time of PEITC was 2.23 min (Fig. 6.2).
180
Chapter 6: Method development fo r  PEITC determination in rat plasma
RT = 2.23 min
MT
Tim e (m in)
Figure 6  2  Chromatogram of the HPLC-UV analysis of PEITC using an isocratic 
mobile phase. PEITC in acetonitrile (0-12 mM), following injection of 10 pi was separated 
y Synergi Hydro reverse phase column 150 x 2.1 mm (4 pm) and monitored using HPLC- 
UV at the wavelength 234 nm. The retention time of PEITC was 2.23 min when using 65% 
acetonitrile + 35% water as the mobile phase
As it can be seen from the chromatogram, the peaks of PEITC elute early but their shape is
not sharp, implying that the use of isocratic system may impede resolution and, therefore the
sensitivity of the analytical method. It was anticipated that increasing the retention time of
PEITC would be beneficial as resolution would improve. In addition, future studies would be
carried out with samples from complex biological matrices such as plasma, and interference
from the matrix would be minimised with improved retention of the analyte of interest.
Consequently, a gradient elution method was considered to be a possible solution to this
problem. As a result, the mass spectrometer, the LC-TOF-MS or LCT, was applied after this
step, so that compatibility of the LC conditions to mass spectrometry analysis could be 
achieved.
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6.2.2 Mass spectrometry conditions for LC-MS analysis
The time of flight mass analyser provides a high mass resolution (6000-10000 full width at 
half maximum, FWHM), thus high in mass accuracy (approximately 5 ppm) (Ferrer et ah, 
2005), and therefore suitable for quantification purposes (Dodonov et ah, 1997). Thus, a 
Micromass LCT™ (Micromass UK Ltd, Manchester, UK) orthogonal acceleration time of 
flight (TOF) mass analyser in positive ion mode (electrospray ionisation, E S f ) was used for 
the detection of PEITC in the current study. A standard solution (1 mg/ml) of PEITC, in 
50:50 water:acetonitrile, was infused directly into the mass spectrometer at 10 pl/min and 
tuning parameters were altered to optimise the signal for the protonated PEITC ion [M+H]"  ^at 
m /z 164. An acceptable instrument calibration was created where the peaks in the uncalibrated 
calibrant mass spectrum are matched with the peaks in the calibration reference file, using a 
sodium iodide (1 ng/pl) solution in 50:50 water:acetonitrile as standard. This calibration file 
was applied to all analyses so that accurate mass is achieved.
The Gradient mobile phase system comprised Solvent A (water + 0.1% formic acid) and 
solvent B (acetonitrile + 0.1% formic acid). The retention time of PEITC using the gradient 
selected was extended to atiout 14.7 min (Fig. 6.3/L), arid occinre;d at a conibinalioricif 41094 
solvent A + 60% solvent B (Fig. 6.3B). Moreover, peak shape improved to a sharp and 
narrow peak, implying better resolution. The gradient mobile phase is shown in Table 6.1.
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Figure 6.3 Chromatogram of PEITC m/z 164 from LC-MS analysis using gradient 
mobile system (A) and the percentage of solvent B, acetonitrile + 0.1% formic acid, (B).
PEITC (1 mM) in acetonitrile following injection of 10 pi was monitored using LCT. The 
retention time of PEITC was 14.7 min when using a gradient mobile phase system.
Time (min) Solvent A (%)
(water+0.1 % formic acid)
Solvent B (%)
(acetonitrile +0.1% formic acid)
0 95 5
2 0 20 80
25 20 80
27 95 5
30 95 5
Table 6.1 Composition of the gradient mobile phase used in LC-MS analysis.
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However, it was observed that the signal intensity for the molecular ion was quite weak, 
possibly due to the poor ionisation efficiency of PEITC. It was necessary to ensure whether 
direct LC-MS analysis of PEITC would be possible at the concentrations that would be of 
interest in the pharmacokinetic studies. To this end, a range of PEITC concentrations was 
analysed by LC-MS to establish the limit of detection. As predicted, the direct detection of 
PEITC by LC-MS was poor, having a limit of detection for PEITC of 20 pM (signal to noise 
ratio > 3:1), as shown in Figure 6.4, which was not sufficient to allow analysis of plasma 
sample, following administration of low doses of PEITC to rats. This is most likely to be due 
to poor ionisation using ESI+, which given its structure (Fig. 6.1) is not unexpected as there 
are no obvious basic sites for protonation of the molecule, on which the electrospray process 
relies to generate ions in positive mode.
BÎIH1ILPB1CMJ
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Figure 6.4 Extracted ion chromatogram of PEITC m/z 164 at the limit of detection (20 
pM). PEITC in acetonitrile (20 pM) following injection of 10 pi was monitored using LCT.
6.2.3 Sample preparation
6.2.3.1 Derivatisation o f PEITC
In order to improve the sensitivity of the LC-MS analysis, derivatisation of PEITC to 
phenethyl thiourea (PETHU) was considered (Song et al., 2005). As already described, 
PETHU is one of PEITC derivatives, containing a basic NH2 functionality making PEITC
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much more amenable to LC-MS analysis using positive ion electrospray ionisation. 
Derivatisation was carried out according to the method described by Ji and Morris (2005), and 
the reaction scheme is shown in Figure 6.5. To a PEITC solution in acetonitrile (5-50 pM), 
2.5 volumes o f 2 M  ammonia solution in isopropanol was added. The mixture was incubated 
m a shaking water bath at room temperature for 6 hr. After drying in a high drying rate mode 
using vacuum evaporator (Savent AES2010), the dried samples were reconstituted in 60:40 
water:acetonitrile to the original volume, and analysed by LCT, using new mass spectrometer 
tuning parameters (Table 6.2) obtained from a direct infusion of a 5 pM PETHU solution. 
The standard curve of the PEITC derivative is shown in Figure 6.6.
^CH2“CH2~N=C=S
PEITC
NH3
 ► I
Phenethyl thiourea
Figure 6.5 Derivatisation scheme: Reaction of PEITC with ammonia to yield PETHU.
I Parameter : Value y j
Capillary Voltage +3.5 kV
Cone Voltage +22 V
Source Temperature 100 “C
Desolvation Temperature 300 °C
Desolvation Gas Flow 600 L/h
Cone Gas Flow 30L/h
Table 6.2 LCT optimum tuning parameters for PETHU.
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Figure 6.6 Standard curve of PETHU. Derivatisation reaction assumed 100% conversion of 
PEITC to PETHU. Results are presented as mean ± SD (n=3).
6.2.3.2 Quantification o f PETHU
An internal standard (IS) has been introduced to enable quantification of PEITC; this is a 
known amount of compound that behaves similarly to the analyte. A consistent concentration 
of IS IS added to every sample, hence concentration of analyte in the sample can be calculated 
based on the ratio of peak areas of analyte to IS.
Isotopically labelled form of PEITC with 4 hydrogen atoms being replaced with deuterium, 1,
1,2,2- H4-PEITC was used for quantitative analysis purposes and also calibration of the LC-
MS operation in the current study. 1,1,2,2-%-PEITC was synthesised as previously
described (Conaway et al., 1999) and was kindly provided by Dr. Nikolai Kuhnert (Jacobs
university, Bremen, Germany). IS (5 pi) at a final concentration of 25 pM, was spiked into 50
pM PEITC (50 pi), both being prepared in acetonitrile, and put through derivatisation as
described in Section 6.2.3.1. Figures 6.7 and 6.8 show respectively the chromatogram and
mass spectra of PETHU and of the internal standard derivative. The retention time of both
compounds is approximately at 14.9 min and m/z are 181 and 185 for PETHU and IS 
respectively.
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Subsequently, a plot was constructed for known concentrations of PEITC versus PETHU (5- 
50 pM) and IS response (25 pM) (Fig 6.9), using the same derivatisation conditions. Linearity 
of the plot was identified by using coefficient of determination (R-squared). As it can be seen, 
a variable peak area of internal standard was increasing along with increasing PEITC 
concentration, and was thought to be due to incomplete derivatisation. To end this problem, a 
number of parameters were further investigated.
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Figure 6.7 Extracted ion chromatograms of IS m/z 185 (top) and PETHU m/z 181 
(bottom).
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Figure 6 .8  Mass spectra of PETHU m/z 181 and internal standard m/z 185.
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Figure 6.9 Peak area of various PETHU concentrations (5-50 jiM) and internal standard 
derivative (25 jiM) against concentration of PEITC. Results are presented as mean ± SD 
(n=3).
6.2.3.3 Effect o f  incubation time on the derivatisation reaction
The low peak area of internal standard at low concentrations of PEITC may possibly arise due 
to insufficient incubation time for the derivatisation reaction to be completed. Consequently, 
peak areas of IS at various PEITC concentrations obtained from 6 and 24 hr incubation 
periods were compared. Table 6.3 shows that peak area of IS after a 24 hr incubation 
remained relatively constant compared with that from a 6 hr incubation.
PEITC (pM) 1 Peak area of IS
1 24 hr incubation 6  hr incubation
1 219.21 ±13.52 46.47 ± 18.91
5 226.39 ± 13.92 48.64 ± 2.66
1 0 243.67 ± 1.92 54.28 ±6.16
15 236.99 ±9.13 1 62.43 ± 14.22
25 234.41 ±25.13 59.80 ±6.34
50 269.11 ±21.78 364.98 ± 20.44
Table 6.3 Effect of incubation time on peak area of internal standard derivative at 
various concentrations of PEITC. PEITC in acetonitrile (1-50 pM) was spiked with IS (25 
p j and put through derivatisation for 6 or 24 hr. Results are presented as mean ± SD (n=3).
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The optimum incubation temperature was also studied, e.g. 23 (room temperature), 37 and 50 
°C. The results revealed that room temperature was sufficient for derivatisation, providing 
high and constant peak area of IS (data not shown). Finally, derivatisation was carried out by 
mixing the samples with 2.5 volumes of 2 M ammonia in isopropanol as described by Ji and 
Morris (2005) and incubated for 24 hr at room temperature. The plot of peak area of PETHU 
and internal standard against PEITC concentration was obtained (Fig. 6.10). The limit of 
detection and quantification of PEITC were 1 and 5 pM, respectively. However, an R-squared 
value of 0.8923 indicated lower linearity of relationship between PETHU response to PEITC 
concentration than expected, which may reflect low sensitivity of LCT detector.
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Figure 6.10 Peak area of PETHU at various concentrations (1-50 pM) and internal 
standard derivative (25 pM) against concentration of PEITC. Various concentrations of 
PEITC (1-50 pM) were spiked with IS (25 pM) and derivatised at room temperature for 24 
hr. Results are presented as mean ± SD (n=3).
6.23.4 Extraction conditions o f PEITC and IS from rat plasma
As the study was aimed to determine the pharmacokinetic characteristics of PEITC, optimal 
extraction conditions of PEITC from rat plasma were investigated. The adopted procedure 
illustrated in Figure 6.11.
IS
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Spike PEITC and IS in rat plasma and mix well
Add extraction solvent and mix thoroughly 
by vortex mixer for 30 sec
I
Centrifuge at 3000 xg for 5 min
I
Collect solvent layer
i
Add 2.5 volumes of 2 M ammonia solution in isopropanol 
Incubate in a shaking water bath at room temperature for 24 hr
I
Dry down (vacuum evaporator)
I
Reconstitute with 40% acetonitrile in water
I
LCT analysis
Figure 6 .1 1  Extraction and derivatisation procedures for PEITC and IS from rat
Effect o f extraction solvent on recovery o f PEITC and TS
The solvent extraction should selectively remove PEITC from the marix and avoid the 
interference of PEITC metabolites. Thus the solvent employed should be nonpolar, since the 
major metabolites of PEITC are polar compounds, e.g. PEITC-NAC. Eor this reason, the 
effect of three different solvents, categorised in order of hydrophobicity (Barton, 1983) 
namely heptane, dichloromethane and ethyl acetate on PEITC recovery was investigated. 
Stock solutions of PEITC and IS (10 mM) were prepared in acetonitrile and diluted with 
water to a working solution. Control rat plasma (50 pi) was spiked with 5 pi working 
solutions, equivalent to a final concentration of 10 pM of PEITC and IS. Solvent at about 2 
volumes (100 pi) was added prior to extraction. Subsequent to organic phase collection, the
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samples were derivatised according to the procedure described in Section 6,2.3.3. Degree of 
recovery was calculated in comparison with the responses of PETHU and IS attained 
following spiking PEITC and IS into methanol and put through the derivatisation process 
without extraction.
As shown in Table 6.4, heptane was the most appropriate solvent, but recovery of PEITC and 
IS was very poor. Consequently, the volume of heptane, based on final volume of the mixture, 
plasma and analytes, namely 1, 4 and 6 volumes and number of extractions namely 1 and 2 
extractions were investigated. Table 6.5 shows that 4 volumes of heptane with 2 extractions 
let to higher recovery of PEITC. The decrease in recovery when 6 volumes of solvent was 
used is possibly due to insufficient reconstitution after drying, as PEITC tended to adhere to 
the glass tube. However, even under these conditions, recovery remained unacceptable. 
Extraction time was also taken into account, but a longer extraction period (>30 sec) did not 
improve recovery (results not shown). Finally, the drying process was considered. Even 
though vacuum drying was employed, exposure to high temperature for very long time (> 4 
hr) may result in loss of PETHU. Results revealed that substitution of the vacuum evaporator 
with a nitrogen gas stream at room temperature enabled higher recovery of PEITC (data not 
shown).
Solvent % Recovery (PEITC) % Recovery (IS)
Heptane 29.73 ± 6.09 27.69 ± 2.22
Dichloromethane 10.99 ±8.55 13.23 ±5.12
Ethyl acetate 4.20 ± 1.86 17.42 ±4.97
Table 6.4 Effect of extraction solvent on the recovery of PEITC and IS. Derivatisation 
reaction assumed 100% conversion of PEITC to PETHU. Percentage recovery was calculated 
by comparison of the peak area retrieved from plasma extraction over peak area of control (no 
extraction). Results are presented as mean ± SD (n=3).
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Volume of heptane % Recovery of PEITC
1 extraction 2  extractions
2 29.51 ±4.72 27.04 ± 8.95
4 39.71 ± 6.36 48.24 ±2.16
6 2.24 ± 0.52 0.72 ±0.19
Table 6.5 Effect of heptane volume and number of extractions on recovery of PEITC.
Volume of heptane was based on the final volume of rat plasma and analytes mixture. 
Derivatisation reaction assumed 100% conversion of PEITC to PETHU. Percentage recovery 
was calculated by comparison of the peak area retrieved from plasma extraction over peak 
area of control (no extraction). Results are presented as mean ± SD (n=3).
Employing the new conditions, the recovery of various PEITC concentrations (0.1-10 pM) 
increased to above 80% (Table 6.6). Subsequently, the LCT detector was replaced for a better 
sensitivity and the mass spectrometry parameters were retuned as shown in Table 6.7. Having 
achieved a higher sensitivity, all subsequent experiments were carried out at the lower range 
of concentrations that are likely to be encountered in the pharmacokinetic studies. Gradient 
mobile phase composition was also altered in order to decrease operating time, but without 
changing of the retention time of analytes (Table 6.8).
PEITC (pM) % Recovery
0 .1 83.53 ± 10.30
0.5 83.74 ±2.20
1 .0 94.47 ± 1.70
2.5 103.26 ±2.60
5.0 92.31 ±5.30
7.5 96.96 ±3.28
1 0 .0 107.28 ± 11.71
Recovery of PEITC and IS from rat plasma. Derivatisation reaction assumed 
lOO /o conversion of PEITC to PETHU. Percentage recovery was calculated by comparison 
of the ratio of peak area of PEITC to IS retrieved from plasma extraction over peak area of 
control (no extraction). Results are presented as mean ± SD (n=3).
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Param eter Value
Capillary Voltage +3.0 kV
Cone Voltage +20 V
Source Temperature 100 T
Desolvation Temperature 300 »C
Desolvation Gas Flow 800 L/h
Cone Gas Flow 80 L/h
Table 6.7 New optimum tuning param eters of LCT for PETHU.
Time (min) 1 Solvent A (%)
(water+0.1% formic acid)
Solvent B (%)
(acetonitrile+0.1 % formic acid)
0 95 5
10 20 80
15 20 80
20 95 5
25 95 5
Table 6.8 New gradient mobile phase composition for LC-MS analysis.
The improved sample preparation process is shown in Figure 6.12. A typical chromatogram, 
retrieved using total ion coimt mode, for PETHU and IS extracted from rat plasma is shown in 
Figure 6.13. Both analytes shared the same retention time (RT = 14.85 min) and no major 
interfering peak was observed.
Spike PEITC and IS in rat plasma and mix well
i
Add 4 volumes of heptane
Extract twice (mix thorough y by vortex mixer for 30 sec)
i
Centrifuge at 3000 xg for 5 min and collect heptane layer
i  Continued
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Continued
Add 2.5 volumes of 2 M ammonia solution in isopropanol 
Incubate in a shaking water bath at room temperature for 24 hr 
Dry down (nitrogen gas at room temperature)
i
Reconstitute with 40% acetonitrile in water
i
LCT
Figure 6.12 Final sample preparation procedure.
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Figure 6.13 Chromatogram showing total ion count (TIC) for PETHU and IS at a 
retention time 14.88 min. PEITC and IS were spiked into rat plasma and put through 
extraction and derivatisation prior to analysis by LCT.
6.2.4 Method validation
6.2.4.1 Limit o f  detection and quantification
Limit of detection, defined as the lowest concentration of analyte that generates a minimum 
signal to noise ratio of 3, and limit of quantification, defined as the lowest concentration of 
analyte that gives rise to an instrument response with a minimum signal to noise ratio of 10, 
were 0.1 (Fig. 6.14A) and 0.5 pM (Fig. 6.14B) respectively, following a 10 pi injection.
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These limits indicated sufficient sensitivity of the method for analysis of PEITC in envisaged 
pharmacokinetic studies.
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Figure 6.14 Extracted ion chromatogram of PETHU m /z 181 at the limit of 
detection, (0.1 jaM) (A), and limit of quantification (0.5 ^M) (B).
6.2.4.2 Inter-day variation
Three concentrations of PEITC 0.5, 1.5 and 2.5 pM, and internal standard at 1.5 pM were 
used throughout the method validation process. Stock solution of either PEITC or IS at 10 
mM was prepared freshly in acetonitrile and then diluted to the working solution using water. 
The samples were put through extraction and derivatisation process (Fig. 6.12) prior to 
analysis by LCT, each of the six replicates was injected twice. These processes were repeated
195
Chapter 6: Method development fo r  PEITC determination in rat plasma
daily for 6 times, 2-day intervals. Inter-assay variation, as exemplified by % CV, is shown in 
Table 6.9. The low CV, less than 20%, illustrates the reproducibility of the process.
6.2.4.3 Intra-day variation
Intra-day variation was similarly determined except that each batch of samples was repeatedly 
prepared on the same day. Intra-assay variation (<10%) is shown in Table 6.9.
PEITC Intra-day Inter-day
(pM) Peak area %CV Peak area %CV
0.5 64.84 ±3.85 8.40 ± 2.69 66.70 ±3.79 7.10±1.81
1.5 215.58 ±20.33 7.60 ±3.12 226.01 ±25.52 4.00 ± 2.48
2.5 448.83 ± 18.25 4.60 ±5.92 464.03 ± 17.84 3.40 ±2.15
Table 6.9 Intra- and inter-day variation of LCT operation. PEITC (0.5, 1.5 and 2.5 pM) 
and IS (1.5 pM) were spiked into control rat plasma in six replicates. Three batches of the 
samples were extracted and derivatised on the same day for intra-day variation assay (n=3) 
whereas that of the six batches of the samples were performed in a regular 2-day intervals 
(n=6) for inter-day variation determination. Results are presented as mean ± SD.
6.2.4.4 Freeze-thaw stability
Since it was anticipated that plasma samples will be stored frozen, the freeze-thaw stability of 
PEITC was assessed. Spiked rat plasma was prepared and divided into two groups. The first 
group was immediately put through extraction and derivatisation whereas the second group 
was stored at -80 C for 15 days. On completion of the storage period, the plasma samples 
was thawed unaided at room temperature for at least 3 hr and re-frozen again. The freezing 
and thawing process cycle was repeated 3 times and samples were then extracted and 
derivatised. Coefficient of variation (CV, %) at 0.5, 1.5 and 2.5 pM PEITC were less than 
(Table 6.10) indicating that PEITC is stable during freezing and thawing. Moreover, 
stability of samples in the 5 °C autosampler chamber was also validated. This was achieved 
by comparing the peak area ratio (PETHU/IS) before and after a 24 hr delay time in the
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autosampler. Results indicate that PETHU is stable for at least 24 hr in autosampler 
conditions (data not shown).
PEITC Control After freezing and thawing
(pM) Peak area ratio Peak area ratio 
(PETHU/IS)
%CV
0.5 0.39 ± 0.04 9.42 0.40 ± 0.02 5.48
1.5 0.97 ±0.08 8.09 1.09 ±0.15 13.39
2.5 1.53 ±0.10 6.71 1.64 ±0.10 6.01
Table 6.10 Effect of freezing and tbawing on stablUty of PEITC. PEITC (0.5, 1.5 and 2.5
pM) and IS (1.5 pM) were spiked into control rat plasma. Extraction and derivatisation were 
carried out on the same day (control) or subsequent to 3 cycles of freezing and thawing 
process. Results are presented as mean ± SD (n=3).
6.2.4.5 Accuracy and precision o f analysis
Finally, accuracy of analysis was established by comparing calculated and theoretical values 
at four plasma concentrations. Accuracy at PEITC concentrations of 1.0, 1.5, 2.5 and 5 pM 
were within ± 15% of the theoretical values (Table 6.11). Moreover, the precision values from 
multiple sampling were evaluated as exemplified by % CV indicating reliability of both the 
method and instrument used (Table 6.11).
Expected 
concentration (pM)
Measured concentration (pM) % Accuracy Precision
(%CV)
1 .0 0.96 ±0.03 95.96 ±3.18 3.31
1.5 1.39 ±0.05 92.57 ±3.01 3.25
2.5 2.47 ±0.16 98.86 ±6.55 6.63
5 5.06 ±0.25 101.13 ±5.06 5.00
Table 6 .1 1  Accuracy and precision of analysis of PEITC in rat plasma. PEITC (1.0, 1.5, 
2.5 and 5 pM) and IS (1.5 pM) were spiked into control rat plasma. The error of measured 
PEITC concentration was calculated. Results are presented as mean ± SD (n=6).
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Subsequently, standard curves were constructed firstly for instrument validation, where 
PETHU standard was directly analysed by LCT. PETHU standard at 10 mM was prepared in 
acetonitrile and then diluted with water to final concentrations of 0-15 pM before LCT 
analysis. An excellent linear relationship between PETHU response (peak area) and 
PETHU concentration was observed, with a coefficient of determination, value of 
0.993 (Fig. 6.15). A second standard curve was generated for the validation of the complete 
process where plasma extraction and derivatisation were taken into account. Aliquots of blank 
plasma were spiked with 5 pi of PEITC solutions to obtain calibration samples at 
concentrations ranging 0-15 pM and a constant IS concentration of 1.5 pM. The mixtures 
were subjected to extraction and derivatisation prior to LCT analysis. A standard curve was 
constructed and an R  ^value of 0.996 indicates that the ratio of PETHU and IS response is 
linearly related to plasma concentration of PEITC (Fig. 6.16).
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Figure 6.15 Standard curve of PETHU standard for validation of LCT operation.
Commercial PETHU was used to prepare a range of solutions (0-15 pM). Peak areas were 
obtained from LC-MS analysis. Results are presented as mean ± SD (n=3).
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Figure 6.16 Standard curve of PETHU following extraction from plasma samples and 
derivatisation. PEITC (0-15 pM) and IS (1.5 pM) were spiked into control rat plasma. Peak 
area ratios were obtained from LC-MS analysis following sample extraction and 
derivatisation. Results are presented as mean ± SD (n=3).
6.2.5 Preliminary study
Following completion of the LC-MS method and sample preparation development, a 
preliminary study was performed in order to establish the application of this analytical 
method for determination of actual plasma concentrations. A single rat received a single dose 
of PEITC, dissolved in 0.1% DMSO, by gavage at a dose level 5.0 mg/kg, a dose that would 
be of interest in the planned pharmacokinetic studies. After intake of PEITC, blood samples 
(150 pi) were withdrawn from the rat tail at 0.25-24 hr and placed into lithium-heparinised 
centrifuge tubes. A sample was also obtained at 0 time, before administration of PEITC. After 
spiking with IS, samples were extracted and derivatised as shown in Figure 6.12. Standard 
curve was constructed by spiking known concentrations of PEITC and IS into control rat 
plasma, and put through the identical process as the test samples. Time-course changes in the 
plasma concentration of PEITC is shown in Figure 6.17 which clearly indicates the 
applicability of the developed method for the analysis of PEITC in rat plasma.
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Figure 6.17 Time-course of plasma levels of PEITC in a rat treated with an oral dose of 
PEITC. A rat was treated with a single oral dose (5.0 mg/kg) of PEITC. Blood samples were 
withdrawn at regular time intervals, and PEITC determined using the developed LC-MS 
method.
6.3 Discussion
Analytical techniques for the determination of glucosinolates and isothiocyanates have been 
developed. Quantification of PEITC using a spectroscopic HPLC-UV method was the first to 
be described, and was utilised to establish the urinary PEITC metabolic profile in mouse 
(Eklind et al., 1990). However, in order to identify peaks of unknown metabolites, NMR was 
employed and a cyclic mercaptopyruvic acid conjugate was classified as the major metabolite 
followed by the V-acetylcysteine conjugate. Further studies using the same method indicated 
that the major metabolite following gluconasturtiin, the PEITC glucosinolate precursor, intake 
in human was the iV-acetylcysteine conjugate (Chung et al., 1992). Even though these studies 
successfully established the major metabolites of PEITC, it is an inconvenient method 
requiring several steps. Scintillation counting of ^"^C-labelled isothiocyanate has been used to 
monitor ^^C-distribution and disposition in a number of mouse and rat organs as well as urine 
and a faeces after [^^C]-PEITC gavage (Conaway et al., 1999; Eklind et al., 1990). These 
studies elucidated important target sites of PEITC which may contribute to its
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chemopreventive action in particular tissues. Subsequently, the cyclocondensation assay has 
been introduced for the analysis of isothiocyanates (Zhang et al., 1992). It is the most widely 
used method based on a quantitative reaction of ITC and ITC-metabolites (dithiocarbamates) 
with 1,2-benzenedithiol, and the cyclic condensation product, l,3-benzodithiole-2-thione, is 
spectroscopically detected by HPLC-UV. This method has been used for the determination of 
the levels of glucosinolates or isothiocyanates in plants (Prestera et al., 1996; Shapiro et al., 
1998; Zhang et al., 1996), and for monitoring excretion of total ITC metabolites in human 
urine prior to glucosinolate-rich plant consumption (Chung et al., 1998; 1997; Shapiro et al., 
1998). However, the cyclocondensation reaction is not suitable for analysis of clinical 
samples at low concentrations of ITCs, particularly in blood plasma, due to interference from 
the high protein content which can also interact with vicinal dithiol. Precipitation of the 
protein by using polyethylene glycol (PEG) or ultrafiltration was subsequently introduced in 
order to overcome this problem (Ye et al., 2002). However, another disadvantage of the 
cyclocondensation reaction is the lack of specificity since all types of ITC, including their 
metabolites, will react with dithiol to form the cyclic condensation product, rendering it 
impossible to monitor individual ITCs or metabolites. Consequently, in 2003, an LC-MS 
method was developed for the separation and detection of PEITC, enabling both sensitive and 
specific detection of PEITC achieved (Ji and Morris, 2003). Pharmacokinetic and oral 
bioavailability of PEITC was subsequently investigated (Ji et al., 2005). The ultimate 
objective of the present study is to determine the absolute bioavailability of PEITC, at a dose 
equivalent to human dietary consumption; an adaptation of the method described by Ji and 
Morris (2003) was, consequently, developed and validated in order to achieve this objective.
In the current study, a method employing liquid chromatography combined with time of flight 
mass spectrometry (LCT) was developed for the identification and quantification of PEITC. 
Liquid extraction using heptane as a solvent granted acceptable recovery levels and is an 
important step in the analysis of trace amounts of PEITC in rat plasma. The extraction process
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also selectively isolates PEITC from its metabolites in rat plasma due to the difference in 
hydrophobicity, as evidenced by the absence of major contaminant peaks. Derivatisation of 
PEITC to phenethyl thiourea was necessary to improve protonation of PEITC leading to 
higher sensitivity. Identification of PEITC was primarily based on HPLC separation indicated 
by retention time and the m/z compared with phenethyl thiourea standard. Quantification was 
based on relative peak area of PETHU to internal standard, 1,1,2,2-%-PEITC, using a 
standard curve displayed the excellent linear relationship between plasma concentrations to 
expected concentrations. A number of method parameters, e.g. limit of detection and 
quantification, accuracy, precision, recovery, stability and inter- and intra-day variability were 
investigated since they are pivotal factors demonstrating an acceptable bioanalytical 
technique (U.S.Department of Health and Human Services, 2001). The studies revealed 
excellent reliability and reproducibility of the entire analytical process. Finally, a preliminary 
study showed that this LC-MS method is suitable for the analysis of plasma PEITC in rats 
following exposure to low doses.
6.4 Conclusions
An LC-TOF-MS analytical method for the determination of PEITC was set up and validated 
as a powerful tool for the determination of plasma levels in rats, following exposure the low 
doses of the isothiocyanate.
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CHAPTER 7
Pharmacokinetic behaviour of PEITC in rats
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7.1 Introduction
PEITC is a naturally-occurring isothiocyanate with potential chemopreventive activity, which 
in animal studies afforded protection against the tumourigenicity of established chemical 
carcinogens (Chung et al., 2000; Hecht et al., 1996a; Nishikawa et al., 1996; Stoner et al., 
1991). Following cruciferous vegetable intake, isothiocyanates, the secondary products 
generated from the hydrolysis of glucosinolate, are passively absorbed across the intestinal 
cell membranes. In blood, isothiocyanates are protein bound (Ji et al., 2005), but the free 
fractions enter the cells where they are conjugated following interaction between central 
carbon atom within the isothiocyanate group with cellular glutathione. The glutathione 
conjugates are exported from the cells and undergo further metabolism through the 
mercapturic acid pathway prior to being excreted through the urine (Brusewitz et al., 1977; 
Mennicke et al., 1987). The chemopreventive effect of isothiocyanates appears to be related 
to their metabolism. For example, depletion of cellular glutathione has been demonstrated to 
activate signal transduction for cancer chemoprevention (Xu and Thomalley, 2001) and, at 
the same time, accumulation levels of isothiocyanates regulate the induction of phase II 
enzymes (Zhang, 2000).
In the current study, PEITC modulated the xenobiotic-metabolising enzymes both in vitro and 
in vivo. Utilising precision-cut liver slices, the effects of PEITC on carcinogen-metabolising 
enzyme systems were emphasised since liver is the major site of xenobiotic metabolism. The 
balance of bioactivation and detoxication of chemical carcinogens and its modulation by 
chemopreventive agents is pivotal to their cancer prevention potential. However, in order to 
relate modulation of the carcinogen-metabolising enzymes to the concentration of PEITC, it is 
indispensable that the pharmacokinetic behaviour of the isothiocyanate is appreciated, in 
particular after intake of dietary levels.
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7.2 Methods
7.2.1 Animal treatment
Rats, four per group, received single daily administrations of PEITC, dissolved in 0.1% 
DMSO, by gastric intubation, at three dose levels, namely 0.5, 1.0 and 5.0 mg/kg, for 4 days. 
Following the first and last intake of PEITC, blood samples (150 pi) were withdrawn from the 
rat tail at regular time intervals (0.25 - 8 hr) following administration, and placed into lithium- 
heparinised centrifuge tubes. A sample was also obtained 24 hours after administration as 
well as at 0 time, i.e. before administration of the isothiocyanate. Finally, in order to 
determine absolute bioavailability, one group of animals was treated through the tail vein with 
a single intravenous dose of PEITC (0.5 mg/kg), dissolved in 15% hydroxypropyl-p- 
cyclodextrin (Ji and Morris, 2003), and blood samples were withdrawn at the same time 
points post-administration.
7.2.2 Sample preparation
The extraction and ammonia derivatisation procedures were performed essentially as 
described in Chapter 6. Aliquots of rat plasma (60 pi) were spiked with the deuterated PEITC 
(final concentration 1.5 pM). Plasma was extracted twice with heptane (200 pi), and to the 
combined extracts was added 2M ammonia in isopropanol (1 ml). Following a 24-hour 
incubation in a shaking water bath at room temperature, the mixture was dried down under a 
stream of nitrogen at room temperature and re-suspended in 60 pi of the HPLC mobile phase 
(40 % acetonitrile in water containing 0.1% formic acid), and 10 pi was injected into the LC- 
MS for analysis.
7.2.3 Determination of PEITC in rat plasma
As described in Chapter 6, plasma concentrations of PEITC in the rat were determined by 
LC-TOF-MS following liquid extraction and conversion of PEITC to phenethyl thiourea 
(PETHU). Under the described conditions, the retention time of PETHU and its deuterated
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analogue, which served as an internal standard, was about 15 min in a total run time of 25 
min.
7.2.4 Pharmacokinetic analysis
Pharmacokinetic analysis was carried out using PK solutions™ software package (version 2.0, 
Summit Research Services, Ohio, USA). Absolute bioavailability (F) was determined from 
the ratio of the oral to intravenous dose-normalised AUCo-oc values. Apparent volume of 
distribution (Vd) was calculated from the equation Vd = FD/ AUCo-oc kei, where kei and D are 
the elimination rate constant and dose respectively. Plasma clearance (Cl) was determined 
using the equation Cl = FD/ AUCo-«. Finally, Cmax and T^ax were determined graphically from 
the plasma concentration versus time plots.
7.3 Results
7.3.1 Pharmacokinetic fate of PEITC in rats following single oral or intravenous 
administration
A single intravenous (0.5 mg/kg) or oral (0.5, 1.0 and 5.0 mg/kg) dose of PEITC was 
administered to rats. In figure 7.1, chromatograms in total ion count mode from rat plasma 
before and after PEITC administration are illustrated; no major interfering peak was observed 
at the elution time of PETHU. Figure 7.2 shows the time-course changes in plasma 
concentrations of PEITC, plotted using a semi logarithmic plot, following a single 
intravenous bolus administration to rats; the plasma profile is best described by an one- 
compartment pharmacokinetic model. Plasma levels declined rapidly with a half-life of 1.36 
hr (Table 7.1), and no PEITC was detectable in the 24-hr samples.
Similarly, following oral administration of the same dose, plasma kinetic profile was better 
described by an one-compartment model (Fig. 7.3). PEITC was rapidly absorbed, with
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maximal levels being attained within an hour. The pharmacokinetic parameters of PEITC 
following single administration are shown in Table 7.1. The bioavailability of PEITC, at the 
dose level of 0.5 mg/kg, was 77%, but decreased with increasing dose, being only 23% at the 
highest dose studied of 5 mg/kg. The Cmax and AUCo-oc values increased with dose, but not 
proportionately; rise in AUCo-oc and Cmax values was lower than would be anticipated. Only 
increase in plasma clearance with dose was observed whereas volume of distribution, 
biological half-life and the absorption and elimination constants were unaffected by dose 
within the investigated range (Table 7.1).
7.3.2 Pharmacokinetic fate of PEITC in rats following repeated oral administration
Repeated oral administration of PEITC influenced the pharmacokinetic behaviour of the 
isothiocyanate, but only at the higher two doses, namely 1 and 5 mg/kg (Fig. 7.3 and Table 
7.1). Although Tmax and absorption rate constant values were unaffected, Cmax values rose 
significantly, being nearly trebled at the 5 mg/kg dose level; elimination rate constant 
increased whereas biological half-life and plasma clearance values as well as volume of 
distribution decreased. Finally, AUCo-oc increased leading to higher bioavailability.
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Figure 7.1 Chromatogram of rat plasma before (A) and after (B) PEITC administration.
Blood samples were withdrawn from the rat tail before and after PEITC administration. 
Following sample extraction and derivatisation, LC-TOF-MS was used to monitor PETHU.
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Figure 7.2 Plasma levels of PEITC in rats treated with a single intravenous dose of 
PEITC. Rats were treated with a single intravenous dose (0.5 mg/kg). Results are presented 
as mean ± SD of four rats.
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PEITC for four days. Results are presented as mean ± SD of four rats.
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7.4 Discussion
The desirable biological characteristics of PEITC required to modulate the carcinogenesis of 
chemicals have been reported, largely in in vitro studies. However, for the outcome of these 
studies to be extrapolated to the human situation and be related to dietary levels of intake, it is 
required that the pharmacokinetic behaviour of PEITC is appreciated. Early pharmacokinetic 
characterisation of PEITC has been carried out in animal models employing a single 
administration of radiolabelled PEITC at high doses, and the time-course of total ^^*C 
concentration in blood and many organs was determined (Conaway et al., 1999). 
Subsequently, measurement of total dithiocarbamate formation from the cyclocondensation 
reaction between PEITC and its metabolites with dithiol was developed and employed in 
humans (Liebes et al., 2001). However, these data represent the sum of the parent compound 
and its metabolites so that the pharmacokinetic characteristics of the parent compound are 
confounded by the presence of metabolites. Since metabolites of isothiocyanates can attain 
concentrations in the plasma higher than those of the parent compound (A1 Janobi et al.,
2006), the plasma levels of total radioactivity or dithiocarbamates reflect mostly metabolites 
and can not be used to define the fate of the parent isothiocyanate. Accordingly, Ji and Morris 
(2003) developed an analytical technique empowering discrimination between the parent 
compound and metabolites, and reported pharmacokinetic studies describing the plasma 
profile of PEITC in rats using an LC-MS-MS method (Ji et al., 2005). However, in these 
studies only single doses were investigated, and the lowest oral dose employed was 10 
fxmole/kg, which is almost twice higher than the human dietary intake.
In the present study, 3 dose levels were used, where the medium dose (1 mg/kg) represents 
human total glucosinolate dietary intake, being equivalent to about 300 g of watercress, the 
principal source of PEITC (Jiao et al., 1998); a lower (0.5 mg/kg) and a higher (5 mg/kg) dose 
were also studied. This is the first study dealing with the effects of repeated intake of PEITC 
on plasma levels and pharmacokinetic parameters.
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Food was not withdrawn from the animals prior to PEITC administration, since this 
influences CYP450 expression (Imaoka et ak, 1990; Ma et a l, 1989) and may modulate 
PEITC metabolism, as a result of decreased glutathione levels (Tateishi et a l, 1974), bearing 
in mind that conjugation with glutathione is the major route of PEITC metabolism (Conaway 
et a l, 2002). Analysis of blank plasma indicated no interfering peak. PEITC was rapidly 
absorbed following oral administration with peak levels attained within an hour, similar to 
previous studies (Ji et al., 2005), presumably due to the fact that PEITC is a small lipophilic 
compound, hence rapid passive diffusion through the intestinal membrane would be 
anticipated. The AUCo^ following intravenous administration did not differ significantly 
from oral administration, suggesting that PEITC was almost completely absorbed after oral 
administration. Thus it is not surprising that PEITC achieved a very good bioavailability of 
over 75%. It is likely that PEITC undergoes modest first-pass metabolism as metabolites of 
isothiocyanates can be generated by intestinal as well as hepatic enzymes, or even possibly in 
the blood as it contains low concentrations of glutathione that can interact chemically with the 
isothiocyanate. Studies using human jejunum in situ have established that sulforaphane, an 
aliphatic isothiocyanate, is conjugated with glutathione in the enterocytes during absorption 
and secreted back into the lumen (Petri et al., 2003). These glutathione conjugates, however, 
can be converted back to the free isothiocyanate by hydrolysis (Bruggeman et al., 1986), and 
the rate of dissociation of dithiocarbamates to free isothiocyanate is the rate limiting step of 
cellular uptake of isothiocyanate (Zhang, 2001).
Similar to studies with sulforaphane carried out in this laboratory (Hanlon et al., 2008a), dose- 
dependent pharmacokinetic behaviour was evident even when the oral dose of PEITC was 
only doubled. The Cmax and AUCo.c^  values in orally-treated rats increased with dose, but not 
proportionately; the rise in AUCq.,^  and Cmax values was lower than would be anticipated. The 
nonlinear increase o f Cmax and AUCq.,^  led to a marked drop in bioavailability so that at the 5 
mg/kg dose bioavailability was only about a third of what was observed at the 0.5 mg/kg
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dose. These observations imply that intake of isothiocyanate supplements containing PEITC
may not be effective at raising the plasma concentrations of the compound. PEITC displays
very high protein binding (Ji et al., 2005), and it is conceivable that at the higher doses
protein-binding sites may be saturated so that the isothiocyanate remains free and available
for elimination, the observation that plasma clearance increases with the dose would support
such a mechanism. However, it has been reported that the protein binding of PEITC in rat
serum remains constant over a wide range of concentrations (Ji et al., 2005). The lowest
concentration utilised in these studies, however, was 10 pM, which is considerably higher
than the C^ax levels achieved in the present study, being 2.0 and 4.7 pM at the 0.5 and 5
mg/kg doses respectively. Furthermore, the increase in volume of distribution with dose, even
though no statistical significance, may indicate higher tissue binding, a consequence of the
high reactivity of the isothiocyanate group. Since nonlinear pharmacokinetics in rats has also
been reported for sulforaphane, having an aliphatic substituent (Hanlon et al., 2008a), it may
be inferred that the isothiocyanate group is more likely to be responsible for this effect rather
than the substituent. Increased plasma clearance and volume of distribution in a dose-
dependent manner resulted in unchanged elimination rate constant and biological half-life.
Similarly, the Tmax was unaffected by increasing dose and with the maximum concentrations
being attained within less than an hour, which is comparable to the observation made in
studies employing higher doses of PEITC (Ji et al., 2005). However, a markedly higher Tmax
and longer biological half-life, compared with the current study, have been reported in the
study determining total ‘"‘C in blood of rats given radiolabelled PEITC (Conaway et al.,
1999). The longer half-life is presumably due to the fact that total '^C represented mostly 
PEITC metabolites.
Comparison o f the single dose plasma levels of PEITC with those attained by sulforaphane, in 
studies conducted at the same dose levels and rat strain (Hanlon et al., 2008a), reveal 
important differences. The C^., values of PEITC are orders of magnitude higher compared
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with sulforaphane at the same dose levels. Most likely this reflects the fact that sulforaphane 
achieves higher intracellular concentrations compared with PEITC, as exemplified by AUC of 
total dithiocarbamate following incubation of mouse skin cells with the isothiocyanates (Ye 
and Zhang, 2001). The much higher volume of distribution of sulforaphane (23.80 1 kg'^) 
compared with PEITC (1.53 1 kg'^), concords with such mechanism.
A principal mechanism of the chemopreventive activity of isothiocyanates is enhanced 
detoxication of the genotoxic metabolites of carcinogens, and repeated intake would be 
required for maximal induction of enzymes, like the glutathione S-transferases and quinone 
reductase, to be achieved (see Chapter 4). Indeed, suppression of the genotoxic effects of 
experimental carcinogens by isothiocyanates in animals was noted after their addition to the 
diet continuously for extended periods of time (Dingley et al., 2003; Staretz et al., 1997; 
Sticha et al., 2000). Consequently, it is important to understand the pharmacokinetic 
behaviour of PEITC after repeated intake as this may differ from what is observed after single 
intake, e.g. as a result of modulation of enzyme systems involved in its metabolism. At the 
doses of 1 and, in particular, 5 mg/kg, the pharmacokinetic profile of PEITC was altered 
following repeated intake; plasma levels and AUCo.oc increased, leading to enhanced 
bioavailability. The rise in plasma levels as a result of repeated intake of PEITC may 
contribute to its ability to enhance the metabolism of IQ which appeared to occur only 
following repeated administration (Chapter 5). As PEITC is a mechanism-based inhibitor 
(Nakajima et al., 2001; von Weymam et al., 2006), the rise in plasma levels may be attributed 
to decreased metabolic clearance of PEITC; however, this is not supported by the fact that 
biological half-life was not prolonged. Although isothiocyanates may be metabolised by 
cytochromes P450 (Lee, 1996), such metabolism is not a major route of isothiocyanate 
biotransformation (Eklind et al., 1990). A plausible mechanism that may be, at least partly, 
responsible for the higher plasma levels is saturation of intracellular levels of PEITC on 
repeated exposure. This hypothesis is consistent with the decrease in apparent volume of
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distribution with increasing dose. Isothiocyanates attain very high intracellular concentrations 
as a result of their interaction with glutathione, and may reflect the catalytic efficiency of 
glutathione ^transferases towards the isothiocyanate (Ye and Zhang, 2001; Zhang and 
Callaway, 2002). As the absorbed isothiocyanate conjugates with glutathione, the 
concentration gradient drives the further cellular uptake of the isothiocyanate, which can 
achieve mM concentrations, and is accompanied by a marked drop in glutathione levels. 
Hydrolysis of these glutathione conjugates is, moreover, required for cellular uptake of 
isothiocyanate (Zhang, 2000). The glutathione and cysteinylglycine conjugates are exported 
through membrane transporters such as P-glycoprotein (Collaway et al., 2003). Inhibition of 
MRP-1 due to the depletion of cellular GSH as a result the conjugation with PEITC, has been 
reported (Hu and Morris, 2004; Tseng et al., 2002) and could possibly cause the decrease in 
PEITC plasma levels. Nonetheless, volume of distribution from repeated administration was 
lower than single dose, implying that inhibition of MPR-1 did not occur.
7.5 Conclusions
Following oral administration to rats, PEITC is absorbed rapidly and achieves high 
bioavailability.
PEITC displays dose-dependent pharmacokinetics in rat, where bioavailability 
decreases with increasing dose.
Repeated administration of PEITC leads to higher plasma levels and increased 
bioavailability in rat.
215
Chapter 8: Discussion
CHAPTER 8
Discussion
216
Chapter 8: Discussion
8.1 Introduction
Protection against harmful chemicals by phytochemicals present in commonly consumed 
glucosinolate-containing cruciferous vegetables is of major current interest. Epidemiological 
studies indicated an inverse association between cruciferous vegetable consumption and 
cancer incidence in various sites such as colon (Voorrips et al., 2000b), oesophagus (Morse et 
al., 1993) and lung (Lam et al., 2009; Voorrips et al., 2000a). Isothiocyanates, the secondary 
products generated from glucosinolate hydrolysis, are believed to be responsible for the 
anticancer actions of these vegetables.
Protective mechanisms of isothiocyanates occur at all levels of carcinogenesis; however, 
inhibition of the biological activation of carcinogens by modulation of xenobiotic- 
metabolising enzymes is one of the most pertinent prevention mechanisms, and can be 
achieved by enhancing phase II detoxifying and/or suppressing of CYP450 bioactivation 
enzyme systems (Lampe and Peterson, 2002; Robbins et al., 2005). Various isothiocyanates 
have been extensively investigated such as sulforaphane, AITC, BITC and PEITC. Among 
aromatic isothiocyanates PEITC has been shown to possess potent anticancer activity (Hecht, 
1995; Lindros et al., 1995; van Lieshout et al., 1996). However, these studies employed doses 
much higher than those reflecting human intake. Thus, the current work was undertaken to 
evaluate the chemopreventive potential of PEITC at doses equivalent to dietary consumption. 
Studies were conducted both in vivo and in vitro, the latter utilising precision-cut tissue slices 
from rat and human; furthermore, in order to be in a position to extrapolate in vitro results to 
the in vivo situation, the pharmacokinetic characteristics of PEITC in rats were established.
8.2 Effect of dietary doses of PEITC on the detoxication of reactive intermediates
8.2.1 Induction o f glutathione S-transferase by PEITC
GST facilitates detoxification of electrophilic compounds by catalysing their conjugation with 
glutathione, prior to excretion of these less toxic metabolites from the body (Mannervik and
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Danielson, 1988). Thus, the ability of ITCs to stimulate GST is advantageous and, moreover, 
similar to many xenobiotics that induce the enzymes involved in their own metabolism, it is 
not surprising that ITCs are also substrates for GST (Kolm et al., 1995; Talalay et al., 1988). 
The conjugation with glutathione is a driving force of cellular uptake of ITCs and their 
intracellular concentration is associated with subsequent up-regulation potency of phase II 
enzymes (Zhang, 2000; Zhang and Talalay, 1998). For these reasons, induction of GST by 
PEITC is believed to be crucial for its anticarcinogenic activity.
It is a surprising fact that many isothiocyanates are inducers of GST and other related phase II 
enzymes since they are relatively soft electrophiles (Talalay et al., 1988). In the case of 
PEITC, GST activity was enhanced with all substrates employed but only at low 
concentrations (Chapter 3), which are achievable in plasma even following administration to 
rats of a low dose of PEITC (Chapter 7). Inconsistent results among donors were observed 
when human liver slices were employed, indicating that inter-individual variation may be a 
factor-limiting PEITC uptake and, therefore, of its chemopreventive potential (Moore et al., 
2007). It is relevant to point out that the major GST isoforms involved in the metabolism of 
isothiocyanates in human are GSTMl and GSTPl, and to a lesser extent GSTAl and GSTM2 
(Kolm et al., 1995; Zhang et al., 1995). Correspondingly, many epidemiological studies 
indicated stronger anticarcinogenic effect following consumption of cruciferous vegetable in 
individuals with deletion of the GSTMl isoform (Fowke et al., 2003; Zhao et al., 2001), 
presumably due to the fact that exposure of the body to ITCs is prolonged as a result of less 
efficient metabolism. In fact, functional and expression polymorphism of genes in GST 
family have been reported (Millikan et al., 2000; Tanaka-Kagawa et al., 2003). Previous 
studies revealed expression polymorphism of Nrf2, a transcription factor that regulates 
expression of phase II enzymes including GST (Cho et al., 2002), which may contribute to the 
different response of human GST to PEITC observed in four donors.
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In rats, administration of PEITC enhanced GSTa to a greater extent than GSTp (Chapter 4), 
indicating that induction of GST by PEITC is favourable for facilitating detoxification of 
other xenobiotics rather than auto-inducing its metabolism. Indeed, induction of GST in rats 
was observed following exposure to a Low dose equivalent to human dietary intake of PEITC 
(Chapter 4), hence daily consumption of cruciferous vegetables has the potential to afford 
protection against the carcinogenicity of chemicals.
8.2.2 Effect o f PEITC on glutathione concentration
For the GST system to function effectively, the levels of glutathione should not be limiting. 
The biological functions of glutathione have been well established, e.g. protection against 
oxidative damage, detoxification of reactive electrophiles and regulation of cell cycle (Friesen 
et al., 2004; Hsu et al., 2002). It is relevant to point out that incubation of human hepatoma 
cells with sulforaphane led to an initial decrease in cellular concentration of GSH whereas 
cellular uptake of sulforaphane was increased. However, after a 24-hr incubation, GSH 
content was restored to levels higher than control, and paralleled an increase in ARE- 
mediated gene expression (Kim et al., 2003). The authors reported that it is the depletion of 
glutathione at the early stage that triggers phase II up-regulation. However, when very high 
concentrations of sulforaphane were employed, a marked decrease in cellular GSH was seen, 
but induction of phase II enzymes was unattained, and the drop in the GSH concentration 
triggered apoptosis.
The current work showed increased GSH levels when rat liver slices were incubated with low 
concentrations of PEITC (Chapter 3). However, a marked drop in GSH content at the highest 
concentration of PEITC, paralleled with decrease activity and apoprotein levels of many 
enzymes (Chapter 3), implies cytotoxicity of PEITC at high concentrations as a result of 
depletion of GSH (Xu and Thomalley, 2001). It is more than likely that the toxicity of 
isothiocyanates in liver slices, whether PEITC (current study), erucin or sulforaphane
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(Hanlon et al., 2009; 2008b), is a consequence of depletion of glutathione leaving the cells 
vulnerable to the deleterious effects of electrophiles. On the other hand, the in vivo study 
revealed that GSH levels were not altered in either liver or lung (Chapter 4), presumably due 
to the fact that cellular glutathione levels in both tissues are relatively higher than in tissue 
slices cultured for 24 hr, and the doses of PEITC employed are inadequate to modulate 
glutathione content; plasma concentrations of PEITC at the highest dose studied (5 mg/kg) to 
rats reached only 13.4 pM (Chapter 7), whereas average glutathione concentration in rat liver 
was about 5 mM (Chapter 4). It may also relate to the fact that glutathione conjugation is 
reversible, and the temporary depletion of reduced glutathione is being maintained at certain 
level in the tissue as a result of glutathione reductase activity (Ballatori et al., 1989). It is 
relevant to note that treatment with PEITC to rats enhanced hepatic glutathione reductase 
activity at Medium and High doses (Chapter 4) which concords with such GSH maintaining 
mechanism (Hammond et al., 2001).
Inconsistent effects of PEITC on glutathione levels among the four donors were observed, 
and are believed to be associated with inter-individual variability of the enzymes responsible 
for glutathione synthesis. Drug sensitivity and resistance due to polymorphism in y- 
glutamylcysteine synthetase (Walsh et al., 2001), the first and rate limiting step in glutathione 
biosynthesis, has been reported (Lu et al., 1991). Increased glutathione content was observed 
in only Donor 4 and was paralleled with induction of phase II enzymes such as NQOl and 
GST, indicating the relationship of GSH level and cellular defence against reactive 
intermediates.
8.2.3 Induction o f quinone reductase by PEITC
Quinone reductase is an important phase II enzyme as it facilitates detoxification of either 
naturally occurring quinones or secondary quinone-containing metabolites of PAHs (Cadenas, 
1995; Gelboin, 1980). The enzyme is highly inducible by isothiocyanates (Posner et al..
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1994). The current work demonstrated that PEITC is also a promising NQOl inducer by 
enhancing activity and expression of NQOl both in vitro and to a greater extent in vivo 
(Chapters 3 and 4). Similar to GST, the low concentrations of PEITC employed in liver slices 
and all doses administered to rats induced NQOl activity, supporting the view that PEITC 
may protect against reactive intermediates even at the low human dietary level of exposure. 
Comparison between isothiocyanates shows that sulforaphane is a stronger NQOl inducer 
than PEITC (Hanlon, 2009), which is probably due to different binding affinity of individual 
isothiocyanate to the cysteine residues in Keapl, the initial step for phase II enzyme up- 
regulation (Dinkova-Kostova et al., 2002). Furthermore, sulforaphane has been reported as 
the most potent phase II inducer among many compounds (Prestera and Talalay, 1995), 
implying that additional mechanisms to disruption of Nrf2-Keapl interaction may be involved 
(Myzak and Dashwood, 2006). Species differences in NQOl induction was illustrated when 
elevation of NQOl activity was clearly observed in rats (Chapter 4) but only in one of the 
four human donors (Chapter 3) mirroring similar results with sulforaphane and erucin 
(Hanlon et al., 2009). This raises the question of the suitability of rats as a surrogate animal 
for human, although human response is clearly varied.
8.3 Effect of PEITC on the bioactivation of xenobiotics
Isothiocyanates are recognised as monofunctional inducers with induction of phase II 
enzymes underling their chemopreventive activity. However, inhibition of CYP450 enzymes, 
preventing bioactivation of carcinogens, is of great importance. PEITC inhibited CYP1A2 
expression and activity in both human and rat liver slices whereas CYPlAl in two of the four 
donors decreased while their apoprotein levels increased (Chapter 3). It should be noted that 
inhibition of human CYPIA was achieved even at the low concentrations, corresponding to 
plasma levels of PEITC achieved following intake of a dose equivalent to human daily intake. 
Following treatment the rats with PEITC (Chapter 4), CYPlAl and 1A2 activities were 
suppressed at only the Low dose, whereas an increase in the apoprotein levels of both
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enzymes was observed at the High dose. It is likely that the available CYPIA enzymes were 
catalytically incompetent. PEITC was demonstrated in the present studies to directly inhibit 
human and rat CYPlAl in a mechanism-based fashion (Chapter 4). Similarly, it has been 
demonstrated in our laboratory that sulforaphane and BITC, aliphatic and aromatic 
isothiocyanates respectively, are also mechanism-based inhibitors of CYPlAl (Arya, 2009; 
Hanlon et al., 2008c; Yoxall et al., 2005). However, PEITC apparently exerted a more marked 
inhibition compared to the other two isothiocyanates, suggesting that both substituent and the 
elongation of methylene chain of isothiocyanate group are important to their inhibition 
mechanism. The presence of aromatic substitutent renders the isothiocyanates more likely to 
interact more readily with the CYPlAl binding site (loannides and Parke, 1990).
Isoform- and tissue-specific effects are illustrated when the High dose of PEITC administered 
to rats led to induction of both activity and expression of hepatic CYP2B whereas in lung 
activity was competitively inhibited (Chapter 4). In fact, similar observations were previously 
reported where treatment with PEITC markedly enhanced rat hepatic PROD activity but 
failed to alter pulmonary PROD (Guo et al., 1992). Induction of CYP2B in the liver may 
contribute to increased PEITC metabolism following a long-term exposure, since this enzyme 
appears to be a principal CYP450 enzyme catalysing PEITC metabolism (Chapter 4).
8.4 Interaction of PEITC with chemical carcinogens
CYPIA activities are inducible by PAHs, and the increase in this activity is related to 
enhanced bioactivation of many carcinogens. Degree of increase in activity depends on the 
amount of enzymatic protein and catalytic activity of enzyme (Iwanari et al., 2002). Many 
studies reported inhibition by sulforaphane of the BaP-mediated CYPIA induction 
(Skupinska et al., 2009a; 2009b) whereas the effect of PEITC has not been well established. 
Similar to the effect of PEITC in human and rat liver slices (Chapter 3), many isothiocyanates
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have been demonstrated as stronger inhibitors of CYP1A2 than CYPlAl (Conaway et al., 
1996; Langouet et al., 2000). Correspondingly, sulforaphane suppressed BaP-mediated 
CYP1A2 induction in human breast cancer cell line more effective than of CYPlAl 
(Skupinska et al., 2009b). Indeed, the CYPlAl inhibition potential of isothiocyanates 
depends on the induction potency of the inducing agent whereas inhibition of CYP1A2 is 
more facile regardless of the type of inducer (Skupinska et al., 2009a).
Co-treatment of PEITC and BaP in rat liver slices revealed an antagonistic effect of PEITC 
against BaP-mediated CYPlAl induction in a concentration dependent manner (Chapter 5). 
Immunoblot analysis revealed that inactivation occurred through down-regulation at protein 
level. Substrates of CYPl are normally heavy aromatic planar compounds (Lewis et al., 
1986), and aromatic isothiocyanates may block translocation of AhR to nucleus by 
competitive binding between inhibitor and BaP for the receptor (Henry et al., 1999); this is 
believed to be a possible mechanism of the antagonistic effect of PEITC. However, this is not 
the case with PEITC, since a recent study from our laboratory established that PEITC does 
not bind to AhR, as determined in the Chemically Activated Luciferase Expression assay 
(CALUX) (A. R. Ahmad Faizal, personal communication), not surprisingly since PEITC is 
only a small aromatic molecule; this is in agreement with the findings in the current work that 
PEITC did not influence mRNA levels of CYPlAl, 1A2 and IB l in rat liver slices (Chapter 
3). It also implies that other possible inhibition mechanisms may account for these features 
such as increased post-transcriptional degradation of mRNA and protein (Oesch- 
Bartlomowicz and Oesch, 2005). Even though up-regulation of CYPl enzymes by alternative 
mechanisms rather than binding to the Ah receptor has been reported (Ayalogu et al., 1995), 
further experimental studies to evaluate whether PEITC prevents the binding of BaP to the 
AhR and subsequent elevation of CYPIA mRNA, would be required before definite 
conclusions can be drawn.
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The current work, for the first time provided experimental evidence that PEITC, even at the 
dietary Low dose, could modulate the metabolism of a carcinogen, the heterocyclic amine IQ. 
In these studies CYPl A2 and GST activities were also monitored because of their pivotal role 
in IQ bioactivation (Apostolides et al., 1997; Inamasu et al., 1989; Kitamura et al., 2007; Luks 
et al., 1989). Neither CYP1A2 nor GST activity were perturbed at this Low dose, indicating 
that effect of PEITC is independent of these enzyme systems. It is likely that the enhanced 
metabolism of IQ by PEITC may involve induction of NAT, SULT and UDPGTs, which also 
play important role in the metabolism of IQ (see Fig. 5.14). Indeed, previous reports indicated 
that treatment of rats with PEITC led to a rise in UDPGT activity whereas SULT decreased 
(Dingley et al., 2003; Guo et al., 1992), but further studies are warranted.
It is relevant to point out that modulation of overall IQ metabolism occurred following long­
term administration of PEITC (Chapter 5), presumably due to the fact that repeated 
administration of PEITC led to an increased bioavailability of the isothiocyanate (Chapter 7) 
and up-regulation of the relevant enzymes. The effect of other ITCs, namely BITC, erucin and 
sulforaphane on IQ mutagenicity has been studied under similar experimental conditions 
(Arya, 2009; Hanlon, 2009). BITC failed to influence the overall metabolism of IQ whereas 
sulforaphane and erucin behaved in the same manner as PEITC.
8.5 Plausible chemopreventive mechanisms of PEITC
It is obvious that dietary doses of PEITC are able to modulate xenobiotic-metabolising 
enzymes. However, whether the underlying chemopreventive mechanism of PEITC is 
confined to suppression of bioactivation or elevated detoxication remains unclear. In rat and 
human liver slices, PEITC impaired both activity and apoprotein levels of CYP1A2 whereas 
modulation of other CYP450 activities was unattained in rat and was inconsistent in humans. 
The Ki of the competitive inhibition of hepatic EROD by PEITC was 12.8 pM (Chapter 4) 
whereas plasma Cmax values of PEITC, following oral exposure to a single dietary dose were
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about 2 pM (Chapter 7), implying that direct inhibition of CYP450 may not be 
physiologically relevant at this dose level. Furthermore, bearing in mind that plasma levels 
may not reflect cellular concentration of PEITC since the isothiocyanate is highly bound to 
plasma protein (Ji et al., 2005) as well as cellular glutathione (Brusewitz et al., 1977; 
Mennicke et al., 1987), it is difficult to relate plasma levels to biological activity. On the 
other hand, this dose of PEITC elevated rat GST and NQOl activities in vitro whereas 
extensive induction of these enzymes in vivo was observed (Chapter 4). Thus enhancing 
detoxication of reactive intermediate is more likely to contribute to the chemopreventive 
activity of PEITC rather than inhibition of carcinogen bioactivation.
It has been reported that even though the primary reaction of PEITC after entering the cell is 
conjugation with glutathione, the conjugates are subsequently dissociated and further 
covalently bind with proteins which accounts for 87% of its total cellular uptake (Mi et al.,
2007). Subsequent studies by the same workers showed that the protein involved in ITC- 
protein binding is tubulin (Mi et al., 2008), an essential protein for cell division and motility 
(Nogales, 2000). Hence tubulin binding, rather than GSH depletion, may be related to their 
ability to induce apoptosis and cell cycle arrest. Comparison studies of the binding affinity of 
isothiocyanates illustrated that PEITC binds to tubulin more efficiently than sulforaphane (Mi 
et al., 2008), and this mechanism may have an important role in the chemoprevention of 
PEITC and deserves further investigation.
8 .6  Chemoprevention by dietary intake of cruciferous vegetable
It is relevant to point out that plasma levels of PEITC following cruciferous vegetables 
consumption depend on various factors. Initial glucosinolate content in the vegetable depends, 
for example, on plant part consumed, cultivar, cultivation conditions, stage of plant growth 
and especially cooking conditions (Nugon-Baudon and Rabot, 1994; Steinbrecher et al., 
2009). Dénaturation of the enzyme myrosinase by heating renders less effective glucosinolate
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hydrolysis, and lower level of exposure to ITCs (Getahun and Chung, 1999); in addition, 
boiling results in the most extensive loss of glucosinolates, which leaches into the water, 
compared with microwaving, steaming and stir hying (Song and Thomalley, 2007). 
Correspondingly, eating the raw vegetable gave rise to higher levels of urinary isothiocyanate 
metabolites than the cooked vegetable in humans (Conaway et al., 2000).
Bioavailability of PEITC following oral intake depends on the rate of absorption, distribution 
and plasma protein binding (van de Waterbeemd et al., 2003). Following single oral 
administration to rats, PEITC was rapidly absorbed across the intestinal membrane, as it is a 
small lipophilic molecule, and reached peak levels within an hour with high bioavailability 
(Chapter 7), suggesting that PEITC only modestly undergoes first-pass metabolism (Somogyi 
et al., 1982). Bioavailability, however, decreased with increasing dose, implying that 
improving plasma levels through consumption of food supplements may not be successful. 
However, repeated administration improved bioavailability, suggesting that frequent intake of 
PEITC may be required to achieve maximal health benefit.
Repeated administration of PEITC to rats, at a dose equivalent to human daily intake (1 
mg/lcg) elevated GST and NQOl activities (Chapter 4). Subsequent studies revealed that, at 
the same dose, peak plasma PEITC concentrations of 3.96 pM were attained (Chapter 7). 
Such concentrations fall within the range that induction of GST and NQOl in rat liver slices 
was achievable (Chapter 3). Similarly, a two-fold induction of NQOl activity by 5 pM of 
PEITC was reported in murine hepatoma cells (Rose et al., 2000), and the protection against 
NDMA-induced oxidative DNA damage in HepG2 cells was achieved at 1 pM of PEITC 
(Arranz et al., 2006). PEITC also suppressed NNK metabolism in mouse lung microsomes at 
a concentration of 51-93 nM (Smith et al., 1990). Collectively, these observations support the 
assertion that frequent intake of PEITC may be sufficient to prevent chemically-induced 
cancer.
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On the other hand, inhibition of carcinogenesis at the post-initiation stage, such as induction 
of apoptosis and cell cycle arrest, by PEITC has also been demonstrated, but required higher 
concentrations. For example, 25 pM of PEITC enhanced apoptosis in human colorectal 
cancer cell line as exemplified by enhanced caspase activity (Hu et al., 2003), whereas 10 pM 
was necessitated for induction of cell cycle arrest and apoptosis in prostate cancer cells (Xiao 
and Singh, 2002; Yin et al., 2009). It is obvious that acute doses and long-term intake of 
dietary supplements are required for achieving the plasma concentrations required for 
suppression of carcinogenesis through these mechanisms.
8.7 PEITC toxicity
Consideration of the toxicity potential of a chemopreventive agent is important in the drug 
development process. It has been reported that the anticarcinogenic activity of chemicals, 
such as BITC, by inducing GST activity is associated with induction of ROS generation 
(Nakamura et al., 2000). This finding raises the possibility that isothiocyanates may be geno- 
and cytotoxic compounds. Toxicity of PEITC towards many tumour cells has been 
demonstrated but no cytotoxicity to normal cells was noted. This may be related to the fact 
that tumour cells are more sensitive to ROS-mediated damage due to their high basal ROS 
generation. Increasing of intrinsic oxidative stress as a result of depletion of cellular GSH by 
PEITC enhanced apoptosis in tumour cells whereas the effect was not sufficient to trigger 
apoptosis in normal cells (Trachootham et al., 2006). In animal models, only mild toxicity of 
PEITC has been revealed when tested at acute doses. Fatty changes in rat liver were observed 
following 13-week administration of 1 mg/g diet (Morse et al., 1989). However, in a longer 
treatment period, the lesions were reversible as indicated by no histological differences 
between treated and control rats (Morse et al., 1989). Nonetheless, hyperplasia in urinary 
bladder following 14-days treatment of rats with very high dose of PEITC (80 mg/kg/day) has 
been reported (Akagi et al., 2003). In the current work, the High dose (100 mg/kg/day) was 
100 times higher than dietary human intake, and no toxicity was evident macroscopically. In
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the in vitro studies, concentrations of 50 pM were required to compromise the viability of 
slices. Overall, no serious adverse effects have been associated with PEITC and it may be 
considered to be a safe phytochemical.
8.8 Future work
•  Garden- and watercress juices efficiently protected against B(a)P-induced DNA damage 
which, however, was not associated with BITC or PEITC (Kassie et al., 2003). 7- 
Methylsulfmyheptyl and 8-methylsulfinyloctyl isothiocyanates which are ITCs derived from 
watercress led to more pronounced induction of NQOl than PEITC, and may explain why 
watercress is a stronger NQOl inducer than PEITC alone (Rose et al., 2000). Thus it would 
be sensible to screen other isothiocyanates to identify those veiy active in the induction of 
detoxification enzyme. Moreover, the combination of PEITC and other compounds such as 
vitamin C, both being abundant in watercress (Palaniswamy et al., 2003), showed stronger 
suppression of carcinogen-induced DNA damage than the isothiocyanate alone (Garcia et al.,
2008). On the other hand, while PEITC has been demonstrated to be a strong mechanism- 
based inhibitor of CYP2A6, the major enzyme involved in NNK metabolism (von Weymam 
et al., 2006), watercress juice intake failed to suppress CYP2A6 activity in human volunteers 
(Murray et al., 2001). Moreover, individual isothiocyanates show tissue and chemical 
carchiogen specfricity (Lin et ah, 1993; TVafrenl)erg, 1987), hence coiidihied exposure to 
various ITCs, or ITCs and other compounds, may offer synergistic or antagonistic outcomes 
on the chemoprevention activity of cruciferous vegetables, and this possibility needs to be 
clarified so as to fully define the mechanisms underpinning the health benefits of these 
vegetables.
•  The current work showed that long-term administration of dietary doses of PEITC to rats 
increased the overall metabolism of IQ, which was not related to major changes in GST and
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CYP1A2 activities. Since the bioactivation of IQ is catalysed by CYP1A2 (Turesky et al., 
2002), these results allow the inference that the bioactivation of IQ through A-hydroxylation 
is unlikely to be stimulated. Moreover, the studies using human precision-cut liver slices 
indicated that PEITC has the potential to suppress this enzyme, hence impairing bioactivation. 
It is likely that the underlying mechanism involves enhanced direct conjugation with sulphate, 
glucuronide or acetate, and studies to assess the modulation of these systems by PEITC would 
be desirable.
•  PEITC was a promising antagonist towards BaP-mediated CYPlAl induction in rat liver 
slices. This is surprising since PEITC alone failed to modulate CYPlAl under identical 
conditions, paralleled with no effect on CYPlAl mRNA levels. It would be interesting to test 
the hypothesis that PEITC, although itself not a ligand, may prevent the binding of BaP to the 
AhR.
•  The pharmacokinetic characteristics of repeated administration of PEITC in rats were 
established. The pharmacokinetic behaviour of PEITC in humans following repeated dietary 
doses remains to be investigated since it is vital for extrapolating in vitro data to the human 
situation. Furthermore, the benefit of ingestion of glucosinolates supplements should be 
ascertained.
•  The role, if any, of post-transcriptional mechanisms in the PEITC chemoprevention should 
be assessed using concentrations reflecting human intake. It would be informative if such 
studies were also conducted in vivo.
•  The current studies illustrated that PEITC successfully modulated overall IQ metabolism in 
rats. It is interesting to ascertain whether the same effect is achievable in humans exposed to 
this heterocyclic amine through the diet. The levels of intake required to influence carcinogen 
metabolism should be defined, and made available to the consumer. If the required levels of
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intake cannot be achieved through diet, the possibility of growing genetically-modified, 
glucosinolate-rich watercress should be considered.
•  It is important to discern the effectiveness of PEITC and its parent gluconasturtiin to protect 
against chemical carcinogens following dietary intake of watercress and other cruciferous 
vegetables.
•  Since humans cook cruciferous vegetables, loss of ITCs by thermal processing may have a 
great impact on their effectiveness. It is essential to assess whether bacterial myrosinase is an 
effective alternative to the plant enzyme for the generation of isothiocyanates.
8.9 Conclusions
PEITC displayed high bioavailability following repeated oral administration at doses 
commensurate with human dietary intake. At the same dose, PEITC successfully enhanced 
GST and NQOl in rats and stimulated the overall metabolism of IQ, a food carcinogen to 
which humans are continuously exposed. Modulation of carcinogen-metabolising enzymes is 
not confined to rats, as similar observations have made in precision-cut human liver slices.
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